Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Feb. 24, 2016 | Jun. 30, 2015 | |
Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2015 | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY | ||
Trading Symbol | MDRX | ||
Entity Registrant Name | ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. | ||
Entity Central Index Key | 1,124,804 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Common Stock, Shares Outstanding | 189,344,178 | ||
Entity Public Float | $ 2,551,607,348 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash and cash equivalents | $ 116,873 | $ 53,173 |
Accounts receivable, net of allowance of $31,266 and $36,047 as of December 31, 2015 and 2014, respectively | 327,851 | 331,625 |
Prepaid expenses and other current assets | 93,622 | 102,392 |
Total current assets | 538,346 | 487,190 |
Long-term marketable securities | 0 | 1,305 |
Fixed assets, net | 125,617 | 145,830 |
Software development costs, net | 85,775 | 86,153 |
Intangible assets, net | 347,646 | 403,362 |
Goodwill | 1,222,601 | 1,200,746 |
Deferred taxes, net | 2,298 | 1,984 |
Other assets | 359,665 | 137,760 |
Total assets | 2,681,948 | 2,464,330 |
Current liabilities: | ||
Accounts payable | 60,004 | 70,824 |
Accrued expenses | 62,021 | 78,967 |
Accrued compensation and benefits | 62,398 | 51,062 |
Deferred revenue | 315,925 | 293,022 |
Current maturities of long-term debt and capital lease obligations | 12,609 | 27,498 |
Total current liabilities | 512,957 | 521,373 |
Long-term debt | 612,405 | 539,193 |
Deferred revenue | 20,273 | 23,168 |
Deferred taxes, net | 22,164 | 21,119 |
Other liabilities | 95,076 | 75,257 |
Total liabilities | $ 1,262,875 | $ 1,180,110 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of December 31, 2015 and 2014 | $ 0 | $ 0 |
Common stock: $0.01 par value, 349,000 shares authorized as of December 31, 2015 and 2014; 266,545 and 189,308 shares issued and outstanding as of December 31, 2015, respectively; 265,138 and 180,466 shares issued and outstanding as of December 31, 2014, respectively | 2,665 | 2,651 |
Treasury stock: at cost, 77,237 and 84,672 shares as of December 31, 2015 and 2014, respectively | (189,753) | (278,036) |
Additional paid-in capital | 1,789,449 | 1,749,593 |
Accumulated deficit | (190,235) | (188,009) |
Accumulated other comprehensive loss | (4,242) | (1,979) |
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity | 1,407,884 | 1,284,220 |
Non-controlling interest | 11,189 | 0 |
Total stockholders' equity | 1,419,073 | 1,284,220 |
Total liabilities and stockholders' equity | $ 2,681,948 | $ 2,464,330 |
CONSOLIDATED BALANCE SHEETS (Un
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Statement Of Financial Position [Abstract] | ||
Accounts receivable, allowance | $ 31,266 | $ 36,047 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 349,000,000 | 349,000,000 |
Common stock, shares issued | 266,545,000 | 265,138,000 |
Common stock, shares outstanding | 189,308,000 | 180,466,000 |
Treasury stock at cost, shares | 77,237,000 | 84,672,000 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Revenue: | |||
Software delivery, support and maintenance | $ 918,430 | $ 907,343 | $ 918,686 |
Client services | 467,963 | 470,530 | 454,375 |
Total revenue | 1,386,393 | 1,377,873 | 1,373,061 |
Cost of revenue: | |||
Software delivery, support and maintenance | 291,804 | 312,898 | 325,471 |
Client services | 432,038 | 437,776 | 427,933 |
Amortization of software development and acquisition-related assets | 81,986 | 81,215 | 85,201 |
Total cost of revenue | 805,828 | 831,889 | 838,605 |
Gross profit | 580,565 | 545,984 | 534,456 |
Selling, general and administrative expenses | 339,175 | 358,681 | 419,599 |
Research and development | 184,791 | 192,821 | 199,751 |
Asset impairment charges | 1,544 | 2,390 | 11,454 |
Amortization of intangible and acquisition-related assets | 23,172 | 31,280 | 31,253 |
Income (loss) from operations | 31,883 | (39,188) | (127,601) |
Interest expense | (31,396) | (29,297) | (28,055) |
Other income, net | 2,183 | 766 | 7,310 |
Equity in net earnings of unconsolidated investments | (2,100) | (398) | 0 |
Income (loss) before income taxes | 570 | (68,117) | (148,346) |
Income tax (provision) benefit | (2,626) | 1,664 | 44,320 |
Net loss | (2,056) | (66,453) | (104,026) |
Less: Net income attributable to non-controlling interest | (170) | 0 | 0 |
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ (2,226) | $ (66,453) | $ (104,026) |
Loss per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ (0.01) | $ (0.37) | $ (0.59) |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Statement Of Income And Comprehensive Income [Abstract] | |||
Net loss | $ (2,056) | $ (66,453) | $ (104,026) |
Other comprehensive (loss) income: | |||
Foreign currency translation adjustments | (2,381) | (529) | (2,482) |
Change in unrealized gains on marketable securities | (228) | 25 | 10 |
Change in fair value of derivatives qualifying as cash flow hedges | 424 | 458 | 1,076 |
Other comprehensive loss before income tax expense | (2,185) | (46) | (1,396) |
Income tax expense related to items in other comprehensive loss | (78) | (188) | (425) |
Total other comprehensive loss | (2,263) | (234) | (1,821) |
Comprehensive loss | (4,319) | (66,687) | (105,847) |
Less: Comprehensive income attributable to non-controlling interest | (170) | 0 | 0 |
Comprehensive loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ (4,489) | $ (66,687) | $ (105,847) |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock Issued [Member] | Treasury Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive (Loss) Income [Member] | Non-controlling interest [Member] |
Beginning Balance, Shares at Dec. 31, 2012 | 257,087 | (84,672) | |||||
Stock-based compensation | $ 36,252 | ||||||
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares | 2,564 | ||||||
Issuance of common stock for acquisition of dbMotion, Shares | 3,823 | ||||||
Ending Balance, Shares at Dec. 31, 2013 | 263,474 | (84,672) | |||||
Beginning Balance at Dec. 31, 2012 | $ 1,284,341 | $ 2,571 | $ (278,036) | 1,577,260 | $ (17,530) | $ 76 | $ 0 |
Common stock issued under stock compensation plans, net of shares withheld for employee taxes | 26 | 2,479 | |||||
Issuance of common stock for acquisition of dbMotion | 38 | 48,023 | |||||
Ending Balance at Dec. 31, 2013 | 1,318,145 | $ 2,635 | $ (278,036) | 1,716,847 | (121,556) | (1,745) | 0 |
Issuance of treasury stock to Nant Capital, LLC | 0 | ||||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | 0 | ||||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | 335 | ||||||
Warrants issued | 52,498 | ||||||
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | (104,026) | (104,026) | |||||
Foreign currency translation adjustments, net | (2,482) | (2,482) | |||||
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 655 | ||||||
Unrecognized gain on marketable securities, net of tax | 6 | ||||||
Acquisition of non-controlling interest | 0 | ||||||
Net income attributable to non-controlling interest | 0 | 0 | |||||
Stock-based compensation | 37,295 | ||||||
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares | 1,664 | ||||||
Issuance of common stock for acquisition of dbMotion, Shares | 0 | ||||||
Ending Balance, Shares at Dec. 31, 2014 | 265,138 | (84,672) | |||||
Common stock issued under stock compensation plans, net of shares withheld for employee taxes | $ 16 | (6,969) | |||||
Issuance of common stock for acquisition of dbMotion | 0 | 0 | |||||
Ending Balance at Dec. 31, 2014 | 1,284,220 | $ 2,651 | $ (278,036) | 1,749,593 | (188,009) | (1,979) | 0 |
Issuance of treasury stock to Nant Capital, LLC | 0 | ||||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | (123) | ||||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | 0 | ||||||
Warrants issued | 2,543 | ||||||
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | (66,453) | (66,453) | |||||
Foreign currency translation adjustments, net | (529) | (529) | |||||
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 279 | ||||||
Unrecognized gain on marketable securities, net of tax | 16 | ||||||
Acquisition of non-controlling interest | 0 | ||||||
Net income attributable to non-controlling interest | 0 | 0 | |||||
Stock-based compensation | 31,961 | ||||||
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares | 1,407 | ||||||
Issuance of common stock for acquisition of dbMotion, Shares | 0 | ||||||
Ending Balance, Shares at Dec. 31, 2015 | 266,545 | (77,237) | |||||
Common stock issued under stock compensation plans, net of shares withheld for employee taxes | $ 14 | (3,445) | |||||
Issuance of common stock for acquisition of dbMotion | 0 | 0 | |||||
Ending Balance at Dec. 31, 2015 | 1,419,073 | $ 2,665 | $ (189,753) | 1,789,449 | (190,235) | (4,242) | 11,189 |
Issuance of treasury stock to Nant Capital, LLC, Shares | 7,435 | ||||||
Issuance of treasury stock to Nant Capital, LLC | $ 88,283 | 10,017 | |||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | (2,920) | ||||||
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation | 0 | ||||||
Warrants issued | $ 4,243 | ||||||
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | (2,226) | $ (2,226) | |||||
Foreign currency translation adjustments, net | (2,381) | (2,381) | |||||
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 258 | ||||||
Unrecognized gain on marketable securities, net of tax | $ (140) | ||||||
Acquisition of non-controlling interest | 11,019 | ||||||
Net income attributable to non-controlling interest | $ 170 | $ 170 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Cash flows from operating activities: | |||
Net loss | $ (2,056) | $ (66,453) | $ (104,026) |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||
Depreciation and amortization | 161,011 | 174,263 | 178,815 |
Stock-based compensation expense | 34,663 | 39,254 | 37,010 |
Excess tax benefits from stock-based compensation | (644) | 0 | (3,887) |
Deferred taxes | (2,206) | (56) | (43,880) |
Asset impairment charges | 1,544 | 2,390 | 11,454 |
Other losses, net | 2,919 | 3,951 | 1,398 |
Changes in operating assets and liabilities (net of businesses acquired): | |||
Accounts receivable, net | 3,215 | (14,644) | (7,705) |
Prepaid expenses and other assets | 17,614 | (7,038) | (23,481) |
Accounts payable | (11,953) | (1,944) | 23,794 |
Accrued expenses | (22,974) | (22,767) | (4,552) |
Accrued compensation and benefits | 10,257 | (29,544) | 33,482 |
Deferred revenue | 20,372 | 33,109 | (1,573) |
Other liabilities | (183) | (7,025) | (15,862) |
Net cash provided by operating activities | 211,579 | 103,496 | 80,987 |
Cash flows from investing activities: | |||
Capital expenditures | (18,322) | (26,438) | (74,130) |
Capitalized software | (49,264) | (40,661) | (42,026) |
Purchase of controlling interest, net of cash acquired | (9,372) | (20,180) | (148,875) |
Purchases of non-marketable securities, other investments and related intangible assets | (215,786) | (21,544) | 0 |
Sales and maturities of marketable securities and other investments | 3,763 | 50 | 12,891 |
Proceeds received from sale of fixed assets | 15 | 85 | 0 |
Net cash used in investing activities | (288,966) | (108,688) | (252,140) |
Cash flows from financing activities: | |||
Proceeds from issuance 1.25% senior cash convertible notes, net of issuance costs | 0 | 0 | 336,662 |
Purchase of call option related to 1.25% senior cash convertible notes | 0 | 0 | (82,800) |
Proceeds from issuance of warrants, net of issuance costs | 0 | 0 | 51,208 |
Proceeds from sale or issuance of common stock | 103,631 | 1,487 | 11,447 |
Excess tax benefits from stock-based compensation | 644 | 0 | 3,887 |
Taxes paid related to net share settlement of equity awards | (7,062) | (10,400) | (9,732) |
Payments of capital lease obligations | (598) | (455) | (458) |
Payments of acquisition financing obligations | 0 | 0 | (29,671) |
Credit facility payments | (238,511) | (96,876) | (609,593) |
Credit facility borrowings | 284,161 | 101,964 | 460,983 |
Net cash provided by (used in) financing activities | 142,265 | (4,280) | 131,933 |
Effect of exchange rate changes on cash and cash equivalents | (1,178) | (309) | (1,782) |
Net increase (decrease) in cash and cash equivalents | 63,700 | (9,781) | (41,002) |
Cash and cash equivalents, beginning of period | 53,173 | 62,954 | 103,956 |
Cash and cash equivalents, end of period | $ 116,873 | $ 53,173 | $ 62,954 |
CONSOLIDATED STATEMENTS OF CAS8
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Senior cash convertible notes [Member] | |||
Debt instrument interest rate | 1.25% | 1.25% | 1.25% |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies | 1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and majority-owned affiliate. All significant intercompany balances and transactions have been eliminated. Investments in less than majority-owned entities where we have significant influence are accounted for under the equity method. The earnings from certain investments accounted for using the equity method are included in our results of operation based on a reporting lag of up to three months from our year end. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc., its wholly-owned subsidiaries and , unless otherwise stated. Change in Presentation In 2015, we adopted a revised presentation of revenue and the associated cost of revenue in our consolidated statements of operations, which we believe is better aligned with and representative of the amount and profitability of our overall software and services revenue streams, as well as with the way we manage our business, review our operating performance and market our products. In recent years, we have experienced a continued shift in customer preferences from up-front software license agreements, and associated support and maintenance, to subscription-based agreements. Under our previous presentation, the revenue and cost of revenue of each of these types of agreements were reported under separate revenue categories. By combining these separate revenue categories, we believe that our revised presentation better reflects the overall trend in our software delivery, support and maintenance revenue. Under the revised presentation, revenue is reported based on two categories: (i) software delivery, support and maintenance, and (ii) client services. Previously, revenue was presented based on four categories: system sales, professional services, maintenance, and transaction processing and other. Software delivery, support and maintenance revenue consists of our previous system sales, maintenance and transaction processing and other revenue categories, excluding outsourcing and remote hosting managed services revenue previously included in transaction processing and other revenue. Client services revenue consists of our previous professional services category and outsourcing and remote hosting managed services revenue previously included in transaction processing and other revenue. The comparable 2014 and 2013 periods were revised for the new presentation. Total revenue and cost of revenue previously reported for the years ended December 31, 2014 and 2013 were not affected by this change in presentation. Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Revenue Recognition Revenue represents the fair value of consideration received or receivable from clients for goods and services provided by us. Software delivery revenue consists of all of our proprietary software sales (either as a perpetual license sale or under a subscription delivery model), transaction-related revenue and the resale of hardware. Support and maintenance revenue consists of revenue from post contract client support and maintenance services. Client services revenue consists of revenue from managed services solutions, such as remote hosting, outsourcing and revenue cycle management, as well as other client services or project-based revenue from implementation, training and consulting services. For some clients, we remotely host the software applications licensed from us using our own or third-party servers, which saves these clients the cost of procuring and maintaining hardware and related facilities. For other clients, we offer an outsourced solution in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. Revenue from software licensing arrangements where the service element is not considered essential to the functionality of the other elements of the arrangement is recognized upon delivery of the software or as services are performed, provided persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. The revenue recognized for each separate element of a multiple-element software contract is based upon vendor-specific objective evidence of fair value (“VSOE”), which is based upon the price the client is required to pay when the element is sold separately or renewed. For arrangements in which VSOE only exists for the undelivered elements, the delivered elements (generally software licenses) are accounted for using the residual method. Revenue from software licensing arrangements, where the service element is considered essential to the functionality of the other elements of the arrangement, is accounted for on an input basis under the percentage of completion accounting method using actual hours worked as a percentage of total expected hours required by the arrangement, provided that persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. Maintenance and support associated with these agreements is recognized over the term of the support agreement based on VSOE of the maintenance revenue, which is based upon contractual renewal rates. For presentation in the statement of operations, consideration from agreements accounted for under the percentage of completion accounting method is allocated between software delivery and client services revenue based on VSOE of our hourly services rate multiplied by the amount of hours performed with the residual amount allocated to the software license fee. Fees related to software-as-a-service (“SaaS”) arrangements are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. These arrangements include client services fees related to the implementation and set-up of our solutions and are typically billed upfront and recorded as deferred revenue until our solutions are made available to the client. The implementation and set-up fees are recognized as revenue ratably over the estimated client relationship period. The estimated length of a client relationship period is based on our experience with client contract renewals and consideration of the period over which such clients use our SaaS solutions. Software remote hosting services are provided to clients that have purchased a perpetual license to our software solutions and contracted with us to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the remote hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. Remote hosting services are not deemed to be essential to the functionality of the software or other elements of the arrangement; accordingly, for these arrangements, we recognize software license fees as software delivery revenue upon delivery, assuming all other revenue recognition criteria have been met, and separately recognize fees for the remote hosting services as client services revenue over the term of the remote hosting arrangement. We also enter into multiple-element arrangements that may include a combination of various software-related and non-software-related products and services. Management applies judgment to ensure appropriate accounting for multiple deliverables, including the allocation of arrangement consideration among multiple units of accounting, the determination of whether undelivered elements are essential to the functionality of delivered elements, and the timing of revenue recognition, among others. In such arrangements, we first allocate the total arrangement consideration based on a selling price hierarchy at the inception of the arrangement. The selling price for each element is based upon the following selling price hierarchy: VSOE, if available, third-party evidence of fair value if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence of fair value is available (discussion as to how we determine VSOE, third-party evidence of fair value and estimated selling price is provided below). Upon allocation of the arrangement consideration to the software elements as a whole and individual non-software elements, we then further allocate consideration within the software group to the respective elements following higher-level, industry-specific guidance and our policies described above. After the arrangement consideration has been allocated to the various elements, we account for each respective element in the arrangement as described above. To determine the selling price in multiple-element arrangements, we establish VSOE using the price charged for a deliverable when sold separately and contractual renewal rates for maintenance fees. For non-software multiple element arrangements, third-party evidence of fair value is established by evaluating similar and interchangeable competitor products or services in standalone arrangements with similarly situated clients. If we are unable to determine the selling price because VSOE or third-party evidence of fair value does not exist, we determine an estimated selling price by considering several external and internal factors including, but not limited to, pricing practices, margin objectives, competition, client demand, internal costs and overall economic trends. The determination of an estimated selling price is made through consultation with and approval by our management, taking into consideration our go-to-market strategy. As our, or our competitors’, pricing and go-to-market strategies evolve, we may modify our pricing practices in the future. These events could result in changes to our determination of VSOE, third-party evidence of fair value and estimated selling price. Selling prices are analyzed on an annual basis or more frequently if we experience significant changes in our selling prices. For those arrangements where the deliverables do not qualify as separate units of accounting, revenue recognition is evaluated for the combined deliverables as a single unit of accounting and the recognition pattern of the final deliverable will dictate the revenue recognition pattern for the single, combined unit of accounting. Changes in circumstances and client data may result in a requirement to either separate or combine deliverables, such that a delivered item could now meet the separation criteria and qualify as a separate unit of accounting, which may lead to an upward or downward adjustment to the amount of revenue recognized under the arrangement on a prospective basis. We assess whether fees are considered fixed or determinable at the time of sale and recognize revenues if all other revenue recognition requirements are met. Our payment arrangements with clients typically include milestone-based software license fee payments and payments based upon delivery for services and hardware. While most of our arrangements include short-term payment terms, we periodically provide extended payment terms to clients from the date of contract signing. We do not recognize revenue under extended payment term arrangements until such payments become due. In certain circumstances, where all other revenue recognition criteria have been met, we occasionally offer discounts to clients with extended payment terms to accelerate the timing of when payments are made. Changes to extended payment term arrangements have not had a material impact on our consolidated results of operations. Maintenance fees are recognized ratably over the period of the contract based on VSOE, which is based upon contractual renewal rates. Revenue from electronic data interchange services is recognized as services are provided and is determined based on the volume of transactions processed or estimated selling price. We provide outsourcing services to our clients under arrangements that typically range from three to ten years in duration. Under these arrangements we assume full, partial or transitional responsibilities for a healthcare organization’s IT operations using our employees. Our outsourcing services include facilities management, network outsourcing and transition management. Revenue from these arrangements is recognized subsequent to the transition period as services are performed. Revenue is recognized net of any taxes collected from clients and subsequently remitted to governmental authorities. We record as revenue any amounts billed to clients for shipping and handling costs and record as cost of revenue the actual shipping costs incurred. We record reimbursements for out-of-pocket expenses incurred as client services revenue in our consolidated statements of operations. These amounts totaled: Year Ended December 31, (In thousands) 2015 2014 2013 Reimbursements for out-of-pocket expenses incurred $ 12,873 $ 16,251 $ 18,445 The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which are included in the balances of accounts receivable and other assets, respectively, in our consolidated balance sheets. Billings are expected to occur according to the contract terms. December 31, (In thousands) 2015 2014 Revenue earned on contracts in excess of billings Unbilled revenue (current) $ 68,444 $ 42,818 Unbilled revenue (long-term) 0 618 Total revenue earned on contracts in excess of billings $ 68,444 $ 43,436 Fair Value Measurements Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments in the past included money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund. There were no outstanding money market funds investments as of December 31, 2015 and 2014. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities, which consist of mortgage and asset-backed bonds. We sold all of our marketable securities during the three months ended March 31, 2015. Prior to the sale, marketable securities were recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 11, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprised of the 1.25% Call Option (as defined in Note 11, “Derivative Financial Instruments”) asset and the 1.25% Notes embedded cash conversion option liability. Refer to Note 11, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses as inputs both observable and unobservable market data. Significant market data inputs used to determine the fair values as of December 31, 2015 and 2014 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the 1.25% Notes embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity associated with changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet December 31, 2015 December 31, 2014 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Marketable securities Long-term marketable securities $ 0 $ 0 $ 0 $ 0 $ 0 $ 1,305 $ 0 $ 1,305 1.25% Call Option Other assets 0 0 80,208 80,208 0 0 57,091 57,091 1.25% Embedded cash conversion option Other liabilities 0 0 (81,210 ) (81,210 ) 0 0 (57,839 ) (57,839 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 424 0 424 0 0 0 0 Total $ 0 $ 424 $ (1,002 ) $ (578 ) $ 0 $ 1,305 $ (748 ) $ 557 During 2014, we acquired certain non-marketable equity securities of four third parties and entered into new, or amended existing, commercial agreements with each of those third parties to license and distribute their products and services, for a total consideration of approximately $21.1 million. The equity investments and the commercial agreements were valued at approximately $19.2 million and $1.9 million, respectively. Three of the equity investments acquired during 2014 are accounted for under the cost method, and one of the equity investments is accounted for under the equity method. During 2015, we invested an additional $0.3 million in one of the third parties and exercised warrants to acquire a new investment of approximately $1.0 million in another third party. Both of these additional investments are accounted for under the equity method. The carrying values of the cost method investments were approximately $17.8 million as of both December 31, 2015 and 2014. The carrying values of the equity method investments were approximately $2.5 million and $1.0 million, respectively, as of December 31, 2015 and 2014. These carrying values are included in other assets and the carrying value of the above-referenced commercial agreements is included in intangible assets, net, in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. During 2015, we also invested $200 million for a 10% ownership stake in Nant Health LLC. This investment is accounted for under the equity method. Refer to Note 2, “Business Combinations and Other Investments” for additional information about the investment in Nant Health LLC. t is not practicable to estimate the fair value of our cost and equity investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined in Note 6, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, as of December 31, 2015, the fair value of the 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) exceeded the 1.25% Notes’ principal balance (or par) by approximately 8%. We utilized the 1.25% Notes’ market trading prices near December 31, 2015 in making this fair value calculation. See Note 6, “Debt,” for further information regarding our long-term financial liabilities. Financial Instruments We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values. Other investments classified as long-term marketable securities include certain debt instruments. Debt securities are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Realized and unrealized gains and losses for all periods presented are immaterial. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income. There were no other-than-temporary impairments for the years ended December 31, 2015, 2014 and 2013. Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation. For derivative instruments designated as cash-flow hedges, the effective portion of the derivative’s gain (loss) is initially reported as a component of other comprehensive income and is subsequently recognized in earnings when the hedged exposure is recognized in earnings. Gains (losses) on derivatives representing either hedge components excluded from the assessment of effectiveness or hedge ineffectiveness are recognized in earnings. See Note 11, “Derivative Financial Instruments,” for information regarding gains and losses from derivative instruments during the years ended December 31, 2015, 2014 and 2013. Allowance for Doubtful Accounts Receivable Accounts receivable are recorded at the invoiced amounts and do not bear interest. An allowance for doubtful accounts is recorded to provide for estimated losses resulting from uncollectible accounts, and is based principally on specifically identified amounts where collection is deemed doubtful. Additional non-specific allowances are recorded based on historical experience and management’s assessment of a variety of factors related to the general financial condition of our clients, the industry in which we operate and general economic conditions. We review the collectability of individual accounts and assess the adequacy of the allowance for doubtful accounts. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required. Contingent Liabilities A liability is contingent if the amount is not presently known, but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments. Fixed Assets Fixed assets are stated at cost. Depreciation and amortization are computed on the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred. Business Combinations Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated statements of operations. Goodwill and Intangible Assets Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, we must determine the amount of implied goodwill that would be established if the reporting unit was hypothetically acquired on the impairment test date. If the carrying amount of a reporting unit’s goodwill exceeds the amount of implied goodwill, an impairment loss equal to the excess would be recorded. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of the asset to its estimated fair value. If we determine that the carrying value of the asset exceeds its estimated fair value, an impairment loss equal to the excess would be recorded. The determination of the fair value of our reporting units is based on a combination of a market approach that considers benchmark company market multiples and an income approach that uses discounted cash flows for each reporting unit utilizing Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent income projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions based on our historical experience, our expectations of future performance, and the expected economic environment. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the fair values estimated for our reporting units. Accounting guidance also requires that definite-lived intangible assets be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize the value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time. Long-Lived Assets and Long-Lived Assets to Be Disposed Of We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Software Development Costs We capitalize purchased software that is ready for service and software development costs incurred from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years. At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine in the future that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value may be recorded as a charge to earnings. The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2015 2014 Software development costs $ 200,531 $ 213,601 Less: accumulated amortization (114,756 ) (127,448 ) Software development costs, net $ 85,775 $ 86,153 Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Capitalized software development costs $ 46,464 $ 45,461 $ 42,026 Write-offs of capitalized software development costs $ - $ 1,444 $ 5,234 Amortization of capitalized software developm |
Business Combinations and Other
Business Combinations and Other Investments | 12 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
Business Combinations and Other Investments | 2. Business Combinations and Other Investments Acquisition of Oasis Medical Solutions Limited On July 8, 2014, we acquired the entire capital stock of Oasis Medical Solutions Limited (“Oasis”), a privately-held, Patient Administration System and health informatics solutions provider headquartered in London, United Kingdom, for approximately $20.6 million, in cash. The allocation of the fair value of the consideration transferred is as follows: approximately $0.4 million of acquired cash; approximately $5.4 million of accounts receivable and other current assets; approximately $5.6 million of intangible assets related to technology; approximately $0.3 million related to Oasis’ tradename; approximately $6.5 million of intangible assets related to customer relationships; goodwill of approximately $11.2 million; approximately $0.2 million of fixed assets; approximately $6.7 million of accounts payable, deferred revenue and accruals; and approximately $2.3 million of net deferred tax liabilities. Goodwill was determined based on the residual difference between the fair value of the consideration transferred and the value assigned to tangible and intangible assets and liabilities, and is not deductible for tax purposes. Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of our product offerings with those of Oasis. The acquired intangible assets relating to technology, customer relationships and the Oasis’ tradename will be amortized on a straight-line basis over estimated lives of 10 years, 12 years and 2 years, respectively. The pro forma impact of the Oasis acquisition on current and prior quarters, as well as the net revenue and results of operations of Oasis subsequent to its acquisition for the six months ended December 31, 2014, were not material. The results of operations of Oasis have been included in our consolidated results from the date of acquisition. We did not incur any significant acquisition and integration-related costs related to the Oasis acquisition during the year ended December 31, 2015 or the six months ended December 31, 2014. Acquisition of dbMotion On March 4, 2013, we acquired all of the issued and outstanding share capital of dbMotion Ltd. (“dbMotion”), a leading supplier of community health solutions, for aggregate consideration with a fair value of approximately $226 million. Immediately prior to the closing, we owned approximately 4.25% of the issued and outstanding share capital of dbMotion on a fully diluted basis. In addition, prior to the acquisition we had an ongoing strategic relationship with dbMotion in connection with the development and sale of software solutions to hospitals, physicians and other participants in the healthcare industry. The total fair value of consideration transferred for the acquisition is comprised of the following: (In thousands) Cash $ 140,079 Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share 48,061 Deferred cash consideration payable on the 18-month anniversary of the closing 23,023 Subordinated promissory note maturing 18 months following the closing 6,648 Fair value of Allscripts' previous interest in dbMotion 8,367 Total fair value of consideration transferred $ 226,178 The carrying value of our 4.25% interest in dbMotion prior to the acquisition was approximately $5.0 million, accounted for using the cost method. In connection with the acquisition, this investment was remeasured to a fair value of approximately $8.4 million resulting in a gain of approximately $3.4 million, which is included in other income, net, in the accompanying consolidated statement of operations and other losses, net in the accompanying consolidated statement of cash flows for the year ended December 31, 2013. The remeasured fair value of our prior interest in dbMotion was estimated based on the fair value of consideration transferred to acquire the remaining 95.75% of dbMotion, less an estimated control premium of 15%. The inputs into this fair value estimate reflect our market assumptions based on premiums observed in similar transactions within our industry. Under the acquisition method of accounting, the fair value of consideration transferred was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. During the three months ended March 31, 2014, we finalized t : (In thousands) Acquired cash and cash equivalents, and restricted cash $ 14,188 Accounts receivable, net 3,226 Prepaid expenses and other current assets 574 Fixed assets and other long-term assets 1,449 Goodwill 137,649 Intangible assets 85,450 Accounts payable and accrued liabilities (10,560 ) Deferred taxes, net (36 ) Deferred revenue (5,100 ) Other liabilities (662 ) Net assets acquired $ 226,178 Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of ours and dbMotion’s product offerings. The goodwill is not deductible for tax purposes. The acquired intangible assets are being amortized on a straight-line basis over their useful lives and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Core technology 10 $ 80,100 Maintenance agreements 12 2,500 Services backlog 2 2,000 Non-compete 3 500 Trade name 2 350 $ 85,450 Acquisition costs related to the dbMotion acquisition are included in selling, general and administrative expenses in the accompanying consolidated statement of operations and totaled approximately $3.7 million and $7.6 million, respectively, for the years ended December 31, 2014 and 2013. These costs include employee compensation costs of $3.7 million and $5.9 million, respectively, for the years ended December 31, 2014 and 2013, and $0.5 million of seller transaction costs for the year ended December 31, 2013. In addition, we incurred $5.5 million for the year ended December 31, 2013 related to product consolidation activities, which are included in asset impairment charges in the accompanying consolidated statement of operations. We did not incur any significant acquisition costs related to the dbMotion acquisition during the year ended December 31, 2015. The following unaudited supplemental pro forma results were calculated after applying our accounting policies and adjusting the results of dbMotion to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2012, together with the consequential tax effects. Supplemental pro forma results for the year ended December 31, 2013 were also adjusted to exclude acquisition-related costs incurred during the period as well as the nonrecurring gain related to the fair value adjustment of our prior cost method investment in dbMotion. The effects of transactions between us and dbMotion during the period presented have been eliminated. The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the year ended December 31, 2013, and the unaudited supplemental pro forma revenue and net loss of the combined entity, are as follows: Year ended (In thousands, except per share amounts) December 31, 2013 (Unaudited) Actual from dbMotion since acquisition date of March 4, 2013: Revenue $ 18,609 Net loss $ (16,272 ) Supplemental pro forma data for combined entity: Revenue $ 1,378,267 Net loss $ (105,119 ) Net loss per share, basic and diluted $ (0.59 ) Amortization of software development and acquisition-related assets in our consolidated statement of operations for the year ended December 31, 2014 includes approximately ($0.8) million related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately ($0.2) million related to software delivery, support and maintenance, and approximately ($0.6) million related to client services. Amortization of software development and acquisition-related assets in our consolidated statement of operations for the year ended December 31, 2013 includes approximately $7.1 million related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately $5.8 million related to software delivery, support and maintenance, and approximately $1.3 million related to client services. Acquisition of Jardogs Also on March 4, 2013, we acquired substantially all of the assets of The pro forma impact of the Jardogs acquisition on current and prior periods, as well as the net revenues and operating losses generated by Jardogs subsequent to its acquisition for the year ended December 31, 2013, were not material. Acquisition costs related to the Jardogs acquisition are included in selling, general and administrative expenses and totaled approximately $0.7 million for the year ended December 31, 2013. We did not incur any significant acquisition and integration-related costs related to the Jardogs acquisition during the years ended December 31, 2015 and 2014. Other Investments On June 26, 2015 we purchased 59,099,908 Series G Units of Nant Health, LLC (“NantHealth”), a cloud-based information technology company that offers comprehensive genomic and protein-based molecular diagnostic testing, for approximately $200.0 million and incurred approximately $5.4 million of transaction-related expenses, resulting in a total investment of approximately $205.4 million. This investment represents a 10% ownership stake, excluding authorized but unissued common units of NantHealth, and is accounted for under the equity method. Additionally, the carrying amount of our investment at December 31, 2015 exceeded the amount of our share of underlying equity in net assets of NantHealth at September 30, 2015 by approximately $180 million. The excess carrying value over the underlying equity in net assets of NantHealth is primarily comprised of amortizable intangible assets and nonamortizable goodwill. During the six months ended December 31, 2015, we recorded a loss of $2.3 million representing our share of equity loss of NantHealth based on a one quarter reporting lag and the amortization of cost basis differences associated with the amortizable intangible assets. The carrying value of our investment in NantHealth is included in other assets in the accompanying consolidated balance sheet as of December 31, 2015. On April 17, 2015 we acquired a majority interest in a third party for approximately $11.1 million, and provided a loan to the third party of approximately $9.3 million to refinance its outstanding indebtedness. The financial results of this third party were consolidated with our financial results starting on the date of the transaction, with a proportionate share allocated to minority interest. The allocations of the estimated fair value of the net assets of the third party to goodwill, intangibles and non-controlling interest were approximately $22.3 million, $4.3 million and $11.0 million, respectively. Summarized Financial Information for Equity Method Investments As of December 31, 2015 we had four equity method investments with a combined carrying value of $205.5 million, which included the carrying value of our investment in NantHealth of approximately $203.1 million. As of December 31, 2014 we had one equity method investment with a carrying value of approximately $1.0 million. Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: September 30, December 31, (In thousands) 2015 2014 Current assets $ 58,550 $ 1,486 Noncurrent assets 411,159 1,812 Current liabilities 77,188 3,300 Noncurrent liabilities 166,898 2,191 Equity of equity method investments $ 225,623 $ (2,193 ) (In thousands) Trailing Twelve Months Ended September 30, 2015 Trailing Twelve Months Ended September 30, 2014 Revenue $ 33,896 $ 2,422 Net loss (20,256 ) (484 ) |
Fixed Assets
Fixed Assets | 12 Months Ended |
Dec. 31, 2015 | |
Property Plant And Equipment [Abstract] | |
Fixed Assets | 3. Fixed Assets Fixed assets consist of the following: Estimated December 31, December 31, (Dollar amounts in thousands) Useful Life 2015 2014 Computer equipment and software 3 to 10 years $ 304,032 $ 284,185 Facility furniture, fixtures and equipment 5 to 7 years 20,302 19,846 Leasehold improvements 7 to 8 years, or life of lease if shorter 30,619 30,795 Assets under capital lease 3 to 5 years 3,266 2,873 Fixed assets, gross 358,219 337,699 Less: Accumulated depreciation and amortization (232,602 ) (191,869 ) Fixed assets, net $ 125,617 $ 145,830 Fixed assets depreciation and amortization expense were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Fixed assets depreciation and amortization expense $ 42,153 $ 48,465 $ 52,545 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | 4. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: December 31, 2015 December 31, 2014 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 450,852 $ (302,284 ) $ 148,568 $ 451,087 $ (267,547 ) $ 183,540 Customer contracts and relationships 552,395 (405,317 ) 147,078 550,287 (382,465 ) 167,822 Total $ 1,003,247 $ (707,601 ) $ 295,646 $ 1,001,374 $ (650,012 ) $ 351,362 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,222,601 1,200,746 Total $ 1,274,601 $ 1,252,746 We revised our reportable segments effective, January 1, 2015 as we completed our transition, which we initiated in 2013, from a functional organization to a strategic business unit model solely aligned with our key products and in order to align our reporting structure with our chief operating decision maker’s (our “CODM”) management of resource allocation and performance assessment. Under our revised organizational structure, we identified two reportable segments: Clinical and Financial Solutions and Population Health. Refer to Note 13, “Business Segments” for additional information. As a result of the revision of our reportable segments, we assessed our revised reporting units and allocated goodwill previously assigned to our former Outsourcing and Remote Hosting reporting units to our other reporting units. The allocated goodwill balances could be attributed to specific services associated with products purchased as part of businesses we previously acquired and, therefore, were allocated to the reporting units where such products are currently managed and sold. The resulting allocation of goodwill to our revised reportable segments is shown in the table below. There were no accumulated impairment losses associated with our goodwill as of December 31, 2015 or 2014, and no impairments were recorded during the years ended December 31, 2015, 2014 and 2013. Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2015 and 2014 were as follows: Clinical and Population (In thousands) Financial Solutions Health Total Balance as of December 31, 2013 $ 764,369 $ 425,216 $ 1,189,585 Additions arising from business acquisitions: Oasis 11,155 0 11,155 dbMotion - 1,018 1,018 Total additions to goodwill 11,155 1,018 12,173 Foreign exchange translation (1,012 ) 0 (1,012 ) Balance as of December 31, 2014 $ 774,512 $ 426,234 $ 1,200,746 Other additions 22,319 0 22,319 Foreign exchange translation (464 ) 0 (464 ) Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 1,222,601 In connection with our acquisition of Oasis, during the year ended December 31, 2014, we recognized additional goodwill of approximately $11.2 million. In addition, during the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration we paid in connection with our acquisitions of dbMotion and Jardogs, which resulted in Other additions relate to goodwill arising from our acquisition of a majority interest in a third party during the three months ended June 30, 2015. We performed a goodwill impairment test as of January 1, 2015 in conjunction with the revision of our reportable segments and related allocation of goodwill to our revised reporting units. We also performed our annual goodwill impairment test as of October 1, 2015, our annual testing date. The fair value of each reporting unit substantially exceeded its carrying value and no indicators of impairment were identified as a result of both tests. We determined the fair value of each of our reporting units using a discounted cash flow analysis and a market approach considering benchmark company market multiples. A discount rate of 10% was applied to the cash flows used in the discounted cash flow analysis. We also considered our market capitalization as of the date of each test. Intangible assets are being amortized over their estimated useful lives and amortization expense related to intangible assets was as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Proprietary technology amortization included in cost of revenue $ 35,144 $ 35,924 $ 33,970 Intangible amortization included in operating expenses 23,172 31,280 31,253 Total intangible amortization expense $ 58,316 $ 67,204 $ 65,223 The decrease in amortization expense for the year ended December 31, 2015 compared with the year ended December 31, 2014 was primarily driven by amortization associated with intangible assets that were fully amortized in 2014. Estimated future amortization expense for the intangible assets that exist as of December 31, 2015, based on foreign currency exchange rates in effect as of such date, is as follows: Year Ended December 31, (In thousands) 2016 $ 45,515 2017 40,401 2018 33,712 2019 33,712 2020 33,008 Thereafter 109,298 Total $ 295,646 |
Asset Impairment Charges
Asset Impairment Charges | 12 Months Ended |
Dec. 31, 2015 | |
Asset Impairment Charges [Abstract] | |
Asset Impairment Charges | 5. Asset Impairment Charges During the year ended December 31, 2015, we recorded asset impairment charges of approximately $1.2 million associated with a decline in the value of a commercial agreement and wrote-off certain deferred costs that were determined to be unrealizable of approximately $0.3 million. In order to better serve our clients and the healthcare market, in October 2012 we initiated a MyWay convergence program aimed at converging, over time, our MyWay and Professional Suite small office EHR and practice management systems. We concluded the MyWay convergence program during the second quarter of 2014. As a result, we recorded non-cash charges to earnings of approximately $0.8 million and $5.0 million during the years ended December 31, 2014 and 2013, respectively, related to the write-off of certain deferred costs relating to MyWay, which were determined to be unrealizable. During the year ended December 31, 2014, we also recorded $1.6 million of non-cash capitalized software impairment charges as a result of our decision to discontinue several software development projects, while during the year ended December 31, 2013, we also recorded approximately $6.5 million of software and fixed asset impairment non-cash charges primarily related to product consolidation activities associated with the dbMotion acquisition. Year Ended December 31, (In thousands) 2015 2014 2013 Asset impairment charges $ 1,544 $ 2,390 $ 11,454 |
Debt
Debt | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Debt | 6. Debt Debt outstanding, excluding capital lease obligations, consisted of the following: December 31, 2015 December 31, 2014 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 61,771 $ 283,229 $ 345,000 $ 73,765 $ 271,235 Senior Secured Credit Facility (long-term portion) 334,375 5,225 329,150 272,410 4,452 267,958 Senior Secured Credit Facility (current portion) 12,500 479 12,021 28,125 892 27,233 Other debt 183 0 183 0 0 0 Total debt $ 692,058 $ 67,475 $ 624,583 $ 645,535 $ 79,109 $ 566,426 Interest expense consisted of the following: Year Ended December 31, (In thousands) 2015 2014 2013 Interest expense $ 16,284 $ 16,020 $ 14,703 Amortization of discounts and debt issuance costs 13,679 13,277 9,451 Write off of unamortized deferred debt issuance costs 1,433 0 3,901 Total interest expense $ 31,396 $ 29,297 $ 28,055 1.25% Cash Convertible Senior Notes due 2020 On June 18, 2013, we issued $345.0 million aggregate principal amount of the 1.25% Cash Convertible Senior Notes due 2020 (the “1.25% Notes”). The aggregate net proceeds of the 1.25% Notes were $305.1 million, after payment of the net cost of the 1.25% Notes Call Spread Overlay (as described below) and transaction costs. Interest on the 1.25% Notes is payable semiannually in arrears on January 1 and July 1 of each year, at a fixed annual rate of 1.25% commencing on January 1, 2014. The 1.25% Notes will mature on July 1, 2020 unless repurchased or converted in accordance with their terms prior to such date. The 1.25% Notes are convertible only into cash, and not into shares of our common stock or any other securities. Holders may convert their 1.25% Notes solely into cash at their option at any time prior to the close of business on the business day immediately preceding January 1, 2020 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2013 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period immediately after any five consecutive trading day period in which the trading price per $1,000 principal amount of the 1.25% Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after January 1, 2020 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 1.25% Notes solely into cash at any time, regardless of the foregoing circumstances. Upon conversion, in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount of the 1.25% Notes, equal to the settlement amount, determined in the manner set forth in the Indenture. The initial conversion rate will be 58.1869 shares of our common stock per $1,000 principal amount of the 1.25% Notes (equivalent to an initial conversion price of approximately $17.19 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, we will pay a cash make-whole premium by increasing the conversion rate for a holder who elects to convert such holder’s 1.25% Notes in connection with such a corporate event in certain circumstances. We may not redeem the 1.25% Notes prior to the maturity date, and no sinking fund is provided for the 1.25% Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or part of their 1.25% Notes at a repurchase price equal to 100% of the principal amount of the 1.25% Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture provides for customary events of default, including cross acceleration to certain other indebtedness of ours, and our subsidiaries. The 1.25% Notes are senior unsecured obligations, and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 1.25% Notes; equal in right of payment to any of our unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. The 1.25% Notes contain an embedded cash conversion option. We have determined that the embedded cash conversion option is a derivative financial instrument, required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the 1.25% Notes, refer to Note 11, “Derivative Financial Instruments.” The reduced carrying value of the 1.25% Notes resulted in a debt discount that is amortized to the 1.25% Notes’ principal amount through the recognition of non-cash interest expense over the expected life of the 1.25% Notes, which extends through their maturity date of July 1, 2020. This has resulted in our recognition of interest expense on the 1.25% Notes at an effective rate approximating what we would have incurred had nonconvertible debt with otherwise similar terms been issued. The effective interest rate of the 1.25% Notes was 5.4%, which was imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the 1.25% Notes. As of December 31, 2015, we expect the 1.25% Notes to be outstanding until their July 1, 2020 maturity date, for a remaining amortization period of approximately four and a half years. As of December 31, 2015, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes principal amount. In connection with the settlement of the 1.25% Notes, we paid approximately $8.4 million in transaction costs. Such costs have been allocated to the 1.25% Notes, the 1.25% Call Option (as defined below) and the 1.25% Warrants (as defined below). The amount allocated to the 1.25% Notes, or $8.3 million, was capitalized and will be amortized over the term of the 1.25% Notes. The remaining aggregate amounts allocated to the 1.25% Call Option and 1.25% Warrants were not significant. The outstanding capitalized amount of transaction costs related to the 1.25% Notes was $5.3 million and is reported as a reduction of long-term debt on our consolidated balance sheet as of December 31, 2015. Interest expense related to the 1.25% Notes was comprised of the following: Year Ended December 31, (In thousands) 2015 2014 2013 Coupon interest at 1.25% $ 4,312 $ 4,312 $ 2,312 Amortization of discounts and debt issuance costs 11,994 11,433 5,910 Total interest expense related to the 1.25% Notes $ 16,306 $ 15,745 $ 8,222 Accrued and unpaid interest on the 1.25% Notes of approximately $2.2 million is included in accrued expenses in the accompanying consolidated balance sheet as of December 31, 2015. 1.25% Notes Call Spread Overlay Also in June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions (collectively, the “1.25% Call Option”) and warrant transactions (collectively, the “1.25% Warrants”), with certain of the initial purchasers of the 1.25% Notes (collectively, the “Call Spread Overlay”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. We used $82.8 million of the proceeds from the settlement of the 1.25% Notes to pay for the 1.25% Call Option, and simultaneously received $51.2 million from the sale of the 1.25% Warrants, for a net cash outlay of $31.6 million for the Call Spread Overlay. The 1.25% Call Option is a derivative financial instrument and is discussed further in Note 11, “Derivative Financial Instruments.” The 1.25% Warrants are equity instruments and are further discussed in Note 9, “Stockholders’ Equity.” Senior Secured Credit Facility Amendment On September 30, 2015, we entered into a Replacement Facility Amendment (the “2015 Credit Agreement”) to our existing Credit Agreement, dated as of June 28, 2013, as amended on June 8, 2015, with a syndicate of financial institutions and JPMorgan Chase Bank, N.A., as administrative agent. The 2015 Credit Agreement provides for a $250 million senior secured term loan (the “Term Loan”) and a $550 million senior secured revolving facility (the “Revolving Facility”), each with a five year term (collectively the “Senior Secured Credit Facility”). These amounts represent increases in total borrowing limits of $25 million and $125 million, respectively, compared with our existing Credit Agreement. The Term Loan is repayable in quarterly installments which commenced on December 31, 2015 and end on September 30, 2020. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies. Proceeds from the borrowings under the 2015 Credit Agreement were used for the refinancing of the term loan and revolving facility under our existing Credit Agreement. The proceeds of the Revolving Facility can be used to finance our working capital needs and for general corporate purposes, including financing of permitted acquisitions, share repurchases, and other investments. We may also request to add one or more incremental revolving and/or term loan facilities in an aggregate amount of up to $300 million, subject to certain conditions. Borrowings under the Senior Secured Credit Facility bear interest, at our option, at a rate per annum equal to either (1) the rate (adjusted for statutory reserve requirements for eurocurrency liabilities and mandatory costs, if any) for deposits in the applicable currency for a period equal to one, two, three or six months or, with respect to loans under the Revolving Facility denominated in United States dollars, subject to availability to all affected lenders, 7 days (as selected by us), appearing on pages LIBOR01, LIBOR02, EURIBOR01, as applicable, or other page displaying such rate for such currency of the Reuters Screen (the “Eurocurrency Rate”) plus the applicable margin or (2) the highest of (a) the rate of interest publicly announced by JPMorgan Chase Bank, N.A. as its prime rate in effect at its principal office in New York City, (b) the federal funds effective rate from time to time plus 0.5%, and (c) the Eurocurrency Rate for United States dollars for a one month interest period plus 1.0% (the “Base Rate”), plus, in each case, the applicable margin. The initial applicable interest rate margin for Base Rate borrowings is 1.25%, and for Eurocurrency Rate borrowings is 2.25%. Since September 30, 2015, the applicable interest rate margins are determined from a pricing table and will depend upon our total leverage ratio. The applicable interest rate margins under the 2015 Credit Agreement for Base Rate borrowings range from 0.00% to 1.25% and for Eurocurrency Rate loans range from 1.00% to 2.25%. These ranges are 50 basis points lower at each level of the leverage-based pricing grid compared with our existing Credit Agreement. Subject to certain agreed upon exceptions, all obligations under the Senior Secured Credit Facility remain guaranteed by each of our existing and future direct and indirect material domestic subsidiaries other than Coniston Exchange LLC and certain domestic subsidiaries owned by our foreign subsidiaries (the “Guarantors”) pursuant to a related Guarantee and Collateral Agreement, dated as of June 28, 2013, among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, certain of our other subsidiaries, and JPMorgan Chase Bank, N.A., as administrative agent. Our obligations under the Senior Secured Credit Facility, any swap agreements and any cash management arrangements provided by any lender, remain secured, subject to permitted liens and other agreed upon exceptions, by a perfected first priority security interest in all of the tangible and intangible assets (including, without limitation, intellectual property, material owned real property and all of the capital stock of each Guarantor and, in the case of foreign subsidiaries, up to 65% of the capital stock of first tier material foreign subsidiaries) of Allscripts Healthcare Solutions, Inc. and certain of our subsidiary guarantors. The Senior Secured Credit Facility requires us to maintain a minimum interest coverage ratio of 4.0 to 1.0, a maximum total leverage ratio of 4.0 to 1.0 and a maximum senior secured leverage ratio of 3.0 to 1.0. The minimum interest coverage ratio is calculated by dividing earnings before interest expense, income tax expense, depreciation and amortization expense by cash interest expense, subject to various agreed upon adjustments. The total leverage ratio is calculated by dividing total indebtedness by earnings before interest expense, income tax expense, depreciation and amortization expense, subject to various agreed upon adjustments. The senior secured leverage ratio is calculated by dividing senior secured indebtedness by earnings before interest expense, income tax expense, depreciation and amortization expense, subject to various agreed upon adjustments. The 2015 Credit Agreement also provides that during the four quarter period following permitted acquisitions that are financed in whole or in part with indebtedness and the consideration paid by us is $100 million or more, we are required to maintain a maximum total leverage ratio of 4.5 to 1.0 and a maximum senior secured leverage ratio of 3.25 to 1.0. In addition, the 2015 Credit Agreement requires mandatory prepayments of the debt outstanding under the Senior Secured Credit Facility in certain specific circumstances, and contains a number of covenants which, among other things, restrict our ability to incur additional indebtedness, engage in mergers, or declare dividends or other payments in respect of our capital stock. The Senior Secured Credit Facility also contains certain customary events of default, including relating to non-payment, breach of covenants, cross-default, bankruptcy and change of control. In connection with our entry into the 2015 Credit Agreement, during the year ended December 31, 2015, we incurred fees and other costs totaling approximately $3.0 million, of which approximately $2.7 million were capitalized and included in the net carrying amounts outstanding under the Senior Secured Credit Facility as of December 31, 2015. In addition, approximately $3.3 million of deferred costs associated with our existing Credit Facility carried over to the 2015 Credit Agreement. Also, in connection with our entry into the 2015 Credit Agreement, approximately $1.1 million of deferred costs associated with our existing Credit Agreement and approximately $0.3 million of fees and other costs associated with the 2015 Credit Agreement were written off to interest expense and are included in other losses, net in the accompanying consolidated statement of cash flows for the year ended December 31, 2015. As of December 31, 2015, approximately $246.9 million under the Term Loan, $100.0 million under the Revolving Facility, and $0.7 million in letters of credit were outstanding under the 2015 Credit Agreement. The increase in the principal balance outstanding under the Senior Secured Credit Facility at December 31, 2015 compared with December 31, 2014 was primarily driven by $100.0 million borrowed under the Revolving Facility during the three months ended June 30, 2015 to finance a portion of our investment in NantHealth. Refer to Note 2, “Business Combinations and Other Investments” for additional information about this transaction As of December 31, 2015, the interest rate on the Senior Secured Credit Facility was LIBOR plus 2.00%, which totaled 2.42%. We were in compliance with all financial covenants under the 2015 Credit Agreement as of December 31, 2015. The net carrying amounts of debt outstanding as of December 31, 2014 were adjusted to reflect the reclassification of approximately $9.5 million of deferred debt issuance costs previously included within other assets on our consolidated balance sheet as of December 31, 2014 as a result of adopting ASU 2015-03 during the three months ended June 30, 2015. As of December 31, 2015, we had approximately $449.3 million available, net of outstanding letters of credit, under the Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes our future payments under the 1.25% Notes and the Senior Secured Credit Facility as of December 31, 2015: (In thousands) Total 2016 2017 2018 2019 2020 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 Term Loan 246,875 12,500 15,625 28,125 40,625 150,000 Revolving Facility 100,000 0 0 0 0 100,000 Other debt 183 183 0 0 0 0 Total debt $ 692,058 $ 12,683 $ 15,625 $ 28,125 $ 40,625 $ 595,000 (1) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 7. Income Taxes The following is a geographic breakdown of income (loss) before income tax benefits: Year Ended December 31, (In thousands) 2015 2014 2013 United States $ (5,357 ) $ (62,987 ) $ (137,468 ) Foreign 5,927 (5,130 ) (10,878 ) Total income (loss) before income taxes $ 570 $ (68,117 ) $ (148,346 ) The following is a summary of the components of the provision (benefit) for income taxes: Year Ended December 31, (In thousands) 2015 2014 2013 Current tax provision Federal $ 570 $ 840 $ (448 ) State 658 213 1,421 Foreign 4,083 (399 ) 45 5,311 654 1,018 Deferred tax provision Federal (2,928 ) (581 ) (43,542 ) State 898 (3,261 ) (7,929 ) Foreign (655 ) 1,524 6,133 (2,685 ) (2,318 ) (45,338 ) Income tax provision (benefit) $ 2,626 $ (1,664 ) $ (44,320 ) Taxes computed at the statutory federal income tax rate of 35% are reconciled to the provision for income taxes as follows: Year Ended December 31, (In thousands) 2015 2014 2013 United States federal tax at statutory rate $ 138 $ (23,844 ) $ (51,921 ) Items affecting federal income tax rate Non-deductible acquisition and reorganization expenses (2 ) (56 ) 234 Research credits (3,000 ) (3,133 ) (7,454 ) Change in unrecognized tax benefits (208 ) (519 ) 1,665 State income taxes, net of federal benefit 182 (2,120 ) (4,841 ) Compensation 765 1,017 844 Meals and entertainment 1,023 954 1,052 Impact of foreign operations 1,848 2,505 1,559 Provision-to-Return adjustments (136 ) 0 0 Settlements with taxing authorities (4,218 ) 0 0 Deemed Dividends 1,408 0 0 Dividends Accrued 1,190 0 0 Federal, state and local rate changes 1,104 (268 ) (1,056 ) Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement 0 0 (4,432 ) Bilateral Advance Pricing Agreement impact 524 (199 ) 4,794 Non-deductible items (5 ) 82 82 Valuation allowance 1,816 24,666 13,627 Other 197 (749 ) 1,527 Effective rate $ 2,626 $ (1,664 ) $ (44,320 ) Significant components of our deferred tax assets and liabilities consist of the following: December 31, December 31, (In thousands) 2015 2014 Deferred tax assets Accruals and reserves, net $ 24,548 $ 26,086 Allowance for doubtful accounts 12,194 14,159 Stock-based compensation, net 12,086 10,773 Deferred revenue 13,294 17,422 Net operating loss carryforwards 78,909 90,463 Research and development tax credit 26,863 24,313 AMT credits 6,070 5,606 Other 7,012 3,617 Less: Valuation Allowance (43,043 ) (41,273 ) Total deferred tax assets 137,933 151,166 Deferred tax liabilities Prepaid expense (8,594 ) (9,268 ) Property and equipment, net (3,953 ) (903 ) Acquired intangibles, net (145,252 ) (160,130 ) Total deferred tax liabilities (157,799 ) (170,301 ) Net deferred tax liabilities $ (19,866 ) $ (19,135 ) The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows: December 31, December 31, (In thousands) 2015 2014 Non-current deferred tax assets, net 2,298 1,984 Non-current deferred tax liabilities, net (22,164 ) (21,119 ) Non-current deferred tax liabilities, net (19,866 ) (19,135 ) As of December 31, 2015 and 2014, we had federal net operating loss (“NOL”) carryforwards of $238 million and $278 million, respectively. Of the total federal NOL carryforwards, approximately $11 million relates to stock-based compensation tax deductions that will be tax-effected and the related benefit credited to additional paid-in capital when realized. As of December 31, 2015 and 2014, we had state NOL carryforwards of approximately $5 million and $8 million, respectively. The NOL carryforwards expire in various amounts starting in 2020 for both federal and state tax purposes. The utilization of the federal NOL carryforwards is subject to limitation under the rules regarding changes in stock ownership as determined by the Internal Revenue Code. Our historical federal NOLs are subject to annual limitation on usage of approximately $62 million per year. In connection with our merger with Eclipsys Corporation (the “Eclipsys Merger”) in 2010, we acquired federal NOLs totaling approximately $265 million. Due to the change in control in Eclipsys, these NOLs are subject to annual limitation on utilization of approximately $48 million per year. NOLs incurred subsequent to the Eclipsys Merger have no restrictions on utilization. We have Israeli NOL carryovers of approximately $74 million that do not expire. We use the tax law ordering approach for determining when tax benefits derived from stock-based awards are utilized. Under this approach, the utilization of excess tax deductions associated with stock-based awards is dictated by provisions in the tax law that identify the sequence in which such benefits are utilized for tax purposes when net operating losses exist. For federal purposes, 2013 to 2014 tax years remain subject to income tax examination by federal authorities. For our state tax jurisdictions, 2004 to 2014 tax years remain open to income tax examination by state tax authorities. In Canada, the 2011 to 2014 tax years remain open for examination and in India the 2011 to 2014 tax years remain open. We have a subsidiary in India that is entitled to a tax holiday that allows for tax-free operations during such tax holiday. The tax holiday for the subsidiary began to partially expire in 2012 and will fully expire in 2017. Tax savings realized from this holiday totaled $0.4 million, $0.8 million and $0.6 million for the years ended December 31, 2015, 2014 and 2013, respectively, which reduced our diluted loss per share by less than $0.01 in each of those years. US GAAP principles prescribe a threshold of more-likely-than-not to be sustained upon examination for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These principles also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Changes in the amounts of unrecognized tax benefits were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Beginning balance as of January 1 $ 15,314 $ 18,283 $ 18,140 Increases for tax positions related to the current year 600 627 1,517 Decreases for tax positions related to prior years 0 (3,239 ) (23 ) Increases for tax positions related to prior years 50 173 3,238 Decreases relating to settlements with taxing authorities (3,805 ) (384 ) (4,099 ) Foreign currency translation (24 ) (26 ) (394 ) Reductions due to lapsed statute of limitations (358 ) (120 ) (96 ) Ending balance as of December 31 $ 11,777 $ 15,314 $ 18,283 During 2013, we completed a Bilateral Advance Pricing Agreement (“BAPA”) with the Canada Revenue Authority and the IRS covering the years 2003 through 2016. This BAPA provides certainty with respect to transactions between our Canadian entity and our US entity. Relating to these transactions, we had previously recorded $4.4 million in uncertain tax benefits, which we reversed during the three months ended December 31, 2013 and recognized as a tax benefit. This benefit was offset by the reversal of an indirect tax benefit of the uncertain tax benefit of $6.3 million, recorded as a tax expense. We also recorded a $1.6 million tax benefit for the estimated impacts of amended returns required under the BAPA, resulting in a net impact of $0.3 million in tax expense recorded during the three months ended December 31, 2013. During the three months ended September 30, 2015, we concluded our IRS audit for all open years through December 31, 2012. The conclusion of this audit provided us with confirmation about the NOL carryforwards actual balance as of December 31, 2012. As a result, we recognized certain unrecognized income tax benefits totaling approximately $4.0 million during the three months ended September 30, 2015. The recognition of these benefits did not impact our effective tax rate due to the valuation allowance. We were not able to obtain confirmation regarding the actual balance of our research and development credit carryforwards because none of these research and development credits have been utilized against any tax liability as of the date of this Form 10-K. Therefore, our analysis of eligible research and development credit carryforwards remains unchanged. We had gross unrecognized tax benefits of approximately $11.8 million and $15.3 million as of December 31, 2015 and 2014, respectively. If the current gross unrecognized tax benefits were recognized, the result would be an increase in our income tax benefit of $1.5 million and $2.3 million, respectively. These amounts are net of accrued interest and penalties relating to unrecognized tax benefits of approximately $1.2 million and $1.3 million, respectively. We believe that it is reasonably possible that approximately $2.5 million of our currently remaining unrecognized tax benefits may be recognized by the end of 2016, as a result of audit settlements and/or a lapse of the applicable statute of limitations. We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Interest and penalties included in the provision for income taxes $ (103 ) $ (715 ) $ (188 ) The amount of interest and penalties included in our consolidated balance sheets is as follows: December 31, December 31, (In thousands) 2015 2014 Interest and penalties included in the liability for uncertain tax positions $ 1,193 $ 1,295 During the years ended December 31, 2015 and 2014, we recorded valuation allowances of $1.7 million and $25.8 million, respectively, for federal credit carryforwards, and foreign and state NOL carryforwards. In evaluating our ability to recover our deferred tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Using all available evidence, we determined that it was uncertain that we will realize the deferred tax asset for certain of these carryforwards within the carryforward period. Our effective rate was higher for the year ended December 31, 2015 as compared with the prior year, primarily due to the impacts of permanent items, such as non-deductible meals and entertainment and officer compensation, and the impacts of foreign operations on the near break-even pre-tax income for the current year as compared with the prior year pre-tax loss. On December 18, 2015, the Consolidated Appropriations Act of 2016 was enacted into law, which both reinstated retroactively to January 1, 2015 the research and development credit and made it permanent. Our effective tax rate for 2015 includes the impact of the estimated 2015 credit of $3.0 million. We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United States. We are subject to the continuous examination of our income tax returns by the IRS and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements. We intend to indefinitely reinvest the undistributed earnings of our foreign subsidiaries. We have formal sales proposals in a number of foreign subsidiaries that would require this investment. Accordingly, no deferred taxes have been recorded for the difference between the financial and tax basis investment in our foreign subsidiaries. If these earnings were distributed to the United States in the form of dividends or otherwise, we would have additional United States taxable income and, depending on our tax position in the year of repatriation, may have to pay additional United States income taxes. Withholding taxes may also apply to the repatriated earnings. Determination of the amount of unrecognized income tax liability related to these permanently reinvested and undistributed foreign subsidiary earnings is currently not practicable. There are limited instances where we may repatriate only current year earnings of any subsidiary at the discretion of management. We will record deferred taxes for these instances on a case by case basis. There is a current intent to repatriate all current 2015 earnings of the India subsidiary, and all estimated deferred taxes have been accrued and reflected in our consolidated balance sheet and statement of operations for the year ended December 31, 2015. During 2015, we determined that approximately $44.4 million of these foreign subsidiaries’ undistributed earnings are now indefinitely reinvested outside the United States. As we have determined that the earnings of these subsidiaries are not required as a source of funding for our United States operations, such earnings are not planned to be distributed to the United States in the foreseeable future. |
Stock Award Plans
Stock Award Plans | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Award Plans | 8. Stock Award Plans Our Amended and Restated 2011 Stock Incentive Plan (“Plan”) provides for the granting of stock options, service-based share awards, performance-based share awards and market-based share awards, among other awards. As of December 31, 2015, there were 5.7 million shares of common stock reserved for issuance under future share-based awards to be granted to any of our employees, officers, directors or independent consultants at terms and prices to be determined by our Board, and subject to the terms of the Plan. We recorded stock-based compensation expense as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Cost of revenue: Software delivery, support and maintenance $ 4,224 $ 1,492 $ 1,746 Client services 4,508 4,422 3,898 Total cost of revenue 8,732 5,914 5,644 Selling, general and administrative expenses 20,069 25,376 23,013 Research and development 7,826 7,964 8,353 Total stock-based compensation expense $ 36,627 $ 39,254 $ 37,010 The estimated income tax benefit of stock-based compensation expense included in the provision for income taxes for the year ended December 31, 2015 is approximately $7 million. No stock-based compensation costs were capitalized during the years ended December 31, 2015, 2014 and 2013. The calculation of stock-based compensation expenses includes an estimate for forfeitures at the time of grant. This estimate can be revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. As of December 31, 2015, total unrecognized stock-based compensation expense related to non-vested awards and options was $46.6 million and this expense is expected to be recognized over a weighted-average period of 2.2 years. We issue service-based awards, performance-based, and market-based awards in the form of restricted stock units, stock options or shares. A description of each category of awards is presented below. Service-based Share Awards Service-based share awards include stock options, restricted stock units and restricted shares, and typically vest over a four-year period commencing on the date of grant subject to continued service with the company. Upon termination of an employee’s employment, any unvested service-based share awards are forfeited unless otherwise provided in an employee’s employment agreement. Deferred share units are awarded to directors and vest within one year, when issued in lieu of annual share awards, or immediately, when issued in lieu of cash compensation. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. As of December 31, 2015, there was $37.7 million of total estimated unrecognized stock-based compensation expense related to the service-based share awards which is expected to be recognized over a weighted-average period of 2.3 years. Performance-based Share Awards Performance-based share awards include restricted stock units and restricted shares. The purpose of such awards is to align management’s compensation with our financial performance and other operational objectives and, in certain cases, to retain key employees over a specified performance period. Awards granted under this category are based on the achievement of various targeted financial measures, including, but not limited to, non-GAAP EBITDA and revenue growth, as defined in the grant agreements. The awards are earned based on actual results achieved compared to targeted amounts. Stock-based compensation expense related to these awards is recognized over three-year and four-year vesting periods under the accelerated attribution method if and when we conclude that it is probable that the performance conditions will be achieved. As of December 31, 2015, there was $4.0 million of total estimated unrecognized stock-based compensation expense, assuming various target attainments related to the performance-based share awards, which is expected to be recognized over a weighted-average period of 1.5 years. Market-based Share Awards Market-based share awards include restricted stock units. The purpose of such awards is to align management’s compensation with the performance of our common stock relative to the market. Awards granted under this category are dependent on our total shareholder returns relative to a specified peer group of companies over three-year performance periods with vesting based on three annual performance segments from the grant dates. Fair values of the awards were estimated at the date of the grants using the Monte Carlo pricing model. Following completion of each of the three-year performance periods, the Compensation Committee of our Board will determine the number of awards that would vest considering overall performance over the three-year performance periods. If the number of shares that would vest under this scenario is greater than the amount vesting under the three annual performance segments, then such greater number of awards shall vest, reduced by the number of awards previously vested. Stock-based compensation expense related to these awards will be recognized over three-year vesting periods under the accelerated attribution method. As of December 31, 2015, there was $4.9 million of total estimated unrecognized stock-based compensation expense, assuming various target attainments related to the market-based share awards, which is expected to be recognized over a weighted-average period of 2.1 years. Restricted Stock Units and Awards The following table summarizes the activity for restricted stock units during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock units as of December 31, 2012 6,728 $ 13.43 Awarded 2,511 $ 15.06 Vested (2,023 ) $ 13.77 Forfeited (1,482 ) $ 13.74 Unvested restricted stock units as of December 31, 2013 5,734 $ 13.94 Awarded 2,199 $ 18.09 Vested (2,044 ) $ 13.90 Forfeited (793 ) $ 14.28 Unvested restricted stock units as of December 31, 2014 5,096 $ 15.69 Awarded 2,937 $ 12.07 Vested (1,612 ) $ 14.84 Forfeited (1,042 ) $ 14.74 Unvested restricted stock units as of December 31, 2015 5,379 $ 14.15 The following table summarizes the activity for restricted stock awards during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock awards as of December 31, 2012 20 $ 15.94 Vested (17 ) $ 15.92 Forfeited (3 ) $ 16.05 Unvested restricted stock awards as of December 31, 2013 0 $ 0.00 Vested 0 $ 0.00 Forfeited 0 $ 0.00 Unvested restricted stock awards as of December 31, 2014 0 $ 0.00 Vested 0 $ 0.00 Forfeited 0 $ 0.00 Unvested restricted stock awards as of December 31, 2015 0 $ 0.00 Net Share-settlements Restricted stock units and awards are generally net share-settled upon vesting to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the years ended December 31, 2015, 2014 and 2013 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees’ minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld during the years ended December 31, 2015, 2014 and 2013 were approximately 523 thousand, 669 thousand and 693 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Options The following table summarizes the status of stock options outstanding and the changes during the periods presented: Options Weighted-Average Options Weighted-Average (In thousands, except per share amounts) Outstanding Exercise Price Exercisable Exercise Price Balance as of December 31, 2012 2,667 $ 12.04 2,548 $ 11.88 Options granted 3,870 $ 13.79 Options exercised (1,442 ) $ 8.47 Options forfeited (773 ) $ 14.94 Balance as of December 31, 2013 4,322 $ 14.28 1,025 $ 15.52 Options granted 0 $ 0.00 Options exercised (289 ) $ 11.88 Options forfeited (606 ) $ 15.03 Balance as of December 31, 2014 3,427 $ 14.35 1,393 $ 14.97 Options granted 0 $ 0.00 Options exercised (317 ) $ 11.44 Options forfeited (767 ) $ 15.89 Balance as of December 31, 2015 2,343 $ 14.24 1,282 $ 14.52 We estimate the fair value of our service and performance-based stock option awards on the date of grant using the Black-Scholes-Merton option-pricing model. Option valuation models, including the Black-Scholes-Merton option-pricing model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense. The following table contains the stock option weighted-average grant date fair value information and related valuation assumptions for the year ended December 31, 2013. No stock option awards were granted during the years ended December 31, 2015 and 2014. Stock options granted (in thousands) 3,870 Fair Value per option $ 6.25 Valuation assumptions: Expected term ( in years) 4.8 Expected volatility 54.0 % Expected dividend yield 0 % Risk-free interest rate 0.9 % The stock option grant prices equaled the closing prices of our common stock on the date of grant and the stock options have a contractual term of 7 years. The expected term is based on historical exercise patterns and post-vesting termination behavior, the risk-free interest rate input is based on United States Treasury instruments and the volatility input is calculated based on the implied volatility of our common stock. The aggregate intrinsic value of stock options outstanding and exercisable as of December 31, 2015 was $3.1 million and $1.5 million, respectively, based on our closing stock price of $15.38 as of December 31, 2015. The intrinsic value of stock options outstanding represents the amount that would have been received by the option holders had all option holders exercised their stock options as of that date. The following activity occurred under our plans: Year Ended December 31, (In thousands) 2015 2014 2013 Total intrinsic value of stock options exercised $ 972 $ 1,535 $ 7,500 Total fair value of share awards vested $ 21,673 $ 31,672 $ 28,609 The following table summarizes information about stock options outstanding as of December 31, 2015: Number of Number of Options Weighted-Average Options Weighted-Average Range of Exercise Prices Outstanding Exercise Price Exercisable Exercise Price $12.50 to $14.78 1,917,799 $ 13.79 937,225 $ 13.78 $14.94 to $16.80 364,097 $ 15.91 283,624 $ 16.10 $18.45 to $18.74 60,720 $ 18.51 60,720 $ 18.51 2,342,616 1,281,569 The weighted average remaining contractual life of the options outstanding and exercisable as of December 31, 2015 is 3.7 years. Employee Stock Purchase Plan Our Employee Stock Purchase Plan (the “ESPP”) allows eligible employees to authorize payroll deductions of up to 20% of their base salary to be applied toward the purchase of full shares of common stock on the last business day of each offering period. Offering periods under the ESPP are three months in duration and begin on each March 1 st st st st We treat the ESPP as a compensatory plan in accordance with GAAP. There were approximately 675 thousand and 644 thousand shares purchased under the ESPP during the years ended December 31, 2015 and 2014, respectively. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Stockholders' Equity | 9. Stockholders’ Equity Stock Repurchases In November 2015, our Board authorized a stock repurchase program under which we may repurchase up to $150 million of our common stock through December 31, 2018. Any share repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. No shares were repurchased under this program during the year ended December 31, 2015. Issuance of Common Stock and Warrants In June 2015, we sold 7,434,944 unregistered shares of our common stock previously held as treasury shares and issued warrants to purchase 1,486,989 shares of our common stock to Nant Capital, LLC in a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. These transactions were meant to strengthen our strategic and commercial relationship with NantHealth and were made in conjunction with our investment in NantHealth as of the same date (refer to Note 2, “Business Combinations and Other Investments”). The common stock shares were sold at a price of $13.45 per share, being the average closing price per share of our common stock on the NASDAQ Global Select Market for the 60 consecutive trading day period ending on and including June 24, 2015, for an aggregate purchase price of approximately $100.0 million. Each warrant has an exercise price equal to $17.675 per share of common stock, subject to customary anti-dilution adjustments. The warrants may be exercised from time to time beginning on the date of issuance and expiring 18 months after the date of issuance. The total proceeds of $100.0 million were allocated to the common stock shares and the warrants in the amounts of approximately $98.3 million and $1.7 million, respectively. In June 2013, in connection with the issuance of the 1.25% Notes, we issued the 1.25% Warrants for approximately 20.1 million shares of our common stock (subject to anti-dilution adjustments under certain circumstances) with an initial exercise price of $23.135 per share, subject to customary adjustments. The net proceeds from the sale of the 1.25% Warrants of approximately $51.2 million are included as additional paid in capital in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. The 1.25% Warrants expire over a period of 70 trading days beginning on October 1, 2020 and are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap. For each 1.25% Warrant that is exercised, we will deliver to the option counterparties a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of fractional shares. We will not receive any additional proceeds if the 1.25% Warrants are exercised. The number of warrants and the strike price are subject to adjustment under certain circumstances. The 1.25% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock (as measured under the terms of the warrant transactions) exceeds the applicable strike price of the 1.25% Warrants. In June 2013, we agreed to issue a warrant to a commercial partner as part of an overall commercial relationship pursuant to which the warrant holder has the right to purchase 1.5 million shares of our common stock at a strike price of $12.94 per share. The warrant vests in four equal annual installments of 375 thousand shares (beginning in June 2014) and expires in June 2020. Our issuance of the warrant was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. This warrant is not actively traded and is valued based on an option pricing model that uses observable and unobservable market data for inputs. The warrant was valued at approximately $10.2 million and is being amortized into earnings over the four year vesting period. The amortization of the warrant value is included in stock-based compensation expense in the accompanying consolidated statements of cash flows. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Accumulated Other Comprehensive Loss | 10. Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss Changes in the balances of each component included in accumulated other comprehensive loss (“AOCI”) are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Interest Rate Swap Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2012 (1) $ 892 $ 118 $ (934 ) $ 0 $ 76 Other comprehensive income (loss) before reclassifications (2,482 ) 6 (85 ) 0 (2,561 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 740 0 740 Net other comprehensive (loss) income (2,482 ) 6 655 0 (1,821 ) Balance as of December 31, 2013 (2) (1,590 ) 124 (279 ) 0 (1,745 ) Other comprehensive income (loss) before reclassifications (529 ) 16 (23 ) 0 (536 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 302 0 302 Net other comprehensive (loss) income (529 ) 16 279 0 (234 ) Balance as of December 31, 2014 (3) (2,119 ) 140 0 0 (1,979 ) Other comprehensive (loss) income before reclassifications (2,381 ) 0 0 191 (2,190 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 0 67 (73 ) Net other comprehensive (loss) income (2,381 ) (140 ) 0 258 (2,263 ) Balance as of December 31, 2015 (4) $ (4,500 ) $ 0 $ 0 $ 258 $ (4,242 ) (1) (2) ( 3 ) (4) Income Tax Effects Related to Components of Other Comprehensive Loss The following tables reflect the tax effects allocated to each component of other comprehensive loss (“OCI”) Year Ended December 31, 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,381 ) $ 0 $ (2,381 ) Marketable securities: Net gain arising during the period 0 0 0 Net gain reclassified into income (228 ) 88 (140 ) Net change in unrealized gains on marketable securities (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period 0 0 0 Net loss reclassified into income 0 0 0 Net change in unrealized losses on interest rate swap 0 0 0 Foreign exchange contracts: Net gains (losses) arising during the period 314 (123 ) 191 Net (gains) losses reclassified into income 110 (43 ) 67 Net change in unrealized gains (losses) on foreign exchange contracts 424 (166 ) 258 Net gain (loss) on cash flow hedges 424 (166 ) 258 Other comprehensive loss $ (2,185 ) $ (78 ) $ (2,263 ) Year Ended December 31, 2014 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (529 ) $ 0 $ (529 ) Marketable securities: Net gain arising during the period 25 (9 ) 16 Net gain reclassified into income 0 0 0 Net change in unrealized gains on marketable securities 25 (9 ) 16 Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period (38 ) 15 (23 ) Net loss reclassified into income 496 (194 ) 302 Net change in unrealized losses on interest rate swap 458 (179 ) 279 Foreign exchange contracts: Net gains (losses) arising during the period 0 0 0 Net (gains) losses reclassified into income 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 0 0 0 Net gain (loss) on cash flow hedges 458 (179 ) 279 Other comprehensive loss $ (46 ) $ (188 ) $ (234 ) Year Ended December 31, 2013 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,482 ) $ 0 $ (2,482 ) Marketable securities: Net gain arising during the period 10 (4 ) 6 Net gain reclassified into income 0 0 0 Net change in unrealized gains on marketable securities 10 (4 ) 6 Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period (139 ) 54 (85 ) Net loss reclassified into income 1,215 (475 ) 740 Net change in unrealized losses on interest rate swap 1,076 (421 ) 655 Foreign exchange contracts: Net gains (losses) arising during the period 0 0 0 Net (gains) losses reclassified into income 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 0 0 0 Net gain (loss) on cash flow hedges 1,076 (421 ) 655 Other comprehensive loss $ (1,396 ) $ (425 ) $ (1,821 ) |
Derivative Financial Instrument
Derivative Financial Instruments | 12 Months Ended |
Dec. 31, 2015 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Derivative Financial Instruments | 11. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 December 31, 2014 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 57,091 N/A 1.25% Embedded cash conversion option N/A Other liabilities 57,839 Total derivatives $ 57,091 $ 57,839 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts In 2015, we entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of December 31, 2015, there were 36 forward contracts outstanding that were staggered to mature monthly starting in January 2016 and ending in December 2017. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2017. As of December 31, 2015, the notional amounts of outstanding forward contracts ranged from 20 million to 170 million INR, or the equivalent of $0.3 million to $2.6 million United States dollars, based on the exchange rate between the United States dollar and the INR in effect as of December 31, 2015. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in AOCI and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the year ended December 31, 2015, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of December 31, 2015, we estimate that approximately $0.3 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. Interest Rate Swap Agreement We previously had entered into an interest rate swap agreement with an effective date of October 29, 2010, which expired on October 31, 2014. The critical terms of the interest rate swap agreement and the related debt agreement matched and allowed us to designate the interest rate swap agreement as a highly effective cash flow hedge. As of December 31, 2015, we did not have any outstanding interest rate swap agreements. No gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur during the year ended December 31, 2014. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Year Ended December 31, Year Ended December 31, (In thousands) 2015 2014 2013 2015 2014 2013 Foreign exchange contracts $ 314 $ 0 $ 0 Cost of Revenue $ (34 ) $ 0 $ 0 Selling, general and administrative expenses (28 ) 0 0 Research and development (48 ) 0 0 Interest rate swap $ 0 $ (38 ) $ (139 ) Interest expense $ 0 $ (496 ) $ (1,215 ) 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into the 1.25% Call Option with certain of the initial purchasers of the 1.25% Notes (the “Option Counterparties”). Assuming full performance by the option counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. Aside from the initial payment of a premium to the Option Counterparties of $82.8 million for the 1.25% Call Option, we will not be required to make any cash payments to the Option Counterparties under the 1.25% Call Option, and, subject to the terms and conditions thereof, will be entitled to receive from the Option Counterparties an amount of cash, generally equal to the amount by which the market price per share of common stock exceeds the strike price of the 1.25% Call Option during the relevant valuation period. The strike price under the 1.25% Call Option is initially equal to the conversion price of the 1.25% Notes of $17.19 per share of common stock. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 1, “Basis of Presentation and Significant Accounting Policies.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed next, we expect the net effect of those two derivative instruments on our results of operations to continue to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value recognized immediately in our consolidated statements of operations in other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 1, “Basis of Presentation and Significant Accounting Policies.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Year Ended December 31, (In thousands) 2015 2014 2013 1.25% Call Option $ 23,117 $ (47,565 ) $ 21,856 1.25% Embedded cash conversion option (23,371 ) 47,798 (22,837 ) Net gain (loss) included in other income, net $ (254 ) $ 233 $ (981 ) |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2015 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments | 12. Commitments Operating and Capital Leases We conduct our operations from leased premises under a number of operating leases. We also lease office equipment and vehicles under operating leases. Certain office leases contain renewal options and rent escalation clauses calling for rent increases over the term of the lease. All leases which contain a rent escalation clause are accounted for on a straight-line basis. Total rent expense recognized, which consists of the base rental amount and other lessor charges when mandated in a lease agreement, was as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Rent expense $ 18,164 $ 16,259 $ 17,062 The long-term portion of capital lease obligations is included on the consolidated balance sheet under other liabilities. Our future commitments under capital and operating leases are shown below. Future operating lease commitments are calculated using the base rental amount and foreign currency exchange rates in effect as of December 31, 2015. Capital Operating (In thousands) Leases Leases 2016 $ 546 $ 17,361 2017 471 14,667 2018 110 11,739 2019 6 10,789 2020 0 9,078 Thereafter 0 46,567 1,133 $ 110,201 Less amount representing interest (142 ) 991 Current maturities of capital lease obligations 431 Capital lease obligations, net of current maturities $ 560 Commitment with Strategic Partner We are currently in the fifth year of a ten-year agreement with Atos (f/k/a Xerox Consultant Services) to provide services to support our remote hosting services for our Sunrise acute care clients. We maintain all client relationships and domain expertise with respect to the hosted applications. This agreement includes the payment of an initial base amount of approximately $50 million per year plus charges for services incremental to the base agreement. Expenses incurred under this agreement are included in cost of revenue in our consolidated statements of operations and were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Expenses incurred under Atos agreement $ 67,058 $ 68,165 $ 62,259 |
Business Segments
Business Segments | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Business Segments | 13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as, outsourcing, remote hosting and revenue cycle management. We revised our reportable segments effective January 1, 2015. Prior to this change, we used three reportable segments: Clinical and Financial Solutions, Population Health, and Managed Services. We revised our reportable segments in order to align our reporting structure with our chief operating decision maker’s (our “CODM”) management of resource allocation and performance assessment. These changes also completed our transition, which we initiated in 2013, from a functional organization to a strategic business unit model solely aligned with our key products. Under our new reporting structure, the revenue and related costs associated with providing outsourcing and remote hosting managed services are allocated to our other strategic business units based on the underlying software products to which these services relate. Outsourcing and remote hosting managed services were previously each deemed to be individual strategic business units and were aggregated into our former Managed Services reportable segment. After these changes to our reporting structure, we identified seven operating segments, which were aggregated into two reportable segments: (i) Clinical and Financial Solutions and (ii) Population Health. During 2015, the separate leadership teams of the Performance and Care Logistics and Population Health strategic business units, which comprised the Population Health reportable segment, were combined and these strategic units became a single operating and reportable segment. Also, during 2015, a similar leadership team change within the Clinical and Financial Solutions reportable segment resulted in the combination of the Sunrise and International strategic business units into a new single operating segment. After the finalization of the changes to our reporting structure, as of December 31, 2015, we had five operating segments and there were no changes to our two reportable segments. Segment data for the years ended December 31, 2014 and 2013 presented in the table below has been restated to conform to the current year’s presentation. The Clinical and Financial Solutions segment includes our Sunrise, TouchWorks, Professional Practices and Payer and Life Sciences strategic business units. This segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include Electronic Health Record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services. The Population Health segment includes our former Performance and Care Logistics and Population Health strategic business units. This segment derives its revenue from the sale of health management and coordinated care solutions, which are mainly targeted at hospitals, health systems, other care facilities and Accountable Care Organizations. These solutions enable clients to connect, transition, analyze, and coordinate care across the entire care community Our CODM uses segment revenues, gross profit and income from operations as measures of performance and to allocate resources. In determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. We exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting, and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware. We do not track our assets by segment. Year Ended December 31, (In thousands) 2015 2014 2013 Revenue: Clinical and Financial Solutions $ 1,072,605 $ 1,079,330 $ 1,094,177 Population Health 296,580 285,383 257,738 Unallocated Amounts 17,208 13,160 21,146 Total revenue $ 1,386,393 $ 1,377,873 $ 1,373,061 Gross Profit: Clinical and Financial Solutions $ 437,229 $ 415,172 $ 428,097 Population Health 196,393 192,584 175,572 Unallocated Amounts (53,057 ) (61,772 ) (69,213 ) Total gross profit $ 580,565 $ 545,984 $ 534,456 Income (loss) from operations: Clinical and Financial Solutions $ 222,958 $ 191,716 $ 186,973 Population Health 131,414 115,871 108,714 Unallocated Amounts (322,489 ) (346,775 ) (423,288 ) Total income (loss) from operations $ 31,883 $ (39,188 ) $ (127,601 ) |
Supplemental Disclosures
Supplemental Disclosures | 12 Months Ended |
Dec. 31, 2015 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Supplemental Disclosures | 14. Supplemental Disclosures Year Ended December 31, (In thousands) 2015 2014 2013 Cash paid during the period for: Interest $ 15,750 $ 15,585 $ 12,997 Income taxes paid, net of tax refunds $ 5,037 $ 7,104 $ 7,944 Non-cash transactions: Obligations incurred to purchase capitalized software or enter into capital leases $ 393 $ 4,800 $ 0 Accrued expenses consist of the following: December 31, December 31, (In thousands) 2015 2014 Royalties, certain third party product costs and licenses $ 16,456 $ 23,946 Other 45,565 55,021 Total accrued expenses $ 62,021 $ 78,967 Other consists of various accrued expenses and no individual item accounted for more than 5% of the current liabilities balance at the respective balance sheet dates. Other assets consist of the following: December 31, December 31, (In thousands) 2015 2014 Investment in Nant Health, LLC $ 203,117 $ - Fair value of 1.25% Call Option 80,208 57,091 Long-term prepaid commissions 43,756 45,683 Investments in non-marketable securities 20,312 18,828 Long-term deposits and other assets 12,272 16,158 Total other assets $ 359,665 $ 137,760 |
Geographic Information
Geographic Information | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Geographic Information | 15. Geographic Information Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below: Year Ended December 31, (In thousands) 2015 2014 2013 United States $ 1,338,095 $ 1,327,840 $ 1,321,779 Canada 18,024 20,727 24,999 Other international 30,274 29,306 26,283 Total $ 1,386,393 $ 1,377,873 $ 1,373,061 A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below: December 31, December 31, (In thousands) 2015 2014 United States $ 116,731 $ 133,485 India 5,739 8,044 Israel 1,786 2,142 Canada 545 935 Other international 816 1,224 Total $ 125,617 $ 145,830 |
Contingencies
Contingencies | 12 Months Ended |
Dec. 31, 2015 | |
Commitments And Contingencies Disclosure [Abstract] | |
Contingencies | 16. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred any material loss, or any material loss in excess of a recorded accrual, with respect to the following matters. Our management will continue to evaluate the potential exposure related to these matters in future periods. On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims, for which the plaintiff has moved for reconsideration. A hearing to hear the plaintiff’s motions was held September 21 and 22, 2015, and we are awaiting a ruling. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Discovery is proceeding. The plaintiff must file a motion for class certification by March 31, 2016. No trial date has been scheduled. On July 11, 2012, RLIS, Inc. filed a complaint in the United States District Court for the Southern District of Texas against us. The complaint alleges, among other things, that our Enterprise EHR product (now Allscripts Touchworks) willfully infringes U.S. Patent No. 7,076,436. On September 28, 2012, the plaintiff filed an amended complaint that alleges, among other things, that certain of our products and services infringe both the foregoing patent as well as U.S. Patent No. 5,823,948. The Company and the plaintiff settled all claims in the fourth quarter of 2015, and the case has been dismissed. Other Matters On May 2, 2012, a lawsuit was filed in the United States District Court for the Northern District of Illinois against us; Glen Tullman, our former Chief Executive Officer; and William Davis, our former Chief Financial Officer, by the Bristol County Retirement System for itself and on behalf of a purported class consisting of stockholders who purchased our common stock between November 18, 2010 and April 26, 2012. In April 2015, the Court granted a motion for preliminary approval of the class settlement in this lawsuit and on July 21, 2015, the Court approved the settlement and entered a final judgment binding on members of the class, minus stockholders who excluded themselves from the settlement, including certain entities affiliated with HealthCor Management, L.P. We do not believe we will incur a material loss in excess of a recorded accrual with respect to this matter. |
North American Site Consolidati
North American Site Consolidation Plan | 12 Months Ended |
Dec. 31, 2015 | |
Restructuring And Related Activities [Abstract] | |
North American Site Consolidation Plan | 17. North American Site Consolidation Plan On February 18, 2013, we announced a North American site consolidation plan (the “Site Consolidation Plan”) designed to create a more simplified and efficient organization that is aligned more closely with our business priorities. The Site Consolidation Plan included the closing of twelve offices and one warehouse in conjunction with changes to our corporate operating models intended to reduce costs associated with product solutions development. The costs of implementing these changes primarily consisted of employee severance and relocation costs. We substantially completed the Site Consolidation Plan during the year ended December 31, 2014 and additional estimated costs yet to be incurred in connection with the Site Consolidation Plan, which primarily consist of lease-related costs, are not expected to be material. During the year ended December 31, 2014, we recognized benefits of approximately $2.2 million due to the release of previously accrued severance costs which we no longer expect to pay and paid the remaining $2.0 million outstanding balance of the severance costs liability that was initially established in the first quarter of 2013. During the year ended December 31, 2013, we incurred approximately $20.1 million in severance, retention bonuses and relocation expenses costs resulting from the Site Consolidation Plan. These amounts are included in selling, general and administrative expenses in our consolidated statements of operations for the years ended December 31, 2014 and 2013, with the exception of $3.9 million for the year ended December 31, 2013, included in research and development. The portion of these amounts allocable to our reportable segments is not material. |
Quarterly Financial Information
Quarterly Financial Information (Unaudited) | 12 Months Ended |
Dec. 31, 2015 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Information (Unaudited) | 18. Quarterly Financial Information (Unaudited) The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters. Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2015 (1) 2015 (1) 2015 (1) 2015 Revenue $ 345,647 $ 354,476 $ 351,718 $ 334,552 Cost of revenue 191,844 201,128 208,094 204,762 Gross profit 153,803 153,348 143,624 129,790 Selling, general and administrative expenses 79,354 91,043 86,749 82,029 Research and development 45,995 47,702 44,367 46,727 Asset impairment charges 1,203 22 293 26 Amortization of intangible and acquisition-related assets 4,133 5,712 6,624 6,703 Income (loss) from operations 23,118 8,869 5,591 (5,695 ) Interest expense (7,403 ) (9,254 ) (3) (7,483 ) (7,256 ) Other (expense) income, net (98 ) 423 (28 ) 1,886 Equity in net earnings of unconsolidated investments (797 ) (1,479 ) 176 0 Income (loss) before income taxes 14,820 (1,441 ) (1,744 ) (11,065 ) Income tax benefit (provision) 1,557 (3,692 ) (2) (1,472 ) 981 Net income (loss) 16,377 (5,133 ) (3,216 ) (10,084 ) Less: Net income attributable to non-controlling interest (50 ) (111 ) (9 ) 0 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 16,327 $ (5,244 ) $ (3,225 ) $ (10,084 ) Earnings (loss) per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 0.09 $ (0.03 ) $ (0.01 ) $ (0.06 ) Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2014 2014 2014 2014 Revenue $ 340,903 $ 345,389 $ 351,296 $ 340,285 Cost of revenue 204,549 213,933 211,308 202,099 Gross profit 136,354 131,456 139,988 138,186 Selling, general and administrative expenses 85,038 97,034 86,663 89,946 Research and development 41,538 45,962 53,016 52,305 Asset impairment charges 256 188 1,751 195 Amortization of intangible and acquisition-related assets 8,866 7,112 7,651 7,651 Income (loss) from operations 656 (18,840 ) (9,093 ) (11,911 ) Interest expense (7,292 ) (7,542 ) (7,230 ) (7,233 ) Other income (expense), net 397 171 230 (32 ) Equity in net earnings of unconsolidated investments (398 ) 0 0 0 Loss before income taxes (6,637 ) (26,211 ) (16,093 ) (19,176 ) Income tax benefit (provision) 4,459 448 (2) (1,677 ) (2) (1,566 ) (2) Net income (loss) (2,178 ) (25,763 ) (17,770 ) (20,742 ) Less: Net income attributable to non-controlling interest 0 0 0 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,178 ) $ (25,763 ) $ (17,770 ) $ (20,742 ) Loss per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.01 ) $ (0.15 ) $ (0.09 ) $ (0.12 ) (1) Results of operations for the quarter include the results of operations of a third party with a proportionate share allocated to non-controlling interest for the period subsequent to April 17, 2015, which was the date on which we acquired a majority interest in the third party. (2) ( 3 ) Interest expense includes the write-off of $1.4 million of deferred debt issuance costs in connection with amending our senior secured credit facility. |
Schedule II-Valuation and Quali
Schedule II-Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2015 | |
Valuation And Qualifying Accounts [Abstract] | |
Schedule II-Valuation and Qualifying Accounts | Schedule II—Valuation and Qualifying Accounts Charged to Balance at Expenses/ Deferred Write-Offs, Balance at Beginning of Against Revenue Net of End of (In thousands) Year Revenue Reclassification Recoveries Year Allowance for doubtful accounts and sales credits Year ended December 31, 2015 $ 36,047 8,089 (363 ) (12,507 ) $ 31,266 Year ended December 31, 2014 $ 54,252 9,592 (5,340 ) (22,457 ) $ 36,047 Year ended December 31, 2013 $ 45,320 20,095 1,116 (12,279 ) $ 54,252 In 2013, we changed our presentation of accounts receivable by reclassifying to the related allowance the deferred revenue directly associated with account balances that were deemed to be uncollectible. All other schedules are omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto. |
Basis of Presentation and Sig28
Basis of Presentation and Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and majority-owned affiliate. All significant intercompany balances and transactions have been eliminated. Investments in less than majority-owned entities where we have significant influence are accounted for under the equity method. The earnings from certain investments accounted for using the equity method are included in our results of operation based on a reporting lag of up to three months from our year end. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc., its wholly-owned subsidiaries and , unless otherwise stated. |
Change in Presentation | Change in Presentation In 2015, we adopted a revised presentation of revenue and the associated cost of revenue in our consolidated statements of operations, which we believe is better aligned with and representative of the amount and profitability of our overall software and services revenue streams, as well as with the way we manage our business, review our operating performance and market our products. In recent years, we have experienced a continued shift in customer preferences from up-front software license agreements, and associated support and maintenance, to subscription-based agreements. Under our previous presentation, the revenue and cost of revenue of each of these types of agreements were reported under separate revenue categories. By combining these separate revenue categories, we believe that our revised presentation better reflects the overall trend in our software delivery, support and maintenance revenue. Under the revised presentation, revenue is reported based on two categories: (i) software delivery, support and maintenance, and (ii) client services. Previously, revenue was presented based on four categories: system sales, professional services, maintenance, and transaction processing and other. Software delivery, support and maintenance revenue consists of our previous system sales, maintenance and transaction processing and other revenue categories, excluding outsourcing and remote hosting managed services revenue previously included in transaction processing and other revenue. Client services revenue consists of our previous professional services category and outsourcing and remote hosting managed services revenue previously included in transaction processing and other revenue. The comparable 2014 and 2013 periods were revised for the new presentation. Total revenue and cost of revenue previously reported for the years ended December 31, 2014 and 2013 were not affected by this change in presentation. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. |
Revenue Recognition | Revenue Recognition Revenue represents the fair value of consideration received or receivable from clients for goods and services provided by us. Software delivery revenue consists of all of our proprietary software sales (either as a perpetual license sale or under a subscription delivery model), transaction-related revenue and the resale of hardware. Support and maintenance revenue consists of revenue from post contract client support and maintenance services. Client services revenue consists of revenue from managed services solutions, such as remote hosting, outsourcing and revenue cycle management, as well as other client services or project-based revenue from implementation, training and consulting services. For some clients, we remotely host the software applications licensed from us using our own or third-party servers, which saves these clients the cost of procuring and maintaining hardware and related facilities. For other clients, we offer an outsourced solution in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees. Revenue from software licensing arrangements where the service element is not considered essential to the functionality of the other elements of the arrangement is recognized upon delivery of the software or as services are performed, provided persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. The revenue recognized for each separate element of a multiple-element software contract is based upon vendor-specific objective evidence of fair value (“VSOE”), which is based upon the price the client is required to pay when the element is sold separately or renewed. For arrangements in which VSOE only exists for the undelivered elements, the delivered elements (generally software licenses) are accounted for using the residual method. Revenue from software licensing arrangements, where the service element is considered essential to the functionality of the other elements of the arrangement, is accounted for on an input basis under the percentage of completion accounting method using actual hours worked as a percentage of total expected hours required by the arrangement, provided that persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. Maintenance and support associated with these agreements is recognized over the term of the support agreement based on VSOE of the maintenance revenue, which is based upon contractual renewal rates. For presentation in the statement of operations, consideration from agreements accounted for under the percentage of completion accounting method is allocated between software delivery and client services revenue based on VSOE of our hourly services rate multiplied by the amount of hours performed with the residual amount allocated to the software license fee. Fees related to software-as-a-service (“SaaS”) arrangements are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. These arrangements include client services fees related to the implementation and set-up of our solutions and are typically billed upfront and recorded as deferred revenue until our solutions are made available to the client. The implementation and set-up fees are recognized as revenue ratably over the estimated client relationship period. The estimated length of a client relationship period is based on our experience with client contract renewals and consideration of the period over which such clients use our SaaS solutions. Software remote hosting services are provided to clients that have purchased a perpetual license to our software solutions and contracted with us to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the remote hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. Remote hosting services are not deemed to be essential to the functionality of the software or other elements of the arrangement; accordingly, for these arrangements, we recognize software license fees as software delivery revenue upon delivery, assuming all other revenue recognition criteria have been met, and separately recognize fees for the remote hosting services as client services revenue over the term of the remote hosting arrangement. We also enter into multiple-element arrangements that may include a combination of various software-related and non-software-related products and services. Management applies judgment to ensure appropriate accounting for multiple deliverables, including the allocation of arrangement consideration among multiple units of accounting, the determination of whether undelivered elements are essential to the functionality of delivered elements, and the timing of revenue recognition, among others. In such arrangements, we first allocate the total arrangement consideration based on a selling price hierarchy at the inception of the arrangement. The selling price for each element is based upon the following selling price hierarchy: VSOE, if available, third-party evidence of fair value if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence of fair value is available (discussion as to how we determine VSOE, third-party evidence of fair value and estimated selling price is provided below). Upon allocation of the arrangement consideration to the software elements as a whole and individual non-software elements, we then further allocate consideration within the software group to the respective elements following higher-level, industry-specific guidance and our policies described above. After the arrangement consideration has been allocated to the various elements, we account for each respective element in the arrangement as described above. To determine the selling price in multiple-element arrangements, we establish VSOE using the price charged for a deliverable when sold separately and contractual renewal rates for maintenance fees. For non-software multiple element arrangements, third-party evidence of fair value is established by evaluating similar and interchangeable competitor products or services in standalone arrangements with similarly situated clients. If we are unable to determine the selling price because VSOE or third-party evidence of fair value does not exist, we determine an estimated selling price by considering several external and internal factors including, but not limited to, pricing practices, margin objectives, competition, client demand, internal costs and overall economic trends. The determination of an estimated selling price is made through consultation with and approval by our management, taking into consideration our go-to-market strategy. As our, or our competitors’, pricing and go-to-market strategies evolve, we may modify our pricing practices in the future. These events could result in changes to our determination of VSOE, third-party evidence of fair value and estimated selling price. Selling prices are analyzed on an annual basis or more frequently if we experience significant changes in our selling prices. For those arrangements where the deliverables do not qualify as separate units of accounting, revenue recognition is evaluated for the combined deliverables as a single unit of accounting and the recognition pattern of the final deliverable will dictate the revenue recognition pattern for the single, combined unit of accounting. Changes in circumstances and client data may result in a requirement to either separate or combine deliverables, such that a delivered item could now meet the separation criteria and qualify as a separate unit of accounting, which may lead to an upward or downward adjustment to the amount of revenue recognized under the arrangement on a prospective basis. We assess whether fees are considered fixed or determinable at the time of sale and recognize revenues if all other revenue recognition requirements are met. Our payment arrangements with clients typically include milestone-based software license fee payments and payments based upon delivery for services and hardware. While most of our arrangements include short-term payment terms, we periodically provide extended payment terms to clients from the date of contract signing. We do not recognize revenue under extended payment term arrangements until such payments become due. In certain circumstances, where all other revenue recognition criteria have been met, we occasionally offer discounts to clients with extended payment terms to accelerate the timing of when payments are made. Changes to extended payment term arrangements have not had a material impact on our consolidated results of operations. Maintenance fees are recognized ratably over the period of the contract based on VSOE, which is based upon contractual renewal rates. Revenue from electronic data interchange services is recognized as services are provided and is determined based on the volume of transactions processed or estimated selling price. We provide outsourcing services to our clients under arrangements that typically range from three to ten years in duration. Under these arrangements we assume full, partial or transitional responsibilities for a healthcare organization’s IT operations using our employees. Our outsourcing services include facilities management, network outsourcing and transition management. Revenue from these arrangements is recognized subsequent to the transition period as services are performed. Revenue is recognized net of any taxes collected from clients and subsequently remitted to governmental authorities. We record as revenue any amounts billed to clients for shipping and handling costs and record as cost of revenue the actual shipping costs incurred. We record reimbursements for out-of-pocket expenses incurred as client services revenue in our consolidated statements of operations. These amounts totaled: Year Ended December 31, (In thousands) 2015 2014 2013 Reimbursements for out-of-pocket expenses incurred $ 12,873 $ 16,251 $ 18,445 The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which are included in the balances of accounts receivable and other assets, respectively, in our consolidated balance sheets. Billings are expected to occur according to the contract terms. December 31, (In thousands) 2015 2014 Revenue earned on contracts in excess of billings Unbilled revenue (current) $ 68,444 $ 42,818 Unbilled revenue (long-term) 0 618 Total revenue earned on contracts in excess of billings $ 68,444 $ 43,436 |
Fair Value Measurements | Fair Value Measurements Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments in the past included money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund. There were no outstanding money market funds investments as of December 31, 2015 and 2014. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities, which consist of mortgage and asset-backed bonds. We sold all of our marketable securities during the three months ended March 31, 2015. Prior to the sale, marketable securities were recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 11, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprised of the 1.25% Call Option (as defined in Note 11, “Derivative Financial Instruments”) asset and the 1.25% Notes embedded cash conversion option liability. Refer to Note 11, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses as inputs both observable and unobservable market data. Significant market data inputs used to determine the fair values as of December 31, 2015 and 2014 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the 1.25% Notes embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity associated with changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet December 31, 2015 December 31, 2014 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Marketable securities Long-term marketable securities $ 0 $ 0 $ 0 $ 0 $ 0 $ 1,305 $ 0 $ 1,305 1.25% Call Option Other assets 0 0 80,208 80,208 0 0 57,091 57,091 1.25% Embedded cash conversion option Other liabilities 0 0 (81,210 ) (81,210 ) 0 0 (57,839 ) (57,839 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 424 0 424 0 0 0 0 Total $ 0 $ 424 $ (1,002 ) $ (578 ) $ 0 $ 1,305 $ (748 ) $ 557 During 2014, we acquired certain non-marketable equity securities of four third parties and entered into new, or amended existing, commercial agreements with each of those third parties to license and distribute their products and services, for a total consideration of approximately $21.1 million. The equity investments and the commercial agreements were valued at approximately $19.2 million and $1.9 million, respectively. Three of the equity investments acquired during 2014 are accounted for under the cost method, and one of the equity investments is accounted for under the equity method. During 2015, we invested an additional $0.3 million in one of the third parties and exercised warrants to acquire a new investment of approximately $1.0 million in another third party. Both of these additional investments are accounted for under the equity method. The carrying values of the cost method investments were approximately $17.8 million as of both December 31, 2015 and 2014. The carrying values of the equity method investments were approximately $2.5 million and $1.0 million, respectively, as of December 31, 2015 and 2014. These carrying values are included in other assets and the carrying value of the above-referenced commercial agreements is included in intangible assets, net, in the accompanying consolidated balance sheets as of December 31, 2015 and 2014. During 2015, we also invested $200 million for a 10% ownership stake in Nant Health LLC. This investment is accounted for under the equity method. Refer to Note 2, “Business Combinations and Other Investments” for additional information about the investment in Nant Health LLC. t is not practicable to estimate the fair value of our cost and equity investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined in Note 6, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, as of December 31, 2015, the fair value of the 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) exceeded the 1.25% Notes’ principal balance (or par) by approximately 8%. We utilized the 1.25% Notes’ market trading prices near December 31, 2015 in making this fair value calculation. See Note 6, “Debt,” for further information regarding our long-term financial liabilities. |
Financial Instruments | Financial Instruments We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values. Other investments classified as long-term marketable securities include certain debt instruments. Debt securities are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Realized and unrealized gains and losses for all periods presented are immaterial. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income. There were no other-than-temporary impairments for the years ended December 31, 2015, 2014 and 2013. Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation. For derivative instruments designated as cash-flow hedges, the effective portion of the derivative’s gain (loss) is initially reported as a component of other comprehensive income and is subsequently recognized in earnings when the hedged exposure is recognized in earnings. Gains (losses) on derivatives representing either hedge components excluded from the assessment of effectiveness or hedge ineffectiveness are recognized in earnings. See Note 11, “Derivative Financial Instruments,” for information regarding gains and losses from derivative instruments during the years ended December 31, 2015, 2014 and 2013. |
Allowance for Doubtful Accounts Receivable | Allowance for Doubtful Accounts Receivable Accounts receivable are recorded at the invoiced amounts and do not bear interest. An allowance for doubtful accounts is recorded to provide for estimated losses resulting from uncollectible accounts, and is based principally on specifically identified amounts where collection is deemed doubtful. Additional non-specific allowances are recorded based on historical experience and management’s assessment of a variety of factors related to the general financial condition of our clients, the industry in which we operate and general economic conditions. We review the collectability of individual accounts and assess the adequacy of the allowance for doubtful accounts. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required. |
Contingent Liabilities | Contingent Liabilities A liability is contingent if the amount is not presently known, but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments. |
Fixed Assets | Fixed Assets Fixed assets are stated at cost. Depreciation and amortization are computed on the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred. |
Business Combinations | Business Combinations Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated statements of operations. |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, we must determine the amount of implied goodwill that would be established if the reporting unit was hypothetically acquired on the impairment test date. If the carrying amount of a reporting unit’s goodwill exceeds the amount of implied goodwill, an impairment loss equal to the excess would be recorded. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of the asset to its estimated fair value. If we determine that the carrying value of the asset exceeds its estimated fair value, an impairment loss equal to the excess would be recorded. The determination of the fair value of our reporting units is based on a combination of a market approach that considers benchmark company market multiples and an income approach that uses discounted cash flows for each reporting unit utilizing Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent income projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions based on our historical experience, our expectations of future performance, and the expected economic environment. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. As part of the goodwill impairment testing, we also consider our market capitalization in assessing the reasonableness of the fair values estimated for our reporting units. Accounting guidance also requires that definite-lived intangible assets be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize the value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time. |
Long-Lived Assets and Long-Lived Assets to Be Disposed Of | Long-Lived Assets and Long-Lived Assets to Be Disposed Of We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. |
Software Development Costs | Software Development Costs We capitalize purchased software that is ready for service and software development costs incurred from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years. At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine in the future that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value may be recorded as a charge to earnings. The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2015 2014 Software development costs $ 200,531 $ 213,601 Less: accumulated amortization (114,756 ) (127,448 ) Software development costs, net $ 85,775 $ 86,153 Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Capitalized software development costs $ 46,464 $ 45,461 $ 42,026 Write-offs of capitalized software development costs $ - $ 1,444 $ 5,234 Amortization of capitalized software development costs $ 46,842 $ 46,108 $ 44,127 |
Income Taxes | Income Taxes We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors. In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements. The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing authorities. To the extent we prevail in matters for which liabilities have been established, or are required to pay amounts in excess of our liabilities, our effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution. We report interest and penalties related to uncertain income tax positions in the income tax (provision) benefit line of our consolidated statements of operations. We file income tax returns in the United States federal jurisdiction, numerous states in the United States and multiple countries outside of the United States. |
Earnings (Loss) Per Share | Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Year Ended December 31, (In thousands, except per share amounts) 2015 2014 2013 Basic Loss per Common Share: Net loss $ (2,056 ) $ (66,453 ) $ (104,026 ) Less: Net income attributable to non-controlling interest $ (170 ) $ 0 $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,226 ) $ (66,453 ) $ (104,026 ) Weighted-average common shares outstanding 185,082 179,849 177,026 Basic Loss per Common Share $ (0.01 ) $ (0.37 ) $ (0.59 ) Diluted Loss per Common Share: Net loss $ (2,056 ) $ (66,453 ) $ (104,026 ) Less: Net income attributable to non-controlling interest $ (170 ) $ 0 $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,226 ) $ (66,453 ) $ (104,026 ) Weighted-average common shares outstanding 185,082 179,849 177,026 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 Weighted-average common shares outstanding assuming dilution 185,082 179,849 177,026 Diluted Loss per Common Share $ (0.01 ) $ (0.37 ) $ (0.59 ) As a result of our net loss available to common stockholders for the years ended December 31, 2015, 2014 and 2013, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these years, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Year Ended December 31, (In thousands) 2015 2014 2013 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,063 24,254 14,926 |
Stock-Based Compensation | Stock-Based Compensation We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation cost at the grant date based on the fair value of the award and recognize the expense over the requisite service period typically on a straight-line basis, net of estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We settle employee stock option exercises and stock awards with newly issued common shares. |
Employee Benefit Plans | Employee Benefit Plans We provide employees with defined contribution savings plans. We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans: Year Ended December 31, (In thousands) 2015 2014 2013 Company contributions to employee benefit plans $ 16,397 $ 16,427 $ 15,276 |
Foreign Currency | Foreign Currency The determination of the functional currency of our foreign subsidiaries is made based on the appropriate economic and management indicators. Our foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our subsidiaries in India and Israel which use the United States dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into United States dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. During the year ended December 31, 2015, we entered into non-deliverable forward foreign currency exchange contracts in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. See Note 11, “Derivative Financial Instruments,” for information regarding these foreign currency exchange contracts. We did not enter into any foreign currency hedging contracts during the years ended December 31, 2014 and 2013. |
Concentrations of Credit Risk | Concentrations of Credit Risk Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally. Our cash equivalents and marketable securities are comprised of interest-bearing, investment-grade securities. We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In general, we do not require collateral from our clients, but we do enter into advance deposit agreements, if appropriate. The majority of revenue is derived from clients located in the United States. The majority of long-lived assets are also located in the United States. No single client accounted for more than 10% of our revenue in the years ended December 31, 2015, 2014 and 2013. No client represented more than 10% of accounts receivable as of December 31, 2015 or 2014. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-12, Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In September 2015, the FASB issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In April 2015, the FASB issued Accounting Standards Update 2015-03, Simplifying the Presentation of Debt Issuance Costs In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes |
Accounting Pronouncements Not Yet Adopted | Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Recognition and Measurement of Financial Assets and Financial Liabilities” In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “ Leases (Topic 842) We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements. |
Basis of Presentation and Sig29
Basis of Presentation and Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Reimbursements for Out-of-Pocket Expenses Incurred as Client Services Revenue | We record reimbursements for out-of-pocket expenses incurred as client services revenue in our consolidated statements of operations. These amounts totaled: Year Ended December 31, (In thousands) 2015 2014 2013 Reimbursements for out-of-pocket expenses incurred $ 12,873 $ 16,251 $ 18,445 |
Revenue Earned on Contracts in Excess of Billings Included in Accounts Receivable and Other Assets | The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which are included in the balances of accounts receivable and other assets, respectively, in our consolidated balance sheets. Billings are expected to occur according to the contract terms. December 31, (In thousands) 2015 2014 Revenue earned on contracts in excess of billings Unbilled revenue (current) $ 68,444 $ 42,818 Unbilled revenue (long-term) 0 618 Total revenue earned on contracts in excess of billings $ 68,444 $ 43,436 |
Summary of Financial Assets and Liabilities Measured at Fair value on Recurring Basis | The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet December 31, 2015 December 31, 2014 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Marketable securities Long-term marketable securities $ 0 $ 0 $ 0 $ 0 $ 0 $ 1,305 $ 0 $ 1,305 1.25% Call Option Other assets 0 0 80,208 80,208 0 0 57,091 57,091 1.25% Embedded cash conversion option Other liabilities 0 0 (81,210 ) (81,210 ) 0 0 (57,839 ) (57,839 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 424 0 424 0 0 0 0 Total $ 0 $ 424 $ (1,002 ) $ (578 ) $ 0 $ 1,305 $ (748 ) $ 557 |
Unamortized Balances of Capitalized Software | The unamortized balances of capitalized software were as follows: December 31, (In thousands) 2015 2014 Software development costs $ 200,531 $ 213,601 Less: accumulated amortization (114,756 ) (127,448 ) Software development costs, net $ 85,775 $ 86,153 |
Capitalized Software Development Costs, Write Offs Included in Asset Impairment Changes and Amortization of Capitalized Software Development Costs Included in Cost of Revenue | Capitalized software development costs, write-offs included in asset impairment changes and amortization of capitalized software development costs included in cost of revenue were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Capitalized software development costs $ 46,464 $ 45,461 $ 42,026 Write-offs of capitalized software development costs $ - $ 1,444 $ 5,234 Amortization of capitalized software development costs $ 46,842 $ 46,108 $ 44,127 |
Calculations of Earnings (Loss) Per Share | The calculations of earnings (loss) per share are as follows: Year Ended December 31, (In thousands, except per share amounts) 2015 2014 2013 Basic Loss per Common Share: Net loss $ (2,056 ) $ (66,453 ) $ (104,026 ) Less: Net income attributable to non-controlling interest $ (170 ) $ 0 $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,226 ) $ (66,453 ) $ (104,026 ) Weighted-average common shares outstanding 185,082 179,849 177,026 Basic Loss per Common Share $ (0.01 ) $ (0.37 ) $ (0.59 ) Diluted Loss per Common Share: Net loss $ (2,056 ) $ (66,453 ) $ (104,026 ) Less: Net income attributable to non-controlling interest $ (170 ) $ 0 $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,226 ) $ (66,453 ) $ (104,026 ) Weighted-average common shares outstanding 185,082 179,849 177,026 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 Weighted-average common shares outstanding assuming dilution 185,082 179,849 177,026 Diluted Loss per Common Share $ (0.01 ) $ (0.37 ) $ (0.59 ) |
Anti-Dilutive Stock Options and Share Awards Excluded from Computation of Diluted Earnings Per Share | The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Year Ended December 31, (In thousands) 2015 2014 2013 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,063 24,254 14,926 |
Company Contributions to Employee Benefit Plan | We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans: Year Ended December 31, (In thousands) 2015 2014 2013 Company contributions to employee benefit plans $ 16,397 $ 16,427 $ 15,276 |
Business Combinations and Oth30
Business Combinations and Other Investments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
Final Fair Value of Consideration Transferred for Acquisition | The total fair value of consideration transferred for the acquisition is comprised of the following: (In thousands) Cash $ 140,079 Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share 48,061 Deferred cash consideration payable on the 18-month anniversary of the closing 23,023 Subordinated promissory note maturing 18 months following the closing 6,648 Fair value of Allscripts' previous interest in dbMotion 8,367 Total fair value of consideration transferred $ 226,178 |
Assets Acquired and Liabilities Assumed | The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows : (In thousands) Acquired cash and cash equivalents, and restricted cash $ 14,188 Accounts receivable, net 3,226 Prepaid expenses and other current assets 574 Fixed assets and other long-term assets 1,449 Goodwill 137,649 Intangible assets 85,450 Accounts payable and accrued liabilities (10,560 ) Deferred taxes, net (36 ) Deferred revenue (5,100 ) Other liabilities (662 ) Net assets acquired $ 226,178 |
Acquired Intangible Assets Amortization | The acquired intangible assets are being amortized on a straight-line basis over their useful lives and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Core technology 10 $ 80,100 Maintenance agreements 12 2,500 Services backlog 2 2,000 Non-compete 3 500 Trade name 2 350 $ 85,450 |
Proforma Results | The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the year ended December 31, 2013, and the unaudited supplemental pro forma revenue and net loss of the combined entity, are as follows: Year ended (In thousands, except per share amounts) December 31, 2013 (Unaudited) Actual from dbMotion since acquisition date of March 4, 2013: Revenue $ 18,609 Net loss $ (16,272 ) Supplemental pro forma data for combined entity: Revenue $ 1,378,267 Net loss $ (105,119 ) Net loss per share, basic and diluted $ (0.59 ) |
Summarized Financial Information for Equity Method Investments | Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: September 30, December 31, (In thousands) 2015 2014 Current assets $ 58,550 $ 1,486 Noncurrent assets 411,159 1,812 Current liabilities 77,188 3,300 Noncurrent liabilities 166,898 2,191 Equity of equity method investments $ 225,623 $ (2,193 ) (In thousands) Trailing Twelve Months Ended September 30, 2015 Trailing Twelve Months Ended September 30, 2014 Revenue $ 33,896 $ 2,422 Net loss (20,256 ) (484 ) |
Fixed Assets (Tables)
Fixed Assets (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Property Plant And Equipment [Abstract] | |
Fixed Assets | Fixed assets consist of the following: Estimated December 31, December 31, (Dollar amounts in thousands) Useful Life 2015 2014 Computer equipment and software 3 to 10 years $ 304,032 $ 284,185 Facility furniture, fixtures and equipment 5 to 7 years 20,302 19,846 Leasehold improvements 7 to 8 years, or life of lease if shorter 30,619 30,795 Assets under capital lease 3 to 5 years 3,266 2,873 Fixed assets, gross 358,219 337,699 Less: Accumulated depreciation and amortization (232,602 ) (191,869 ) Fixed assets, net $ 125,617 $ 145,830 |
Depreciation and Amortization Expense | Fixed assets depreciation and amortization expense were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Fixed assets depreciation and amortization expense $ 42,153 $ 48,465 $ 52,545 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill And Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | Goodwill and intangible assets consist of the following: December 31, 2015 December 31, 2014 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 450,852 $ (302,284 ) $ 148,568 $ 451,087 $ (267,547 ) $ 183,540 Customer contracts and relationships 552,395 (405,317 ) 147,078 550,287 (382,465 ) 167,822 Total $ 1,003,247 $ (707,601 ) $ 295,646 $ 1,001,374 $ (650,012 ) $ 351,362 Intangibles not subject to amortization: Registered trademarks $ 52,000 $ 52,000 Goodwill 1,222,601 1,200,746 Total $ 1,274,601 $ 1,252,746 |
Changes in Carrying Amount of Goodwill | Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2015 and 2014 were as follows: Clinical and Population (In thousands) Financial Solutions Health Total Balance as of December 31, 2013 $ 764,369 $ 425,216 $ 1,189,585 Additions arising from business acquisitions: Oasis 11,155 0 11,155 dbMotion - 1,018 1,018 Total additions to goodwill 11,155 1,018 12,173 Foreign exchange translation (1,012 ) 0 (1,012 ) Balance as of December 31, 2014 $ 774,512 $ 426,234 $ 1,200,746 Other additions 22,319 0 22,319 Foreign exchange translation (464 ) 0 (464 ) Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 1,222,601 |
Amortization Expense Related to Intangible Assets | Intangible assets are being amortized over their estimated useful lives and amortization expense related to intangible assets was as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Proprietary technology amortization included in cost of revenue $ 35,144 $ 35,924 $ 33,970 Intangible amortization included in operating expenses 23,172 31,280 31,253 Total intangible amortization expense $ 58,316 $ 67,204 $ 65,223 |
Estimated Future Amortization Expense for Intangible Assets | The decrease in amortization expense for the year ended December 31, 2015 compared with the year ended December 31, 2014 was primarily driven by amortization associated with intangible assets that were fully amortized in 2014. Estimated future amortization expense for the intangible assets that exist as of December 31, 2015, based on foreign currency exchange rates in effect as of such date, is as follows: Year Ended December 31, (In thousands) 2016 $ 45,515 2017 40,401 2018 33,712 2019 33,712 2020 33,008 Thereafter 109,298 Total $ 295,646 |
Asset Impairment Charges (Table
Asset Impairment Charges (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Asset Impairment Charges [Abstract] | |
Asset Impairment Charges | Year Ended December 31, (In thousands) 2015 2014 2013 Asset impairment charges $ 1,544 $ 2,390 $ 11,454 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Debt Outstanding Excluding Capital Lease | Debt outstanding, excluding capital lease obligations, consisted of the following: December 31, 2015 December 31, 2014 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 61,771 $ 283,229 $ 345,000 $ 73,765 $ 271,235 Senior Secured Credit Facility (long-term portion) 334,375 5,225 329,150 272,410 4,452 267,958 Senior Secured Credit Facility (current portion) 12,500 479 12,021 28,125 892 27,233 Other debt 183 0 183 0 0 0 Total debt $ 692,058 $ 67,475 $ 624,583 $ 645,535 $ 79,109 $ 566,426 |
Interest Expense | Interest expense consisted of the following: Year Ended December 31, (In thousands) 2015 2014 2013 Interest expense $ 16,284 $ 16,020 $ 14,703 Amortization of discounts and debt issuance costs 13,679 13,277 9,451 Write off of unamortized deferred debt issuance costs 1,433 0 3,901 Total interest expense $ 31,396 $ 29,297 $ 28,055 |
Interest Expense Related to Notes | Interest expense related to the 1.25% Notes was comprised of the following: Year Ended December 31, (In thousands) 2015 2014 2013 Coupon interest at 1.25% $ 4,312 $ 4,312 $ 2,312 Amortization of discounts and debt issuance costs 11,994 11,433 5,910 Total interest expense related to the 1.25% Notes $ 16,306 $ 15,745 $ 8,222 |
Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities | The following table summarizes our future payments under the 1.25% Notes and the Senior Secured Credit Facility as of December 31, 2015: (In thousands) Total 2016 2017 2018 2019 2020 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 Term Loan 246,875 12,500 15,625 28,125 40,625 150,000 Revolving Facility 100,000 0 0 0 0 100,000 Other debt 183 183 0 0 0 0 Total debt $ 692,058 $ 12,683 $ 15,625 $ 28,125 $ 40,625 $ 595,000 (1) Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Geographic Breakdown of (Loss) Income Before Income Tax Benefits | The following is a geographic breakdown of income (loss) before income tax benefits: Year Ended December 31, (In thousands) 2015 2014 2013 United States $ (5,357 ) $ (62,987 ) $ (137,468 ) Foreign 5,927 (5,130 ) (10,878 ) Total income (loss) before income taxes $ 570 $ (68,117 ) $ (148,346 ) |
Components of Provision (Benefit) for Income Taxes | The following is a summary of the components of the provision (benefit) for income taxes: Year Ended December 31, (In thousands) 2015 2014 2013 Current tax provision Federal $ 570 $ 840 $ (448 ) State 658 213 1,421 Foreign 4,083 (399 ) 45 5,311 654 1,018 Deferred tax provision Federal (2,928 ) (581 ) (43,542 ) State 898 (3,261 ) (7,929 ) Foreign (655 ) 1,524 6,133 (2,685 ) (2,318 ) (45,338 ) Income tax provision (benefit) $ 2,626 $ (1,664 ) $ (44,320 ) |
Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes | Taxes computed at the statutory federal income tax rate of 35% are reconciled to the provision for income taxes as follows: Year Ended December 31, (In thousands) 2015 2014 2013 United States federal tax at statutory rate $ 138 $ (23,844 ) $ (51,921 ) Items affecting federal income tax rate Non-deductible acquisition and reorganization expenses (2 ) (56 ) 234 Research credits (3,000 ) (3,133 ) (7,454 ) Change in unrecognized tax benefits (208 ) (519 ) 1,665 State income taxes, net of federal benefit 182 (2,120 ) (4,841 ) Compensation 765 1,017 844 Meals and entertainment 1,023 954 1,052 Impact of foreign operations 1,848 2,505 1,559 Provision-to-Return adjustments (136 ) 0 0 Settlements with taxing authorities (4,218 ) 0 0 Deemed Dividends 1,408 0 0 Dividends Accrued 1,190 0 0 Federal, state and local rate changes 1,104 (268 ) (1,056 ) Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement 0 0 (4,432 ) Bilateral Advance Pricing Agreement impact 524 (199 ) 4,794 Non-deductible items (5 ) 82 82 Valuation allowance 1,816 24,666 13,627 Other 197 (749 ) 1,527 Effective rate $ 2,626 $ (1,664 ) $ (44,320 ) |
Components of Deferred Tax Assets and Liabilities | Significant components of our deferred tax assets and liabilities consist of the following: December 31, December 31, (In thousands) 2015 2014 Deferred tax assets Accruals and reserves, net $ 24,548 $ 26,086 Allowance for doubtful accounts 12,194 14,159 Stock-based compensation, net 12,086 10,773 Deferred revenue 13,294 17,422 Net operating loss carryforwards 78,909 90,463 Research and development tax credit 26,863 24,313 AMT credits 6,070 5,606 Other 7,012 3,617 Less: Valuation Allowance (43,043 ) (41,273 ) Total deferred tax assets 137,933 151,166 Deferred tax liabilities Prepaid expense (8,594 ) (9,268 ) Property and equipment, net (3,953 ) (903 ) Acquired intangibles, net (145,252 ) (160,130 ) Total deferred tax liabilities (157,799 ) (170,301 ) Net deferred tax liabilities $ (19,866 ) $ (19,135 ) |
Deferred Tax Assets (Liabilities) Classified in Consolidated Balance Sheets | The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows: December 31, December 31, (In thousands) 2015 2014 Non-current deferred tax assets, net 2,298 1,984 Non-current deferred tax liabilities, net (22,164 ) (21,119 ) Non-current deferred tax liabilities, net (19,866 ) (19,135 ) |
Change in the Amount of Unrecognized Tax Benefits | Changes in the amounts of unrecognized tax benefits were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Beginning balance as of January 1 $ 15,314 $ 18,283 $ 18,140 Increases for tax positions related to the current year 600 627 1,517 Decreases for tax positions related to prior years 0 (3,239 ) (23 ) Increases for tax positions related to prior years 50 173 3,238 Decreases relating to settlements with taxing authorities (3,805 ) (384 ) (4,099 ) Foreign currency translation (24 ) (26 ) (394 ) Reductions due to lapsed statute of limitations (358 ) (120 ) (96 ) Ending balance as of December 31 $ 11,777 $ 15,314 $ 18,283 |
Recognized Interest and Penalties Related to Uncertain Tax Positions | We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Interest and penalties included in the provision for income taxes $ (103 ) $ (715 ) $ (188 ) |
Amount of Interest and Penalties Included in Consolidated Balance Sheets | The amount of interest and penalties included in our consolidated balance sheets is as follows: December 31, December 31, (In thousands) 2015 2014 Interest and penalties included in the liability for uncertain tax positions $ 1,193 $ 1,295 |
Stock Award Plans (Tables)
Stock Award Plans (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Stock-Based Compensation Expense | We recorded stock-based compensation expense as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Cost of revenue: Software delivery, support and maintenance $ 4,224 $ 1,492 $ 1,746 Client services 4,508 4,422 3,898 Total cost of revenue 8,732 5,914 5,644 Selling, general and administrative expenses 20,069 25,376 23,013 Research and development 7,826 7,964 8,353 Total stock-based compensation expense $ 36,627 $ 39,254 $ 37,010 |
Stock Options Outstanding | The following table summarizes the status of stock options outstanding and the changes during the periods presented: Options Weighted-Average Options Weighted-Average (In thousands, except per share amounts) Outstanding Exercise Price Exercisable Exercise Price Balance as of December 31, 2012 2,667 $ 12.04 2,548 $ 11.88 Options granted 3,870 $ 13.79 Options exercised (1,442 ) $ 8.47 Options forfeited (773 ) $ 14.94 Balance as of December 31, 2013 4,322 $ 14.28 1,025 $ 15.52 Options granted 0 $ 0.00 Options exercised (289 ) $ 11.88 Options forfeited (606 ) $ 15.03 Balance as of December 31, 2014 3,427 $ 14.35 1,393 $ 14.97 Options granted 0 $ 0.00 Options exercised (317 ) $ 11.44 Options forfeited (767 ) $ 15.89 Balance as of December 31, 2015 2,343 $ 14.24 1,282 $ 14.52 |
Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions | The following table contains the stock option weighted-average grant date fair value information and related valuation assumptions for the year ended December 31, 2013. No stock option awards were granted during the years ended December 31, 2015 and 2014. Stock options granted (in thousands) 3,870 Fair Value per option $ 6.25 Valuation assumptions: Expected term ( in years) 4.8 Expected volatility 54.0 % Expected dividend yield 0 % Risk-free interest rate 0.9 % |
Stock Option Activity | The following activity occurred under our plans: Year Ended December 31, (In thousands) 2015 2014 2013 Total intrinsic value of stock options exercised $ 972 $ 1,535 $ 7,500 Total fair value of share awards vested $ 21,673 $ 31,672 $ 28,609 |
Stock Option Awards | The following table summarizes information about stock options outstanding as of December 31, 2015: Number of Number of Options Weighted-Average Options Weighted-Average Range of Exercise Prices Outstanding Exercise Price Exercisable Exercise Price $12.50 to $14.78 1,917,799 $ 13.79 937,225 $ 13.78 $14.94 to $16.80 364,097 $ 15.91 283,624 $ 16.10 $18.45 to $18.74 60,720 $ 18.51 60,720 $ 18.51 2,342,616 1,281,569 |
Restricted Stock Units (RSUs) [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Activity for Restricted Stock Awards | The following table summarizes the activity for restricted stock units during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock units as of December 31, 2012 6,728 $ 13.43 Awarded 2,511 $ 15.06 Vested (2,023 ) $ 13.77 Forfeited (1,482 ) $ 13.74 Unvested restricted stock units as of December 31, 2013 5,734 $ 13.94 Awarded 2,199 $ 18.09 Vested (2,044 ) $ 13.90 Forfeited (793 ) $ 14.28 Unvested restricted stock units as of December 31, 2014 5,096 $ 15.69 Awarded 2,937 $ 12.07 Vested (1,612 ) $ 14.84 Forfeited (1,042 ) $ 14.74 Unvested restricted stock units as of December 31, 2015 5,379 $ 14.15 |
Restricted Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Activity for Restricted Stock Awards | The following table summarizes the activity for restricted stock awards during the periods presented: Weighted-Average (In thousands, except per share amounts) Shares Grant Date Fair Value Unvested restricted stock awards as of December 31, 2012 20 $ 15.94 Vested (17 ) $ 15.92 Forfeited (3 ) $ 16.05 Unvested restricted stock awards as of December 31, 2013 0 $ 0.00 Vested 0 $ 0.00 Forfeited 0 $ 0.00 Unvested restricted stock awards as of December 31, 2014 0 $ 0.00 Vested 0 $ 0.00 Forfeited 0 $ 0.00 Unvested restricted stock awards as of December 31, 2015 0 $ 0.00 |
Accumulated Other Comprehensi37
Accumulated Other Comprehensive Loss (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Loss | Changes in the balances of each component included in accumulated other comprehensive loss (“AOCI”) are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains (Losses) on Interest Rate Swap Unrealized Net Gains (Losses) on Foreign Exchange Contracts Total Balance as of December 31, 2012 (1) $ 892 $ 118 $ (934 ) $ 0 $ 76 Other comprehensive income (loss) before reclassifications (2,482 ) 6 (85 ) 0 (2,561 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 740 0 740 Net other comprehensive (loss) income (2,482 ) 6 655 0 (1,821 ) Balance as of December 31, 2013 (2) (1,590 ) 124 (279 ) 0 (1,745 ) Other comprehensive income (loss) before reclassifications (529 ) 16 (23 ) 0 (536 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 302 0 302 Net other comprehensive (loss) income (529 ) 16 279 0 (234 ) Balance as of December 31, 2014 (3) (2,119 ) 140 0 0 (1,979 ) Other comprehensive (loss) income before reclassifications (2,381 ) 0 0 191 (2,190 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 (140 ) 0 67 (73 ) Net other comprehensive (loss) income (2,381 ) (140 ) 0 258 (2,263 ) Balance as of December 31, 2015 (4) $ (4,500 ) $ 0 $ 0 $ 258 $ (4,242 ) (1) (2) ( 3 ) (4) |
Income Tax Effects Related to Components of Other Comprehensive Loss | The following tables reflect the tax effects allocated to each component of other comprehensive loss (“OCI”) Year Ended December 31, 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,381 ) $ 0 $ (2,381 ) Marketable securities: Net gain arising during the period 0 0 0 Net gain reclassified into income (228 ) 88 (140 ) Net change in unrealized gains on marketable securities (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period 0 0 0 Net loss reclassified into income 0 0 0 Net change in unrealized losses on interest rate swap 0 0 0 Foreign exchange contracts: Net gains (losses) arising during the period 314 (123 ) 191 Net (gains) losses reclassified into income 110 (43 ) 67 Net change in unrealized gains (losses) on foreign exchange contracts 424 (166 ) 258 Net gain (loss) on cash flow hedges 424 (166 ) 258 Other comprehensive loss $ (2,185 ) $ (78 ) $ (2,263 ) Year Ended December 31, 2014 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (529 ) $ 0 $ (529 ) Marketable securities: Net gain arising during the period 25 (9 ) 16 Net gain reclassified into income 0 0 0 Net change in unrealized gains on marketable securities 25 (9 ) 16 Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period (38 ) 15 (23 ) Net loss reclassified into income 496 (194 ) 302 Net change in unrealized losses on interest rate swap 458 (179 ) 279 Foreign exchange contracts: Net gains (losses) arising during the period 0 0 0 Net (gains) losses reclassified into income 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 0 0 0 Net gain (loss) on cash flow hedges 458 (179 ) 279 Other comprehensive loss $ (46 ) $ (188 ) $ (234 ) Year Ended December 31, 2013 (In thousands) Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (2,482 ) $ 0 $ (2,482 ) Marketable securities: Net gain arising during the period 10 (4 ) 6 Net gain reclassified into income 0 0 0 Net change in unrealized gains on marketable securities 10 (4 ) 6 Derivatives qualifying as cash flow hedges: Interest rate swap: Net loss arising during the period (139 ) 54 (85 ) Net loss reclassified into income 1,215 (475 ) 740 Net change in unrealized losses on interest rate swap 1,076 (421 ) 655 Foreign exchange contracts: Net gains (losses) arising during the period 0 0 0 Net (gains) losses reclassified into income 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 0 0 0 Net gain (loss) on cash flow hedges 1,076 (421 ) 655 Other comprehensive loss $ (1,396 ) $ (425 ) $ (1,821 ) |
Derivative Financial Instrume38
Derivative Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Fair Value and Balance Sheet Locations | The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ - Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 December 31, 2014 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 57,091 N/A 1.25% Embedded cash conversion option N/A Other liabilities 57,839 Total derivatives $ 57,091 $ 57,839 N/A – We define “N/A” as disclosure not being applicable |
Derivatives Instruments Designated as Cash Flow Hedges | The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Year Ended December 31, Year Ended December 31, (In thousands) 2015 2014 2013 2015 2014 2013 Foreign exchange contracts $ 314 $ 0 $ 0 Cost of Revenue $ (34 ) $ 0 $ 0 Selling, general and administrative expenses (28 ) 0 0 Research and development (48 ) 0 0 Interest rate swap $ 0 $ (38 ) $ (139 ) Interest expense $ 0 $ (496 ) $ (1,215 ) |
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option | The following table shows the net impact of the changes in fair values of the 1.25% Call Option and 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Year Ended December 31, (In thousands) 2015 2014 2013 1.25% Call Option $ 23,117 $ (47,565 ) $ 21,856 1.25% Embedded cash conversion option (23,371 ) 47,798 (22,837 ) Net gain (loss) included in other income, net $ (254 ) $ 233 $ (981 ) |
Commitments (Tables)
Commitments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Commitments And Contingencies Disclosure [Abstract] | |
Rent Expense | Total rent expense recognized, which consists of the base rental amount and other lessor charges when mandated in a lease agreement, was as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Rent expense $ 18,164 $ 16,259 $ 17,062 |
Future Commitments under Capital and Operating Leases | The long-term portion of capital lease obligations is included on the consolidated balance sheet under other liabilities. Our future commitments under capital and operating leases are shown below. Future operating lease commitments are calculated using the base rental amount and foreign currency exchange rates in effect as of December 31, 2015. Capital Operating (In thousands) Leases Leases 2016 $ 546 $ 17,361 2017 471 14,667 2018 110 11,739 2019 6 10,789 2020 0 9,078 Thereafter 0 46,567 1,133 $ 110,201 Less amount representing interest (142 ) 991 Current maturities of capital lease obligations 431 Capital lease obligations, net of current maturities $ 560 |
Summary of Expense Incurred under Atos Agreement | Expenses incurred under this agreement are included in cost of revenue in our consolidated statements of operations and were as follows: Year Ended December 31, (In thousands) 2015 2014 2013 Expenses incurred under Atos agreement $ 67,058 $ 68,165 $ 62,259 |
Business Segments (Tables)
Business Segments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts | Year Ended December 31, (In thousands) 2015 2014 2013 Revenue: Clinical and Financial Solutions $ 1,072,605 $ 1,079,330 $ 1,094,177 Population Health 296,580 285,383 257,738 Unallocated Amounts 17,208 13,160 21,146 Total revenue $ 1,386,393 $ 1,377,873 $ 1,373,061 Gross Profit: Clinical and Financial Solutions $ 437,229 $ 415,172 $ 428,097 Population Health 196,393 192,584 175,572 Unallocated Amounts (53,057 ) (61,772 ) (69,213 ) Total gross profit $ 580,565 $ 545,984 $ 534,456 Income (loss) from operations: Clinical and Financial Solutions $ 222,958 $ 191,716 $ 186,973 Population Health 131,414 115,871 108,714 Unallocated Amounts (322,489 ) (346,775 ) (423,288 ) Total income (loss) from operations $ 31,883 $ (39,188 ) $ (127,601 ) |
Supplemental Disclosures (Table
Supplemental Disclosures (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Supplemental Disclosures | Year Ended December 31, (In thousands) 2015 2014 2013 Cash paid during the period for: Interest $ 15,750 $ 15,585 $ 12,997 Income taxes paid, net of tax refunds $ 5,037 $ 7,104 $ 7,944 Non-cash transactions: Obligations incurred to purchase capitalized software or enter into capital leases $ 393 $ 4,800 $ 0 |
Accrued Expenses | Accrued expenses consist of the following: December 31, December 31, (In thousands) 2015 2014 Royalties, certain third party product costs and licenses $ 16,456 $ 23,946 Other 45,565 55,021 Total accrued expenses $ 62,021 $ 78,967 |
Geographic Information (Tables)
Geographic Information (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Revenues by Geographic Area | Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below: Year Ended December 31, (In thousands) 2015 2014 2013 United States $ 1,338,095 $ 1,327,840 $ 1,321,779 Canada 18,024 20,727 24,999 Other international 30,274 29,306 26,283 Total $ 1,386,393 $ 1,377,873 $ 1,373,061 |
Long-Lived Assets by Geographic Area | A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below: December 31, December 31, (In thousands) 2015 2014 United States $ 116,731 $ 133,485 India 5,739 8,044 Israel 1,786 2,142 Canada 545 935 Other international 816 1,224 Total $ 125,617 $ 145,830 |
Quarterly Financial Informati43
Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Quarterly Financial Information Disclosure [Abstract] | |
Summary of Quarterly Financial Information | The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters. Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2015 (1) 2015 (1) 2015 (1) 2015 Revenue $ 345,647 $ 354,476 $ 351,718 $ 334,552 Cost of revenue 191,844 201,128 208,094 204,762 Gross profit 153,803 153,348 143,624 129,790 Selling, general and administrative expenses 79,354 91,043 86,749 82,029 Research and development 45,995 47,702 44,367 46,727 Asset impairment charges 1,203 22 293 26 Amortization of intangible and acquisition-related assets 4,133 5,712 6,624 6,703 Income (loss) from operations 23,118 8,869 5,591 (5,695 ) Interest expense (7,403 ) (9,254 ) (3) (7,483 ) (7,256 ) Other (expense) income, net (98 ) 423 (28 ) 1,886 Equity in net earnings of unconsolidated investments (797 ) (1,479 ) 176 0 Income (loss) before income taxes 14,820 (1,441 ) (1,744 ) (11,065 ) Income tax benefit (provision) 1,557 (3,692 ) (2) (1,472 ) 981 Net income (loss) 16,377 (5,133 ) (3,216 ) (10,084 ) Less: Net income attributable to non-controlling interest (50 ) (111 ) (9 ) 0 Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 16,327 $ (5,244 ) $ (3,225 ) $ (10,084 ) Earnings (loss) per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ 0.09 $ (0.03 ) $ (0.01 ) $ (0.06 ) Quarter Ended December 31, September 30, June 30, March 31, (In thousands, except per share amounts) 2014 2014 2014 2014 Revenue $ 340,903 $ 345,389 $ 351,296 $ 340,285 Cost of revenue 204,549 213,933 211,308 202,099 Gross profit 136,354 131,456 139,988 138,186 Selling, general and administrative expenses 85,038 97,034 86,663 89,946 Research and development 41,538 45,962 53,016 52,305 Asset impairment charges 256 188 1,751 195 Amortization of intangible and acquisition-related assets 8,866 7,112 7,651 7,651 Income (loss) from operations 656 (18,840 ) (9,093 ) (11,911 ) Interest expense (7,292 ) (7,542 ) (7,230 ) (7,233 ) Other income (expense), net 397 171 230 (32 ) Equity in net earnings of unconsolidated investments (398 ) 0 0 0 Loss before income taxes (6,637 ) (26,211 ) (16,093 ) (19,176 ) Income tax benefit (provision) 4,459 448 (2) (1,677 ) (2) (1,566 ) (2) Net income (loss) (2,178 ) (25,763 ) (17,770 ) (20,742 ) Less: Net income attributable to non-controlling interest 0 0 0 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (2,178 ) $ (25,763 ) $ (17,770 ) $ (20,742 ) Loss per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (0.01 ) $ (0.15 ) $ (0.09 ) $ (0.12 ) (1) Results of operations for the quarter include the results of operations of a third party with a proportionate share allocated to non-controlling interest for the period subsequent to April 17, 2015, which was the date on which we acquired a majority interest in the third party. (2) ( 3 ) Interest expense includes the write-off of $1.4 million of deferred debt issuance costs in connection with amending our senior secured credit facility. |
Basis of Presentation and Sig44
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) | Jun. 26, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Outstanding money market funds investments | $ 0 | $ 0 | ||
Total consideration for non marketable equity securities | 21,100,000 | |||
Value of equity investments | 19,200,000 | |||
Value of commercial agreement | 1,900,000 | |||
Carrying values of equity method investment | 205,500,000 | 1,000,000 | ||
Payment for investment | 300,000 | |||
Other-than-temporary impairments | $ 0 | 0 | $ 0 | |
Percentage of revenues | No single client accounted for more than 10% of our revenue in the years ended December 31, 2015, 2014 and 2013. | |||
Customer concentration | No client represented more than 10% of accounts receivable as of December 31, 2015 or 2014. | |||
Non-current deferred tax assets | $ 2,298,000 | 1,984,000 | ||
Non-current deferred tax liabilities | $ 22,164,000 | 21,119,000 | ||
Secured Debt [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Debt issuance costs | 9,500,000 | |||
1.25% Cash Convertible Senior Notes [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Interest rate | 1.25% | |||
Interest rate increase (decrease) | 8.00% | |||
Nant Health, LLC [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Carrying values of equity method investment | $ 205,400,000 | $ 203,100,000 | ||
Payment for investment | $ 200,000,000 | $ 200,000,000 | ||
Equity ownership percentage | 10.00% | 10.00% | ||
Warrants Exercised [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Carrying values of equity method investment | $ 1,000,000 | |||
Other Assets [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Carrying values of cost method investments | 17,800,000 | 17,800,000 | ||
Carrying values of equity method investment | $ 2,500,000 | 1,000,000 | ||
Deferred Tax Assets Current [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Current deferred tax assets | 35,600,000 | |||
Deferred Tax Assets Noncurrent [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Non-current deferred tax assets | 1,300,000 | |||
Deferred Tax Liabilities Noncurrent [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Non-current deferred tax liabilities | $ 34,300,000 | |||
Minimum [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Outsourcing services arrangements period | 3 years | |||
Capitalized software estimated economic life | 3 years | |||
Maximum [Member] | ||||
Basis Of Presentation And Significant Accounting Policies [Line Items] | ||||
Outsourcing services arrangements period | 10 years | |||
Capitalized software estimated economic life | 5 years |
Reimbursements for Out-of-Pocke
Reimbursements for Out-of-Pocket Expenses Incurred as Client Services Revenue (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accounting Policies [Abstract] | |||
Reimbursements for out-of-pocket expenses incurred | $ 12,873 | $ 16,251 | $ 18,445 |
Revenue Earned on Contracts in
Revenue Earned on Contracts in Excess of Billings Included in Accounts Receivable and Other Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Accounting Policies [Abstract] | ||
Unbilled revenue (current) | $ 68,444 | $ 42,818 |
Unbilled revenue (long-term) | 0 | 618 |
Total revenue earned on contracts in excess of billings | $ 68,444 | $ 43,436 |
Summary of Financial Assets and
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Long-term marketable securities | $ 0 | $ 1,305 |
Prepaid expenses and other current assets | 93,622 | 102,392 |
Total | (578) | 557 |
Foreign exchange derivative assets [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Prepaid expenses and other current assets | 424 | 0 |
1.25% Notes Embedded Cash Conversion Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other liabilities | (81,210) | (57,839) |
1.25% Call Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other assets | 80,208 | 57,091 |
Level 1 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Long-term marketable securities | 0 | 0 |
Total | 0 | 0 |
Level 1 [Member] | Foreign exchange derivative assets [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Prepaid expenses and other current assets | 0 | 0 |
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other liabilities | 0 | 0 |
Level 1 [Member] | 1.25% Call Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other assets | 0 | 0 |
Level 2 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Long-term marketable securities | 0 | 1,305 |
Total | 424 | 1,305 |
Level 2 [Member] | Foreign exchange derivative assets [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Prepaid expenses and other current assets | 424 | 0 |
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other liabilities | 0 | 0 |
Level 2 [Member] | 1.25% Call Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other assets | 0 | 0 |
Level 3 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Long-term marketable securities | 0 | 0 |
Total | (1,002) | (748) |
Level 3 [Member] | Foreign exchange derivative assets [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Prepaid expenses and other current assets | 0 | 0 |
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other liabilities | (81,210) | (57,839) |
Level 3 [Member] | 1.25% Call Option [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Other assets | $ 80,208 | $ 57,091 |
Unamortized Balances of Capital
Unamortized Balances of Capitalized Software (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Accounting Policies [Abstract] | ||
Software development costs | $ 200,531 | $ 213,601 |
Less: accumulated amortization | (114,756) | (127,448) |
Software development costs, net | $ 85,775 | $ 86,153 |
Capitalized Software Developmen
Capitalized Software Development Costs, Write Offs Included in Asset Impairment Changes and Amortization of Capitalized Software Development Costs Included in Cost of Revenue (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accounting Policies [Abstract] | |||
Capitalized software development costs | $ 46,464 | $ 45,461 | $ 42,026 |
Write-offs of capitalized software development costs | 1,444 | 5,234 | |
Amortization of capitalized software development costs | $ 46,842 | $ 46,108 | $ 44,127 |
Calculations of Earnings (Loss)
Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Basic Loss per Common Share: | |||||||||||
Net loss | $ 16,377 | $ (5,133) | $ (3,216) | $ (10,084) | $ (2,178) | $ (25,763) | $ (17,770) | $ (20,742) | $ (2,056) | $ (66,453) | $ (104,026) |
Less: Net income attributable to non-controlling interest | (50) | (111) | (9) | 0 | 0 | 0 | 0 | 0 | (170) | 0 | 0 |
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | 16,327 | (5,244) | (3,225) | (10,084) | (2,178) | (25,763) | (17,770) | (20,742) | $ (2,226) | $ (66,453) | $ (104,026) |
Weighted-average common shares outstanding | 185,082 | 179,849 | 177,026 | ||||||||
Basic Loss per Common Share | $ (0.01) | $ (0.37) | $ (0.59) | ||||||||
Diluted Loss per Common Share: | |||||||||||
Net loss | 16,377 | (5,133) | (3,216) | (10,084) | (2,178) | (25,763) | (17,770) | (20,742) | $ (2,056) | $ (66,453) | $ (104,026) |
Less: Net income attributable to non-controlling interest | (50) | (111) | (9) | 0 | 0 | 0 | 0 | 0 | (170) | 0 | 0 |
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ 16,327 | $ (5,244) | $ (3,225) | $ (10,084) | $ (2,178) | $ (25,763) | $ (17,770) | $ (20,742) | $ (2,226) | $ (66,453) | $ (104,026) |
Weighted-average common shares outstanding | 185,082 | 179,849 | 177,026 | ||||||||
Dilutive effect of stock options, restricted stock unit awards and warrants | 0 | 0 | 0 | ||||||||
Weighted-average common shares outstanding assuming dilution | 185,082 | 179,849 | 177,026 | ||||||||
Diluted Loss per Common Share | $ (0.01) | $ (0.37) | $ (0.59) |
Anti-Dilutive Stock Options, Re
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Earnings Per Share [Abstract] | |||
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation | 25,063 | 24,254 | 14,926 |
Company Contributions to Employ
Company Contributions to Employee Benefit Plan (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accounting Policies [Abstract] | |||
Company contributions to employee benefit plans | $ 16,397 | $ 16,427 | $ 15,276 |
Business Combinations and Oth53
Business Combinations and Other Investments - Acquisition of Oasis Medical Solutions Limited - Additional Information (Detail) - USD ($) | Jul. 08, 2014 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2013 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 1,200,746,000 | $ 1,222,601,000 | $ 1,189,585,000 | |
Oasis Medical Solutions Limited [Member] | ||||
Business Acquisition [Line Items] | ||||
Aggregate consideration with a fair value | $ 20,600,000 | |||
Date of acquisition | Jul. 8, 2014 | |||
Acquired cash and cash equivalents, and restricted cash | 400,000 | |||
Assets acquired ,accounts receivable and other current assets | 5,400,000 | |||
Goodwill | 11,200,000 | |||
Assets acquired, fixed assets | 200,000 | |||
Liabilities assumed, accounts payable, deferred revenue and accruals | 6,700,000 | |||
Liabilities assumed, deferred tax liabilities net | 2,300,000 | |||
Acquisition-related costs | $ 0 | $ 0 | ||
Oasis Medical Solutions Limited [Member] | Technology [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquired, intangible assets | 5,600,000 | |||
Intangible assets, useful life (in years) | 10 years | |||
Oasis Medical Solutions Limited [Member] | Trade Name [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquired, intangible assets | 300,000 | |||
Intangible assets, useful life (in years) | 2 years | |||
Oasis Medical Solutions Limited [Member] | Customer Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquired, intangible assets | $ 6,500,000 | |||
Intangible assets, useful life (in years) | 12 years |
Business Combinations and Oth54
Business Combinations and Other Investments - Acquisition of dbMotion - Additional Information (Detail) - USD ($) | Mar. 04, 2013 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Business Acquisition [Line Items] | ||||||||||||
Product consolidation activities | $ 1,203,000 | $ 22,000 | $ 293,000 | $ 26,000 | $ 256,000 | $ 188,000 | $ 1,751,000 | $ 195,000 | $ 1,544,000 | $ 2,390,000 | $ 11,454,000 | |
dbMotion [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Date of acquisition | Mar. 4, 2013 | |||||||||||
Aggregate consideration with a fair value | $ 226,000,000 | |||||||||||
Acquisition, percentage of interest in dbMotion | 4.25% | 4.25% | ||||||||||
Carrying value of interest in dbMotion prior to the acquisition | $ 5,000,000 | $ 5,000,000 | ||||||||||
Remeasurement of interest in dbMotion in connection with the acquisition | 8,367,000 | |||||||||||
Business combination, remeasurement gain | $ 3,400,000 | |||||||||||
Percentage of non-marketable equity securities | 95.75% | 95.75% | ||||||||||
Percentage of estimated control premium | 15.00% | |||||||||||
Increase in fair value of the consideration transferred | $ 1,000,000 | |||||||||||
Acquisition-related costs | $ 0 | |||||||||||
Product consolidation activities | 6,500,000 | |||||||||||
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Acquisition-related costs | 3,700,000 | 7,600,000 | ||||||||||
Product consolidation activities | 5,500,000 | |||||||||||
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Employee Compensation Costs [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Acquisition-related costs | 3,700,000 | 5,900,000 | ||||||||||
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Seller Transaction Costs [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Acquisition-related costs | 500,000 | |||||||||||
dbMotion [Member] | Cost of revenue [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Amortization of software development costs and acquisition-related assets | (800,000) | 7,100,000 | ||||||||||
dbMotion [Member] | Cost of revenue [Member] | Software delivery, Support and Maintenance [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Amortization of software development costs and acquisition-related assets | (200,000) | 5,800,000 | ||||||||||
dbMotion [Member] | Cost of revenue [Member] | Client services [Member] | ||||||||||||
Business Acquisition [Line Items] | ||||||||||||
Amortization of software development costs and acquisition-related assets | $ (600,000) | $ 1,300,000 |
Final Fair Value of Considerati
Final Fair Value of Consideration Transferred for Acquisition (Detail) - dbMotion [Member] $ in Thousands | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Business Acquisition [Line Items] | |
Cash | $ 140,079 |
Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share | 48,061 |
Fair value of Allscripts' previous interest in dbMotion | 8,367 |
Total fair value of consideration transferred | 226,178 |
Deferred Cash Consideration [Member] | |
Business Acquisition [Line Items] | |
Liabilities incurred on total consideration transferred | 23,023 |
Subordinated Promissory Note [Member] | |
Business Acquisition [Line Items] | |
Liabilities incurred on total consideration transferred | $ 6,648 |
Final Fair Value of Considera56
Final Fair Value of Consideration Transferred for Acquisition (Parenthetical) (Detail) - $ / shares | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Business Acquisition [Line Items] | ||
Common stock, par value | $ 0.01 | $ 0.01 |
dbMotion [Member] | ||
Business Acquisition [Line Items] | ||
Common stock, shares | 3,823,453 | |
Common stock, par value | $ 0.01 | |
Common stock, fair value | $ 12.57 | |
dbMotion [Member] | Deferred Cash Consideration [Member] | ||
Business Acquisition [Line Items] | ||
Period of acquisition liability incurred | 18 months | |
dbMotion [Member] | Subordinated Promissory Note [Member] | ||
Business Acquisition [Line Items] | ||
Period of acquisition liability incurred | 18 months |
Assets Acquired and Liabilities
Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Business Acquisition [Line Items] | |||
Goodwill | $ 1,222,601 | $ 1,200,746 | $ 1,189,585 |
dbMotion [Member] | |||
Business Acquisition [Line Items] | |||
Acquired cash and cash equivalents, and restricted cash | 14,188 | ||
Accounts receivable, net | 3,226 | ||
Prepaid expenses and other current assets | 574 | ||
Fixed assets and other long-term assets | 1,449 | ||
Goodwill | 137,649 | ||
Intangible assets | 85,450 | ||
Accounts payable and accrued liabilities | (10,560) | ||
Deferred taxes, net | (36) | ||
Deferred revenue | (5,100) | ||
Other liabilities | (662) | ||
Net assets acquired | $ 226,178 |
Acquired Intangible Assets Amor
Acquired Intangible Assets Amortization (Detail) - dbMotion [Member] $ in Thousands | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Business Acquisition [Line Items] | |
Intangible assets, fair value | $ 85,450 |
Core Technology [Member] | |
Business Acquisition [Line Items] | |
Intangible assets, useful life (in years) | 10 years |
Intangible assets, fair value | $ 80,100 |
Maintenance Agreements [Member] | |
Business Acquisition [Line Items] | |
Intangible assets, useful life (in years) | 12 years |
Intangible assets, fair value | $ 2,500 |
Services Backlog [Member] | |
Business Acquisition [Line Items] | |
Intangible assets, useful life (in years) | 2 years |
Intangible assets, fair value | $ 2,000 |
Non-compete [Member] | |
Business Acquisition [Line Items] | |
Intangible assets, useful life (in years) | 3 years |
Intangible assets, fair value | $ 500 |
Trade Name [Member] | |
Business Acquisition [Line Items] | |
Intangible assets, useful life (in years) | 2 years |
Intangible assets, fair value | $ 350 |
Proforma Results (Detail)
Proforma Results (Detail) $ / shares in Units, $ in Thousands | 12 Months Ended |
Dec. 31, 2013USD ($)$ / shares | |
dbMotion [Member] | |
Business Acquisition [Line Items] | |
Revenue | $ 18,609 |
Net loss | (16,272) |
Combined Entity [Member] | |
Business Acquisition [Line Items] | |
Revenue | 1,378,267 |
Net loss | $ (105,119) |
Net loss per share, basic and diluted | $ / shares | $ (0.59) |
Business Combinations and Oth60
Business Combinations and Other Investments - Acquisition of Jardogs - Additional Information (Detail) - USD ($) | Mar. 04, 2013 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 1,222,601,000 | $ 1,200,746,000 | $ 1,189,585,000 | |
Jardogs [Member] | ||||
Business Acquisition [Line Items] | ||||
Date of acquisition | Mar. 4, 2013 | |||
Aggregate consideration with a fair value | $ 24,000,000 | |||
Assets Acquired, deferred tax assets | 400,000 | |||
Goodwill | $ 17,000,000 | |||
Intangible assets, useful life (in years) | 10 years | |||
Acquisition-related costs | $ 0 | $ 0 | $ 700,000 | |
Jardogs [Member] | Technology [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquired, intangible assets | $ 4,200,000 | |||
Jardogs [Member] | Customer Relationships [Member] | ||||
Business Acquisition [Line Items] | ||||
Assets acquired, intangible assets | $ 2,400,000 |
Business Combinations and Oth61
Business Combinations and Other Investments - Other Investments - Additional Information (Detail) - USD ($) $ in Thousands | Jun. 26, 2015 | Apr. 17, 2015 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Business Acquisition [Line Items] | ||||||||||||||
Payment for investment | $ 300 | |||||||||||||
Carrying values of equity method investment | $ 205,500 | $ 1,000 | $ 205,500 | 205,500 | $ 1,000 | |||||||||
Equity in net loss of unconsolidated investments | 797 | $ 1,479 | $ (176) | $ 0 | $ 398 | $ 0 | $ 0 | $ 0 | 2,100 | $ 398 | $ 0 | |||
Third Party [Member] | ||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||
Payment for acquiring a majority interest in a third party | $ 11,100 | |||||||||||||
Provided loan to third party to refinance outstanding indebtedness | 9,300 | |||||||||||||
Allocations of the estimated fair value, net assets of the third party to goodwill | 22,300 | |||||||||||||
Allocations of the estimated fair value, net assets of the third party to intangibles | 4,300 | |||||||||||||
Allocations of the estimated fair value, net assets of the third party to non-controlling interest | $ 11,000 | |||||||||||||
Nant Health, LLC [Member] | ||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||
Number of shares purchased | 59,099,908 | |||||||||||||
Payment for investment | $ 200,000 | 200,000 | ||||||||||||
Transaction-related expenses | 5,400 | |||||||||||||
Carrying values of equity method investment | $ 205,400 | $ 203,100 | $ 203,100 | $ 203,100 | ||||||||||
Equity ownership percentage | 10.00% | 10.00% | 10.00% | 10.00% | ||||||||||
Underlying equity of net assets | $ 180,000 | |||||||||||||
Equity in net loss of unconsolidated investments | $ 2,300 |
Business Combinations and Oth62
Business Combinations and Other Investments - Summarized Financial Information for Equity Method Investments - Additional Information (Detail) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015USD ($)Investment | Dec. 31, 2014USD ($)Investment | Jun. 26, 2015USD ($) | |
Business Acquisition [Line Items] | |||
Number of equity method investments | Investment | 4 | 1 | |
Carrying values of equity method investment | $ 205.5 | $ 1 | |
Nant Health, LLC [Member] | |||
Business Acquisition [Line Items] | |||
Carrying values of equity method investment | $ 203.1 | $ 205.4 |
Summarized Financial Informatio
Summarized Financial Information for Equity Method Investments (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Sep. 30, 2015 | Sep. 30, 2014 | Dec. 31, 2014 | |
Equity Method Investments And Joint Ventures [Abstract] | |||
Current assets | $ 58,550 | $ 1,486 | |
Noncurrent assets | 411,159 | 1,812 | |
Current liabilities | 77,188 | 3,300 | |
Noncurrent liabilities | 166,898 | 2,191 | |
Equity of equity method investments | 225,623 | $ (2,193) | |
Revenue | 33,896 | $ 2,422 | |
Net loss | $ (20,256) | $ (484) |
Fixed Assets (Detail)
Fixed Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Property Plant And Equipment [Line Items] | ||
Fixed assets, gross | $ 358,219 | $ 337,699 |
Less: Accumulated depreciation and amortization | (232,602) | (191,869) |
Fixed assets, net | 125,617 | 145,830 |
Computer Equipment and Software [Member] | ||
Property Plant And Equipment [Line Items] | ||
Fixed assets, gross | $ 304,032 | 284,185 |
Computer Equipment and Software [Member] | Minimum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 3 years | |
Computer Equipment and Software [Member] | Maximum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 10 years | |
Facility Furniture, Fixtures and Equipment [Member] | ||
Property Plant And Equipment [Line Items] | ||
Fixed assets, gross | $ 20,302 | 19,846 |
Facility Furniture, Fixtures and Equipment [Member] | Minimum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 5 years | |
Facility Furniture, Fixtures and Equipment [Member] | Maximum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 7 years | |
Leasehold Improvements [Member] | ||
Property Plant And Equipment [Line Items] | ||
Fixed assets, gross | $ 30,619 | 30,795 |
Estimated useful life, description | 7 to 8 years, or life of lease if shorter | |
Leasehold Improvements [Member] | Minimum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 7 years | |
Leasehold Improvements [Member] | Maximum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 8 years | |
Assets Under Capital Lease [Member] | ||
Property Plant And Equipment [Line Items] | ||
Fixed assets, gross | $ 3,266 | $ 2,873 |
Assets Under Capital Lease [Member] | Minimum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 3 years | |
Assets Under Capital Lease [Member] | Maximum [Member] | ||
Property Plant And Equipment [Line Items] | ||
Estimated useful life (in years) | 5 years |
Depreciation and Amortization E
Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Property Plant And Equipment [Abstract] | |||
Fixed assets depreciation and amortization expense | $ 42,153 | $ 48,465 | $ 52,545 |
Goodwill and Intangible Asset66
Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Schedule Of Goodwill And Intangible Assets [Line Items] | |||
Gross Carrying Amount | $ 1,003,247 | $ 1,001,374 | |
Accumulated Amortization | (707,601) | (650,012) | |
Intangible Assets, Net | 295,646 | 351,362 | |
Registered trademarks | 52,000 | 52,000 | |
Goodwill | 1,222,601 | 1,200,746 | $ 1,189,585 |
Total | 1,274,601 | 1,252,746 | |
Proprietary Technology [Member] | |||
Schedule Of Goodwill And Intangible Assets [Line Items] | |||
Gross Carrying Amount | 450,852 | 451,087 | |
Accumulated Amortization | (302,284) | (267,547) | |
Intangible Assets, Net | 148,568 | 183,540 | |
Customer Contracts and Relationships [Member] | |||
Schedule Of Goodwill And Intangible Assets [Line Items] | |||
Gross Carrying Amount | 552,395 | 550,287 | |
Accumulated Amortization | (405,317) | (382,465) | |
Intangible Assets, Net | $ 147,078 | $ 167,822 |
Goodwill and Intangible Asset67
Goodwill and Intangible Assets - Additional Information (Detail) | Sep. 30, 2015 | Mar. 31, 2014USD ($) | Dec. 31, 2015USD ($)Segment | Dec. 31, 2014USD ($)Segment | Dec. 31, 2013USD ($) |
Schedule Of Goodwill And Intangible Assets [Line Items] | |||||
Number of reportable segments | Segment | 2 | 3 | |||
Accumulated impairment losses associated with goodwill | $ 0 | $ 0 | |||
Goodwill, impairments recorded | 0 | 0 | $ 0 | ||
Additional goodwill recognized | $ 22,319,000 | 12,173,000 | |||
Cash flow discount rate | 10.00% | ||||
Oasis Medical Solutions Limited [Member] | |||||
Schedule Of Goodwill And Intangible Assets [Line Items] | |||||
Additional goodwill recognized | 11,155,000 | ||||
dbMotion [Member] | |||||
Schedule Of Goodwill And Intangible Assets [Line Items] | |||||
Additional goodwill recognized | $ 1,000,000 | $ 1,018,000 |
Changes in Carrying Amount of G
Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Goodwill [Line Items] | |||
Goodwill | $ 1,189,585 | $ 1,200,746 | $ 1,189,585 |
Additions arising from business acquisitions | 22,319 | 12,173 | |
Foreign exchange translation | (464) | (1,012) | |
Goodwill, net | 1,222,601 | 1,200,746 | |
Oasis Medical Solutions Limited [Member] | |||
Goodwill [Line Items] | |||
Additions arising from business acquisitions | 11,155 | ||
dbMotion [Member] | |||
Goodwill [Line Items] | |||
Additions arising from business acquisitions | 1,000 | 1,018 | |
Goodwill, net | 137,649 | ||
Clinical and Financial Solutions [Member] | |||
Goodwill [Line Items] | |||
Goodwill | 764,369 | 774,512 | 764,369 |
Additions arising from business acquisitions | 22,319 | 11,155 | |
Foreign exchange translation | (464) | (1,012) | |
Goodwill, net | 796,367 | 774,512 | |
Clinical and Financial Solutions [Member] | Oasis Medical Solutions Limited [Member] | |||
Goodwill [Line Items] | |||
Additions arising from business acquisitions | 11,155 | ||
Population Health [Member] | |||
Goodwill [Line Items] | |||
Goodwill | $ 425,216 | 426,234 | 425,216 |
Additions arising from business acquisitions | 0 | 1,018 | |
Foreign exchange translation | 0 | 0 | |
Goodwill, net | $ 426,234 | 426,234 | |
Population Health [Member] | Oasis Medical Solutions Limited [Member] | |||
Goodwill [Line Items] | |||
Additions arising from business acquisitions | 0 | ||
Population Health [Member] | dbMotion [Member] | |||
Goodwill [Line Items] | |||
Additions arising from business acquisitions | $ 1,018 |
Amortization Expense Related to
Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Goodwill And Intangible Assets [Line Items] | |||||||||||
Proprietary technology amortization included in cost of revenue | $ 81,986 | $ 81,215 | $ 85,201 | ||||||||
Intangible amortization included in operating expenses | $ 4,133 | $ 5,712 | $ 6,624 | $ 6,703 | $ 8,866 | $ 7,112 | $ 7,651 | $ 7,651 | 23,172 | 31,280 | 31,253 |
Total intangible amortization expense | $ 58,316 | $ 67,204 | 58,316 | 67,204 | 65,223 | ||||||
Proprietary Technology [Member] | |||||||||||
Goodwill And Intangible Assets [Line Items] | |||||||||||
Proprietary technology amortization included in cost of revenue | $ 35,144 | $ 35,924 | $ 33,970 |
Estimated Future Amortization E
Estimated Future Amortization Expense for Intangible Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Goodwill And Intangible Assets Disclosure [Abstract] | ||
2,016 | $ 45,515 | |
2,017 | 40,401 | |
2,018 | 33,712 | |
2,019 | 33,712 | |
2,020 | 33,008 | |
Thereafter | 109,298 | |
Intangible Assets, Net | $ 295,646 | $ 351,362 |
Asset Impairment Charges - Addi
Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Asset Impairment Charges [Line Items] | |||||||||||
Non-cash charges recorded to earnings | $ 1,203 | $ 22 | $ 293 | $ 26 | $ 256 | $ 188 | $ 1,751 | $ 195 | $ 1,544 | $ 2,390 | $ 11,454 |
Wrote-off certain deferred costs | 300 | ||||||||||
MyWay [Member] | |||||||||||
Asset Impairment Charges [Line Items] | |||||||||||
Non-cash charges recorded to earnings | 800 | 5,000 | |||||||||
Capitalized Software Development Projects [Member] | |||||||||||
Asset Impairment Charges [Line Items] | |||||||||||
Non-cash charges recorded to earnings | $ 1,600 | ||||||||||
Commercial Agreement[Member] | |||||||||||
Asset Impairment Charges [Line Items] | |||||||||||
Non-cash charges recorded to earnings | $ 1,200 | ||||||||||
dbMotion [Member] | |||||||||||
Asset Impairment Charges [Line Items] | |||||||||||
Non-cash charges recorded to earnings | $ 6,500 |
Asset Impairment Charges (Detai
Asset Impairment Charges (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Asset Impairment Charges [Abstract] | |||||||||||
Asset impairment charges | $ 1,203 | $ 22 | $ 293 | $ 26 | $ 256 | $ 188 | $ 1,751 | $ 195 | $ 1,544 | $ 2,390 | $ 11,454 |
Debt Outstanding Excluding Capi
Debt Outstanding Excluding Capital Lease Obligations (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 | Jun. 18, 2013 | |
Debt Instrument [Line Items] | ||||
Principal Balance | $ 692,058 | $ 645,535 | ||
Unamortized Discount and Debt Issuance Costs | 67,475 | 79,109 | ||
Net Carrying Amount | 624,583 | 566,426 | ||
1.25% Cash Convertible Senior Notes [Member] | ||||
Debt Instrument [Line Items] | ||||
Principal Balance | 345,000 | [1] | 345,000 | $ 345,000 |
Unamortized Discount and Debt Issuance Costs | 61,771 | 73,765 | ||
Net Carrying Amount | 283,229 | 271,235 | ||
Senior Secured Credit Facility (long-term portion) [Member] | ||||
Debt Instrument [Line Items] | ||||
Principal Balance | 334,375 | 272,410 | ||
Unamortized Discount and Debt Issuance Costs | 5,225 | 4,452 | ||
Net Carrying Amount | 329,150 | 267,958 | ||
Senior Secured Credit Facility (current portion) [Member] | ||||
Debt Instrument [Line Items] | ||||
Principal Balance | 12,500 | 28,125 | ||
Unamortized Discount and Debt Issuance Costs | 479 | 892 | ||
Net Carrying Amount | 12,021 | 27,233 | ||
Other Debt [Member] | ||||
Debt Instrument [Line Items] | ||||
Principal Balance | 183 | 0 | ||
Unamortized Discount and Debt Issuance Costs | 0 | 0 | ||
Net Carrying Amount | $ 183 | $ 0 | ||
[1] | Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. |
Interest Expense (Detail)
Interest Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Debt Disclosure [Abstract] | |||||||||||
Interest expense | $ 16,284 | $ 16,020 | $ 14,703 | ||||||||
Amortization of discounts and debt issuance costs | 13,679 | 13,277 | 9,451 | ||||||||
Write off of unamortized deferred debt issuance costs | 1,433 | 0 | 3,901 | ||||||||
Total interest expense | $ 7,403 | $ 9,254 | $ 7,483 | $ 7,256 | $ 7,292 | $ 7,542 | $ 7,230 | $ 7,233 | $ 31,396 | $ 29,297 | $ 28,055 |
Debt - Additional Information (
Debt - Additional Information (Detail) - USD ($) | 3 Months Ended | 12 Months Ended | |||||
Jun. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2015 | Jun. 18, 2013 | ||
Debt Instrument [Line Items] | |||||||
Debt instrument principal amount | $ 692,058,000 | $ 645,535,000 | |||||
Debt instrument capitalized amount | 3,300,000 | ||||||
Payments for 1.25% Call Option | 0 | 0 | $ 82,800,000 | ||||
Proceeds from issuance of warrants, net of issuance costs | $ 0 | 0 | 51,208,000 | ||||
Net cash payment for 1.25% Notes call spread overlay | 31,600,000 | ||||||
Maximum percentage of foreign subsidiary capital stock guaranteeing credit facility | 65.00% | ||||||
Deferred debt issuance cost written off with existing Credit Facility | $ 1,433,000 | 0 | 3,901,000 | ||||
Secured Debt [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt issuance costs | 9,500,000 | ||||||
Letter of Credit [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Portion of facility available for issuance of letters of credit | $ 50,000,000 | ||||||
Line of Credit [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Portion of facility available for issuance of swingline loans | 10,000,000 | ||||||
Revolving Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument principal amount | 100,000,000 | ||||||
Credit facility borrowings | $ 100,000,000 | ||||||
1.25% Cash Convertible Senior Notes [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument principal amount | 345,000,000 | [1] | $ 345,000,000 | $ 345,000,000 | |||
Proceeds from debt | $ 305,100,000 | ||||||
Interest payment, terms | Interest on the 1.25% Notes is payable semiannually in arrears on January 1 and July 1 of each year | ||||||
Debt, Maturity date | Jul. 1, 2020 | ||||||
Debt instrument convertible, principal amount | $ 1,000 | ||||||
Convertible number of equity instrument | 58.1869 | ||||||
Conversion price per common stock | $ 17.19 | ||||||
Repurchase percentage on principal | 100.00% | ||||||
Fair value liability of embedded cash conversion option | $ 82,800,000 | ||||||
Convertible debt instrument remaining discount amortization period | 4 years 6 months | ||||||
Debt instrument, interest rate, effective percentage | 5.40% | ||||||
Debt instrument interest rate | 1.25% | ||||||
Debt Instrument, fees and aggregate cost | $ 8,400,000 | ||||||
Debt instrument capitalized amount | 8,300,000 | ||||||
Deferred charges capitalized amount outstanding | 5,300,000 | ||||||
Accrued and unpaid interest | $ 2,200,000 | ||||||
Payments for 1.25% Call Option | $ 82,800,000 | ||||||
1.25% Cash Convertible Senior Notes [Member] | Condition One [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Threshold trading days | 20 days | ||||||
Threshold consecutive trading days | 30 days | ||||||
Debt instrument conversion price percentage | 130.00% | ||||||
1.25% Cash Convertible Senior Notes [Member] | Condition Two [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Threshold trading days | 5 days | ||||||
Threshold consecutive trading days | 5 days | ||||||
Debt instrument conversion price percentage | 98.00% | ||||||
Debt instrument convertible, principal amount | $ 1,000 | ||||||
Senior Secured Term Loan [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument principal amount | $ 246,875,000 | ||||||
Credit facility, maximum borrowing capacity | 250,000,000 | ||||||
Term Loan repayment, end date | Sep. 30, 2020 | ||||||
Credit facility, increase in total borrowing limits | 25,000,000 | ||||||
Senior secured credit facilities term, years | 5 years | ||||||
Senior Secured Revolving Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument principal amount | $ 100,000,000 | ||||||
Credit facility, maximum borrowing capacity | 550,000,000 | ||||||
Credit facility, increase in total borrowing limits | 125,000,000 | ||||||
Credit facility, maximum borrowing capacity, foreign currencies | $ 100,000,000 | ||||||
Senior secured credit facilities term, years | 5 years | ||||||
Applicable margin for borrowings based on federal funds rate | 0.50% | ||||||
Initial margin for borrowings based on non-Eurocurrency rate | 1.25% | ||||||
Initial margin for borrowings based on Eurocurrency rate | 2.25% | ||||||
Basis point reduction in applicable interest rate margin ranges | 0.50% | ||||||
Credit facility, amount available | $ 449,300,000 | ||||||
Senior Secured Revolving Facility [Member] | Eurocurrency Rate for U.S. Dollars [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 1.00% | ||||||
Senior Secured Revolving Facility [Member] | 2015 Credit Agreement [Member] | Base Rate [Member] | Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 0.00% | ||||||
Senior Secured Revolving Facility [Member] | 2015 Credit Agreement [Member] | Base Rate [Member] | Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 1.25% | ||||||
Senior Secured Revolving Facility [Member] | 2015 Credit Agreement [Member] | Eurocurrency Rate [Member] | Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 1.00% | ||||||
Senior Secured Revolving Facility [Member] | 2015 Credit Agreement [Member] | Eurocurrency Rate [Member] | Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 2.25% | ||||||
Senior Secured Credit Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Aggregate amount of additional credit facilities authorized | $ 300,000,000 | ||||||
Letters of credit outstanding | $ 700,000 | ||||||
Senior Secured Credit Facility [Member] | United States dollars [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt instrument, interest rate, effective percentage | 2.42% | ||||||
Senior Secured Credit Facility [Member] | Minimum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Interest coverage ratio | 400.00% | ||||||
Senior Secured Credit Facility [Member] | Maximum [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Leverage ratio | 400.00% | ||||||
Secured leverage ratio | 300.00% | ||||||
Senior Secured Credit Facility [Member] | LIBOR [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Senior secured credit facility interest rate spread | 2.00% | ||||||
Senior Secured Credit Facility [Member] | 2015 Credit Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, fees and aggregate cost | $ 3,000,000 | ||||||
Debt issuance costs | 2,700,000 | ||||||
Deferred debt issuance cost written off with existing Credit Facility | 1,100,000 | ||||||
Debt Instrument fees and other costs expensed | 300,000 | ||||||
Senior Secured Credit Facility [Member] | 2015 Credit Agreement [Member] | Minimum [Member] | Covenant On Potential Acquisition [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Consideration paid for acquisitions | $ 100,000,000 | ||||||
Senior Secured Credit Facility [Member] | 2015 Credit Agreement [Member] | Maximum [Member] | Covenant On Potential Acquisition [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Leverage ratio | 450.00% | ||||||
Secured leverage ratio | 325.00% | ||||||
[1] | Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. |
Interest Expense Related to Not
Interest Expense Related to Notes (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Debt Instrument [Line Items] | |||||||||||
Coupon interest at 1.25% | $ 16,284 | $ 16,020 | $ 14,703 | ||||||||
Amortization of discounts and debt issuance costs | 13,679 | 13,277 | 9,451 | ||||||||
Total interest expense | $ 7,403 | $ 9,254 | $ 7,483 | $ 7,256 | $ 7,292 | $ 7,542 | $ 7,230 | $ 7,233 | 31,396 | 29,297 | 28,055 |
1.25% Cash Convertible Senior Notes [Member] | |||||||||||
Debt Instrument [Line Items] | |||||||||||
Coupon interest at 1.25% | 4,312 | 4,312 | 2,312 | ||||||||
Amortization of discounts and debt issuance costs | 11,994 | 11,433 | 5,910 | ||||||||
Total interest expense | $ 16,306 | $ 15,745 | $ 8,222 |
Summary of Future Payments unde
Summary of Future Payments under Notes and Senior Secured Credit Facilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 | Jun. 18, 2013 | ||
Debt Instrument [Line Items] | |||||
Total | $ 692,058 | $ 645,535 | |||
2,016 | 12,683 | ||||
2,017 | 15,625 | ||||
2,018 | 28,125 | ||||
2,019 | 40,625 | ||||
2,020 | 595,000 | ||||
1.25% Cash Convertible Senior Notes [Member] | |||||
Debt Instrument [Line Items] | |||||
Total | 345,000 | [1] | 345,000 | $ 345,000 | |
2,016 | [1] | 0 | |||
2,017 | [1] | 0 | |||
2,018 | [1] | 0 | |||
2,019 | [1] | 0 | |||
2,020 | [1] | 345,000 | |||
Term Loan [Member] | |||||
Debt Instrument [Line Items] | |||||
Total | 246,875 | ||||
2,016 | 12,500 | ||||
2,017 | 15,625 | ||||
2,018 | 28,125 | ||||
2,019 | 40,625 | ||||
2,020 | 150,000 | ||||
Other Debt [Member] | |||||
Debt Instrument [Line Items] | |||||
Total | 183 | $ 0 | |||
2,016 | 183 | ||||
2,017 | 0 | ||||
2,018 | 0 | ||||
2,019 | 0 | ||||
2,020 | 0 | ||||
Revolving Facility [Member] | |||||
Debt Instrument [Line Items] | |||||
Total | 100,000 | ||||
2,016 | 0 | ||||
2,017 | 0 | ||||
2,018 | 0 | ||||
2,019 | 0 | ||||
2,020 | $ 100,000 | ||||
[1] | Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020. |
Summary of Future Payments un78
Summary of Future Payments under Notes and Senior Secured Credit Facilities (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2015 | |
1.25% Cash Convertible Senior Notes [Member] | |
Debt Instrument [Line Items] | |
Notes maturity period | Jul. 1, 2020 |
Geographic Breakdown of Income
Geographic Breakdown of Income (Loss) Before Income Tax Benefits (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | |||||||||||
United States | $ (5,357) | $ (62,987) | $ (137,468) | ||||||||
Foreign | 5,927 | (5,130) | (10,878) | ||||||||
Income (loss) before income taxes | $ 14,820 | $ (1,441) | $ (1,744) | $ (11,065) | $ (6,637) | $ (26,211) | $ (16,093) | $ (19,176) | $ 570 | $ (68,117) | $ (148,346) |
Components of Provision (Benefi
Components of Provision (Benefit) for Income Taxes (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | |||||||||||
Current tax provision, Federal | $ 570 | $ 840 | $ (448) | ||||||||
Current tax provision, State | 658 | 213 | 1,421 | ||||||||
Current tax provision, Foreign | 4,083 | (399) | 45 | ||||||||
Current tax provision | 5,311 | 654 | 1,018 | ||||||||
Deferred tax provision, Federal | (2,928) | (581) | (43,542) | ||||||||
Deferred tax provision, State | 898 | (3,261) | (7,929) | ||||||||
Deferred tax provision, Foreign | (655) | 1,524 | 6,133 | ||||||||
Deferred tax provision | (2,685) | (2,318) | (45,338) | ||||||||
Income tax provision (benefit) | $ (1,557) | $ 3,692 | $ 1,472 | $ (981) | $ (4,459) | $ (448) | $ 1,677 | $ 1,566 | $ 2,626 | $ (1,664) | $ (44,320) |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||||
Sep. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2010 | |
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Statutory rate | 35.00% | |||||
Net operating loss carryforwards expiry beginning period | 2,020 | |||||
Tax holiday savings | $ 400 | $ 800 | $ 600 | |||
Diluted earnings per share, increase | $ 0.01 | $ 0.01 | $ 0.01 | |||
Unrecognized tax benefits | $ 11,777 | $ 15,314 | $ 18,283 | $ 18,140 | ||
Unrecognized income tax benefits recognized | $ 4,000 | 0 | 3,239 | 23 | ||
Estimated increase in income tax benefit | 1,500 | 2,300 | ||||
Unrecognized tax benefits, accrued interest and penalties | 1,193 | 1,295 | ||||
Other Tax Expense (Benefit) | 2,500 | |||||
Valuation allowance | $ 1,816 | 24,666 | 13,627 | |||
Cumulative operating income loss period considered | 3 years | |||||
Research and development tax credit | $ 3,000 | 3,133 | 7,454 | |||
Undistributed earnings indefinitely reinvested outside the United States | 44,400 | |||||
Valuation Allowance Tax Credit Carryforward | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Valuation allowance | $ 1,700 | 25,800 | ||||
Bilateral Advance Pricing Agreement [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Unrecognized tax benefits | 4,400 | |||||
Reversal Of Unrecognized Tax Benefits | 6,300 | |||||
Impact Of Unrecognized Tax | 300 | |||||
Bilateral Advance Pricing Agreement [Member] | Amended Returns[Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Unrecognized tax benefits | $ 1,600 | |||||
India [Member] | Partially Expire [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Tax holiday expiration date | 2,012 | |||||
India [Member] | Fully Expire [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Tax holiday expiration date | 2,017 | |||||
Eclipsys [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Net operating losses subject to annual limitation on usage per year | $ 48,000 | |||||
Related To Stock Compensation [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Net operating loss carryforwards | $ 11,000 | |||||
State [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Net operating loss carryforwards | $ 5,000 | 8,000 | ||||
State [Member] | Minimum [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,004 | |||||
State [Member] | Maximum [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,014 | |||||
Israeli [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Net operating loss carryforwards | 74,000 | |||||
Canadian [Member] | Minimum [Member] | C A | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,011 | |||||
Canadian [Member] | Minimum [Member] | India [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,011 | |||||
Canadian [Member] | Maximum [Member] | C A | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,014 | |||||
Canadian [Member] | Maximum [Member] | India [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,014 | |||||
Federal [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Net operating loss carryforwards | $ 238,000 | $ 278,000 | ||||
Net operating losses subject to annual limitation on usage per year | $ 62,000 | |||||
Federal [Member] | Minimum [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,013 | |||||
Federal [Member] | Maximum [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Income tax examination, remaining tax years | 2,014 | |||||
Federal [Member] | Eclipsys [Member] | ||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | ||||||
Acquired net operating losses | $ 265,000 |
Taxes Computed at Statutory Fed
Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | |||||||||||
United States federal tax at statutory rate | $ 138 | $ (23,844) | $ (51,921) | ||||||||
Non-deductible acquisition and reorganization expenses | (2) | (56) | 234 | ||||||||
Research credits | (3,000) | (3,133) | (7,454) | ||||||||
Change in unrecognized tax benefits | (208) | (519) | 1,665 | ||||||||
State income taxes, net of federal benefit | 182 | (2,120) | (4,841) | ||||||||
Compensation | 765 | 1,017 | 844 | ||||||||
Meals and entertainment | 1,023 | 954 | 1,052 | ||||||||
Impact of foreign operations | 1,848 | 2,505 | 1,559 | ||||||||
Provision-to-Return adjustments | (136) | 0 | 0 | ||||||||
Settlements with taxing authorities | (4,218) | 0 | 0 | ||||||||
Deemed Dividends | 1,408 | 0 | 0 | ||||||||
Dividends Accrued | 1,190 | 0 | 0 | ||||||||
Federal, state and local rate changes | 1,104 | (268) | (1,056) | ||||||||
Non-deductible items | (5) | 82 | 82 | ||||||||
Valuation allowance | 1,816 | 24,666 | 13,627 | ||||||||
Other | 197 | (749) | 1,527 | ||||||||
Income tax provision (benefit) | $ (1,557) | $ 3,692 | $ 1,472 | $ (981) | $ (4,459) | $ (448) | $ 1,677 | $ 1,566 | 2,626 | (1,664) | (44,320) |
Bilateral Advance Pricing Agreement [Member] | |||||||||||
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items] | |||||||||||
Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement | 0 | 0 | (4,432) | ||||||||
Bilateral Advance Pricing Agreement impact | $ 524 | $ (199) | $ 4,794 |
Components of Deferred Tax Asse
Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Deferred tax assets | ||
Accruals and reserves, net | $ 24,548 | $ 26,086 |
Allowance for doubtful accounts | 12,194 | 14,159 |
Stock-based compensation, net | 12,086 | 10,773 |
Deferred revenue | 13,294 | 17,422 |
Net operating loss carryforwards | 78,909 | 90,463 |
Research and development tax credit | 26,863 | 24,313 |
AMT credits | 6,070 | 5,606 |
Other | 7,012 | 3,617 |
Less: Valuation Allowance | (43,043) | (41,273) |
Total deferred tax assets | 137,933 | 151,166 |
Deferred tax liabilities | ||
Prepaid expense | (8,594) | (9,268) |
Property and equipment, net | (3,953) | (903) |
Acquired intangibles, net | (145,252) | (160,130) |
Total deferred tax liabilities | (157,799) | (170,301) |
Net deferred tax liabilities | $ (19,866) | $ (19,135) |
Deferred Tax Assets (Liabilitie
Deferred Tax Assets (Liabilities) Classified in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Income Tax Disclosure [Abstract] | ||
Non-current deferred tax assets | $ 2,298 | $ 1,984 |
Non-current deferred tax liabilities, net | (22,164) | (21,119) |
Net deferred tax liabilities | $ (19,866) | $ (19,135) |
Change in the Amount of Unrecog
Change in the Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Sep. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | ||||
Unrecognized tax benefit, beginning balance | $ 15,314 | $ 18,283 | $ 18,140 | |
Increases for tax positions related to the current year | 600 | 627 | 1,517 | |
Decreases for tax positions related to prior years | $ (4,000) | 0 | (3,239) | (23) |
Increases for tax positions related to prior years | 50 | 173 | 3,238 | |
Decreases relating to settlements with taxing authorities | (3,805) | (384) | (4,099) | |
Foreign currency translation | (24) | (26) | (394) | |
Reductions due to lapsed statute of limitations | (358) | (120) | (96) | |
Unrecognized tax benefit, ending balance | $ 11,777 | $ 15,314 | $ 18,283 |
Recognized Interest and Penalti
Recognized Interest and Penalties Related to Uncertain Tax Positions (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | |||
Interest and penalties included in the provision for income taxes | $ (103) | $ (715) | $ (188) |
Amount of Interest and Penaltie
Amount of Interest and Penalties Included in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Income Tax Disclosure [Abstract] | ||
Interest and penalties included in the liability for uncertain tax positions | $ 1,193 | $ 1,295 |
Stock Award Plans - Additional
Stock Award Plans - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Common stock shares reserved for issuance under future share-based awards | 5,700 | ||
Stock-based compensation expense included in provision for income taxes | $ 7,000,000 | ||
Capitalized stock-based compensation costs | 0 | $ 0 | $ 0 |
Unrecognized compensation cost | $ 46,600,000 | ||
Unrecognized compensation expense expected to recognized over weighted-average period, in years | 2 years 2 months 12 days | ||
Shares settled for tax withholding | 523 | 669 | 693 |
Stock options granted | 0 | 0 | 3,870 |
Stock options, contractual terms | 7 years | ||
Aggregate intrinsic value of stock options outstanding | $ 3,100,000 | ||
Aggregate intrinsic value of stock options exercisable | $ 1,500,000 | ||
Aggregate intrinsic value of stock options exercisable, Weighted-Average | $ 15.38 | ||
Weighted average remaining contractual life of options outstanding, in years | 3 years 8 months 12 days | ||
Weighted average remaining contractual life of options exercisable, in years | 3 years 8 months 12 days | ||
Employee Stock Purchase Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Payroll deductions | 20.00% | ||
Offering price percentage | 15.00% | ||
Shares purchased under the ESPP | 675 | 644 | |
Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Annual fair value limit on shares purchased | $ 25,000 | ||
Service-based share awards include restricted stock units [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based compensation award vesting period | 4 years | ||
Deferred share units awarded to directors [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based compensation award vesting period | 1 year | ||
Service-Based Share Awards [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation cost | $ 37,700,000 | ||
Unrecognized compensation expense expected to recognized over weighted-average period, in years | 2 years 3 months 18 days | ||
Awards Granted Under Financial Performance [Member] | Minimum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based compensation award vesting period | 3 years | ||
Awards Granted Under Financial Performance [Member] | Maximum [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Share based compensation award vesting period | 4 years | ||
Performance-Based Share Awards [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation cost | $ 4,000,000 | ||
Unrecognized compensation expense expected to recognized over weighted-average period, in years | 1 year 6 months | ||
Market-Based Share Awards [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Unrecognized compensation cost | $ 4,900,000 | ||
Unrecognized compensation expense expected to recognized over weighted-average period, in years | 2 years 1 month 6 days | ||
Share based compensation award vesting period | 3 years |
Stock-Based Compensation Expens
Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | $ 36,627 | $ 39,254 | $ 37,010 |
Cost of revenue [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | 8,732 | 5,914 | 5,644 |
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | 4,224 | 1,492 | 1,746 |
Cost of revenue [Member] | Client services [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | 4,508 | 4,422 | 3,898 |
Selling, General and Administrative Expenses [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | 20,069 | 25,376 | 23,013 |
Research and development [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Stock based compensation expense | $ 7,826 | $ 7,964 | $ 8,353 |
Activity for Restricted Stock U
Activity for Restricted Stock Units (Detail) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Shares | |||
Shares, Unvested service-based/performance-based share awards as of beginning balance | 5,096 | 5,734 | 6,728 |
Shares, Awarded | 2,937 | 2,199 | 2,511 |
Shares, Vested | (1,612) | (2,044) | (2,023) |
Shares, Forfeited | (1,042) | (793) | (1,482) |
Shares, Unvested service-based/performance-based share awards as of ending balance | 5,379 | 5,096 | 5,734 |
Weighted-Average Grant Date Fair Value | |||
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of beginning balance | $ 15.69 | $ 13.94 | $ 13.43 |
Weighted-Average Grant Date Fair Value, Awarded | 12.07 | 18.09 | 15.06 |
Weighted-Average Grant Date Fair Value, Vested | 14.84 | 13.90 | 13.77 |
Weighted-Average Grant Date Fair Value, Forfeited | 14.74 | 14.28 | 13.74 |
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of ending balance | $ 14.15 | $ 15.69 | $ 13.94 |
Activity for Restricted Stock A
Activity for Restricted Stock Awards (Detail) - Restricted Stock [Member] - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Shares | |||
Shares, Unvested service-based/performance-based share awards as of beginning balance | 0 | 0 | 20 |
Shares, Vested | 0 | 0 | (17) |
Shares, Forfeited | 0 | 0 | (3) |
Shares, Unvested service-based/performance-based share awards as of ending balance | 0 | 0 | 0 |
Weighted-Average Grant Date Fair Value | |||
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of beginning balance | $ 0 | $ 0 | $ 15.94 |
Weighted-Average Grant Date Fair Value, Vested | 0 | 0 | 15.92 |
Weighted-Average Grant Date Fair Value, Forfeited | 0 | 0 | 16.05 |
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of ending balance | $ 0 | $ 0 | $ 0 |
Stock Options Outstanding (Deta
Stock Options Outstanding (Detail) - $ / shares | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Options Outstanding | ||||
Options Outstanding, beginning balance | 3,427,000 | 4,322,000 | 2,667,000 | |
Options Outstanding, options granted | 0 | 0 | 3,870,000 | |
Options Outstanding, options exercised | (317,000) | (289,000) | (1,442,000) | |
Options Outstanding, options forfeited | (767,000) | (606,000) | (773,000) | |
Options Outstanding, ending balance | 2,342,616 | 3,427,000 | 4,322,000 | |
Weighted-Average Exercise Price | ||||
Weighted-average exercise price, beginning balance | $ 14.35 | $ 14.28 | $ 12.04 | |
Weighted-average exercise price, Options granted | 0 | 0 | 13.79 | |
Weighted-average exercise price, options exercised | 11.44 | 11.88 | 8.47 | |
Weighted-average exercise price, options forfeited | 15.89 | 15.03 | 14.94 | |
Weighted-average exercise price, ending balance | $ 14.24 | $ 14.35 | $ 14.28 | |
Options Exercisable | ||||
Options Exercisable | 1,281,569 | 1,393,000 | 1,025,000 | 2,548,000 |
Weighted-average exercise price, exercisable | $ 14.52 | $ 14.97 | $ 15.52 | $ 11.88 |
Weighted Average Grant Date Fai
Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions (Detail) - $ / shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||
Stock options granted | 0 | 0 | 3,870 |
Fair Value per option | $ 6.25 | ||
Expected term ( in years) | 4 years 9 months 18 days | ||
Expected volatility | 54.00% | ||
Expected dividend yield | 0.00% | ||
Risk-free interest rate | 0.90% |
Stock Option Activity (Detail)
Stock Option Activity (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |||
Total intrinsic value of stock options exercised | $ 972 | $ 1,535 | $ 7,500 |
Total fair value of share awards vested | $ 21,673 | $ 31,672 | $ 28,609 |
Stock Option Awards (Detail)
Stock Option Awards (Detail) - $ / shares | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Schedule Of Stock Options [Line Items] | ||||
Number of options Outstanding | 2,342,616 | 3,427,000 | 4,322,000 | 2,667,000 |
Weighted-average exercise price, outstanding | $ 14.24 | $ 14.35 | $ 14.28 | $ 12.04 |
Number of options exercisable | 1,281,569 | 1,393,000 | 1,025,000 | 2,548,000 |
Weighted-average exercise price, exercisable | $ 14.52 | $ 14.97 | $ 15.52 | $ 11.88 |
$12.50 to $14.78 [Member] | ||||
Schedule Of Stock Options [Line Items] | ||||
Range of exercise prices, lower limit | 12.50 | |||
Range of exercise prices, upper limit | $ 14.78 | |||
Number of options Outstanding | 1,917,799 | |||
Weighted-average exercise price, outstanding | $ 13.79 | |||
Number of options exercisable | 937,225 | |||
Weighted-average exercise price, exercisable | $ 13.78 | |||
$14.94 to $16.80 [Member] | ||||
Schedule Of Stock Options [Line Items] | ||||
Range of exercise prices, lower limit | 14.94 | |||
Range of exercise prices, upper limit | $ 16.80 | |||
Number of options Outstanding | 364,097 | |||
Weighted-average exercise price, outstanding | $ 15.91 | |||
Number of options exercisable | 283,624 | |||
Weighted-average exercise price, exercisable | $ 16.10 | |||
$18.45 to $18.74 [Member] | ||||
Schedule Of Stock Options [Line Items] | ||||
Range of exercise prices, lower limit | 18.45 | |||
Range of exercise prices, upper limit | $ 18.74 | |||
Number of options Outstanding | 60,720 | |||
Weighted-average exercise price, outstanding | $ 18.51 | |||
Number of options exercisable | 60,720 | |||
Weighted-average exercise price, exercisable | $ 18.51 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Detail) | Jun. 26, 2015USD ($)$ / sharesshares | Jun. 24, 2015 | Dec. 31, 2015USD ($)Installment$ / sharesshares | Dec. 31, 2014USD ($)$ / sharesshares | Dec. 31, 2013USD ($) | Nov. 30, 2015USD ($) | Jun. 30, 2013shares |
Class Of Stock [Line Items] | |||||||
Stock repurchase program, authorized amount | $ 150,000,000 | ||||||
Common stock repurchased, shares | shares | 0 | ||||||
Unregistered common stock, shares issued | shares | 266,545,000 | 265,138,000 | |||||
Proceeds from sale or issuance of common stock | $ 103,631,000 | $ 1,487,000 | $ 11,447,000 | ||||
Proceeds allocated to warrants | $ 0 | $ 0 | $ 51,208,000 | ||||
1.25% Warrants [Member] | |||||||
Class Of Stock [Line Items] | |||||||
Number of warrants issued | shares | 20,100,000 | ||||||
Warrant expiration term | The 1.25% Warrants expire over a period of 70 trading days beginning on October 1, 2020 and are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap. | ||||||
Initial exercise price of warrant per share | $ / shares | $ 23.135 | ||||||
Warrants issued | $ 51,200,000 | $ 51,200,000 | |||||
Warrant expiration period | 70 days | ||||||
Warrant expiration beginning period | Oct. 1, 2020 | ||||||
Warrant Issued to Commercial Partner [Member] | |||||||
Class Of Stock [Line Items] | |||||||
Number of warrants issued | shares | 1,500,000 | ||||||
Initial exercise price of warrant per share | $ / shares | $ 12.94 | ||||||
Number of installments | Installment | 4 | ||||||
Number of warrants vesting annually | shares | 375,000 | ||||||
Warrant expiration period | 2020-06 | ||||||
Warrants amortized into earnings | $ 10,200,000 | ||||||
Warrants vesting period | 4 years | ||||||
Nant Capital, LLC [Member] | |||||||
Class Of Stock [Line Items] | |||||||
Unregistered common stock, shares issued | shares | 7,434,944 | ||||||
Number of warrants issued | shares | 1,486,989 | ||||||
Sale of common stock, price per share | $ / shares | $ 13.45 | ||||||
Consecutive trading day period | 60 days | ||||||
Proceeds from issuance of common stock | $ 100,000,000 | ||||||
Warrant expiration term | The warrants may be exercised from time to time beginning on the date of issuance and expiring 18 months after the date of issuance. | ||||||
Warrant expiry period from date of issuance | 18 months | ||||||
Initial exercise price of warrant per share | $ / shares | $ 17.675 | ||||||
Proceeds from sale or issuance of common stock | $ 98,300,000 | ||||||
Proceeds allocated to warrants | $ 1,700,000 |
Components of Accumulated Other
Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Balance at the beginning of the period | $ (1,979) | $ (1,745) | $ 76 |
Other comprehensive income (loss) before reclassifications | (2,190) | (536) | (2,561) |
Net losses (gains) reclassified from accumulated other comprehensive loss | (73) | 302 | 740 |
Net other comprehensive (loss) income | (2,263) | (234) | (1,821) |
Balance at the end of the period | (4,242) | (1,979) | (1,745) |
Foreign Currency Translation Adjustments [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Balance at the beginning of the period | (2,119) | (1,590) | 892 |
Other comprehensive income (loss) before reclassifications | (2,381) | (529) | (2,482) |
Net losses (gains) reclassified from accumulated other comprehensive loss | 0 | 0 | 0 |
Net other comprehensive (loss) income | (2,381) | (529) | (2,482) |
Balance at the end of the period | (4,500) | (2,119) | (1,590) |
Unrealized Net Gains (Losses) on Marketable Securities [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Balance at the beginning of the period | 140 | 124 | 118 |
Other comprehensive income (loss) before reclassifications | 0 | 16 | 6 |
Net losses (gains) reclassified from accumulated other comprehensive loss | (140) | 0 | 0 |
Net other comprehensive (loss) income | (140) | 16 | 6 |
Balance at the end of the period | 0 | 140 | 124 |
Derivatives Qualifying as Cash Flow Hedges [Member] | Interest Rate Swap [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Balance at the beginning of the period | 0 | (279) | (934) |
Other comprehensive income (loss) before reclassifications | 0 | (23) | (85) |
Net losses (gains) reclassified from accumulated other comprehensive loss | 0 | 302 | 740 |
Net other comprehensive (loss) income | 0 | 279 | 655 |
Balance at the end of the period | 0 | 0 | (279) |
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Balance at the beginning of the period | 0 | 0 | 0 |
Other comprehensive income (loss) before reclassifications | 191 | 0 | 0 |
Net losses (gains) reclassified from accumulated other comprehensive loss | 67 | 0 | 0 |
Net other comprehensive (loss) income | 258 | 0 | 0 |
Balance at the end of the period | $ 258 | $ 0 | $ 0 |
Components of Accumulated Oth98
Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Unrealized Net Gains (Losses) on Marketable Securities [Member] | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Unrealized net gains (losses), taxes (benefits) | $ 88 | $ 79 | $ 74 | |
Foreign Exchange Contract [Member] | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Unrealized net gains (losses), taxes (benefits) | $ 166 | |||
Interest Rate Swap [Member] | ||||
Accumulated Other Comprehensive Income Loss [Line Items] | ||||
Unrealized net gains (losses), taxes (benefits) | $ (179) | $ (600) |
Income Tax Effects Related to C
Income Tax Effects Related to Components of Other Comprehensive Loss (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Foreign currency translation adjustments, Before-Tax Amount | $ (2,381) | $ (529) | $ (2,482) |
Net change in unrealized gains on marketable securities, Before-Tax Amount | (228) | 25 | 10 |
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount | 424 | 458 | 1,076 |
Other comprehensive loss, Before-Tax Amount | (2,185) | (46) | (1,396) |
Foreign currency translation adjustments, Tax Effect | 0 | 0 | 0 |
Other comprehensive loss, Tax Effect | (78) | (188) | (425) |
Foreign currency translation adjustments, Net | (2,381) | (529) | (2,482) |
Other comprehensive loss, Net | (2,263) | (234) | (1,821) |
Unrealized Net Gains (Losses) on Marketable Securities [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Marketable securities, net gain arising during the period, Before-Tax Amount | 0 | 25 | 10 |
Marketable securities, net gain reclassified into income, Before-Tax Amount | (228) | 0 | 0 |
Net change in unrealized gains on marketable securities, Before-Tax Amount | (228) | 25 | 10 |
Marketable securities, net gain arising during the period, Tax Effect | 0 | (9) | (4) |
Marketable securities, net gain reclassified into income, Tax Effect | 88 | 0 | 0 |
Net change in unrealized gains on marketable securities, Tax Effect | 88 | (9) | (4) |
Marketable securities, net gain arising during the period, Net | 0 | 16 | 6 |
Marketable securities, net gain reclassified into income, Net | (140) | 0 | 0 |
Unrecognized gain on marketable securities, net of tax | (140) | 16 | 6 |
Other comprehensive loss, Net | (140) | 16 | 6 |
Derivatives Qualifying as Cash Flow Hedges [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount | 424 | 458 | 1,076 |
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect | (166) | (179) | (421) |
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 258 | 279 | 655 |
Derivatives Qualifying as Cash Flow Hedges [Member] | Interest Rate Swap [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount | 0 | (38) | (139) |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount | 0 | 496 | 1,215 |
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount | 0 | 458 | 1,076 |
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect | 0 | 15 | 54 |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect | 0 | (194) | (475) |
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect | 0 | (179) | (421) |
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net | 0 | (23) | (85) |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net | 0 | 302 | 740 |
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 0 | 279 | 655 |
Other comprehensive loss, Net | 0 | 279 | 655 |
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member] | |||
Accumulated Other Comprehensive Income Loss [Line Items] | |||
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount | 314 | 0 | 0 |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount | 110 | 0 | 0 |
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount | 424 | 0 | 0 |
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect | (123) | 0 | 0 |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect | (43) | 0 | 0 |
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect | (166) | 0 | 0 |
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net | 191 | 0 | 0 |
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net | 67 | 0 | 0 |
Unrecognized gain on derivatives qualifying as cash flow hedges, net of tax | 258 | 0 | 0 |
Other comprehensive loss, Net | $ 258 | $ 0 | $ 0 |
Fair Value and Balance Sheet Lo
Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Derivatives Fair Value [Line Items] | ||
Derivative asset, fair value | $ 80,632 | $ 57,091 |
Derivative liability, fair value | 81,210 | 57,839 |
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member] | ||
Derivatives Fair Value [Line Items] | ||
Derivative asset, fair value | 424 | |
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member] | ||
Derivatives Fair Value [Line Items] | ||
Derivative asset, fair value | 80,208 | 57,091 |
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member] | ||
Derivatives Fair Value [Line Items] | ||
Derivative liability, fair value | $ 81,210 | $ 57,839 |
Derivative Financial Instrum101
Derivative Financial Instruments - Additional Information (Detail) | Oct. 29, 2010 | Dec. 31, 2015USD ($)DerivativeAgreement$ / shares | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Dec. 31, 2015INR (₨)DerivativeAgreement | Jun. 18, 2013USD ($) |
Derivative [Line Items] | ||||||
Purchase of call option related to 1.25% senior cash convertible notes | $ 0 | $ 0 | $ 82,800,000 | |||
1.25% Cash Convertible Senior Notes [Member] | ||||||
Derivative [Line Items] | ||||||
Purchase of call option related to 1.25% senior cash convertible notes | $ 82,800,000 | |||||
Conversion price per common stock | $ / shares | $ 17.19 | |||||
Fair value liability of embedded cash conversion option | $ 82,800,000 | |||||
Foreign Exchange Forward Contracts [Member] | ||||||
Derivative [Line Items] | ||||||
Number of contracts | Derivative | 36 | 36 | ||||
Period of contracts staggered to mature | 12 months | |||||
Amount of Gain (Loss) Recognized in AOCI (Effective Portion) | $ 0 | |||||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | 0 | |||||
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income | $ 300,000 | |||||
Estimated period of unrealized gains included in AOCI reclassified into income | 12 months | |||||
Foreign Exchange Forward Contracts [Member] | Minimum [Member] | ||||||
Derivative [Line Items] | ||||||
Date of contracts mature | Jan. 31, 2016 | |||||
Derivative notional amount outstanding | $ 300,000 | ₨ 20,000,000 | ||||
Foreign Exchange Forward Contracts [Member] | Maximum [Member] | ||||||
Derivative [Line Items] | ||||||
Date of contracts mature | Dec. 31, 2017 | |||||
Derivative notional amount outstanding | $ 2,600,000 | ₨ 170,000,000 | ||||
Interest Rate Swap [Member] | ||||||
Derivative [Line Items] | ||||||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | $ 0 | |||||
Interest rate swap agreement effective date | Oct. 29, 2010 | |||||
Interest rate swap agreement termination date | Oct. 31, 2014 | |||||
Outstanding interest rate swap agreements | Agreement | 0 | 0 | ||||
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member] | ||||||
Derivative [Line Items] | ||||||
Fair value liability of embedded cash conversion option | $ 82,800,000 |
Derivatives Instruments Designa
Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | $ 2,015 | $ 2,014 | $ 2,013 |
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Recognized in OCI (Effective Portion) | 314 | 0 | 0 |
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of revenue [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | (34) | 0 | 0 |
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Selling, General and Administrative Expenses [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | (28) | 0 | 0 |
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Research and development [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | (48) | 0 | 0 |
Cash Flow Hedging [Member] | Interest Rate Swap [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Recognized in OCI (Effective Portion) | 0 | (38) | (139) |
Cash Flow Hedging [Member] | Interest Rate Swap [Member] | Interest Expense [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) | $ 0 | $ (496) | $ (1,215) |
Net Impact of Changes in Fair V
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Derivative Instruments Gain Loss [Line Items] | |||
Net gain (loss) included in other income, net | $ (254) | $ 233 | $ (981) |
1.25% Notes Embedded Cash Conversion Option [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Net gain (loss) included in other income, net | (23,371) | 47,798 | (22,837) |
1.25% Call Option [Member] | |||
Derivative Instruments Gain Loss [Line Items] | |||
Net gain (loss) included in other income, net | $ 23,117 | $ (47,565) | $ 21,856 |
Rent Expense (Detail)
Rent Expense (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Commitments And Contingencies Disclosure [Abstract] | |||
Rent expense | $ 18,164 | $ 16,259 | $ 17,062 |
Future Commitments under Capita
Future Commitments under Capital and Operating Leases (Detail) $ in Thousands | Dec. 31, 2015USD ($) |
Commitments And Contingencies Disclosure [Abstract] | |
Capital Leases, 2016 | $ 546 |
Capital Leases, 2017 | 471 |
Capital Leases, 2018 | 110 |
Capital Leases, 2019 | 6 |
Capital Leases, 2020 | 0 |
Capital Leases, thereafter | 0 |
Capital Leases, total | 1,133 |
Capital Leases, less amount representing interest | (142) |
Capital Leases, future minimum payments, present value of net minimum payments | 991 |
Capital Leases, Current maturities of capital lease obligations | 431 |
Capital lease obligations, net of current maturities | 560 |
Operating Leases, 2016 | 17,361 |
Operating Leases, 2017 | 14,667 |
Operating Leases, 2018 | 11,739 |
Operating Leases, 2019 | 10,789 |
Operating Leases, 2020 | 9,078 |
Operating Leases, Thereafter | 46,567 |
Operating Leases, Total | $ 110,201 |
Commitments - Additional Inform
Commitments - Additional Information (Detail) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Commitments And Contingencies Disclosure [Abstract] | |
Remote hosting service support agreement term (in years) | 10 years |
Base annual payment obligation for data center and hosting services | $ 50 |
Summary of Expense Incurred und
Summary of Expense Incurred under Atos Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Long Term Purchase Commitment [Line Items] | |||||||||||
Expenses incurred under Atos agreement | $ 191,844 | $ 201,128 | $ 208,094 | $ 204,762 | $ 204,549 | $ 213,933 | $ 211,308 | $ 202,099 | $ 805,828 | $ 831,889 | $ 838,605 |
Atos | |||||||||||
Long Term Purchase Commitment [Line Items] | |||||||||||
Expenses incurred under Atos agreement | $ 67,058 | $ 68,165 | $ 62,259 |
Business Segments - Additional
Business Segments - Additional Information (Detail) - Segment | Jan. 01, 2015 | Dec. 31, 2015 | Dec. 31, 2014 |
Segment Reporting [Abstract] | |||
Number of reportable segments | 2 | 3 | |
Number of operating segments | 7 | 5 |
Revenues and Income from Operat
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Segment Reporting Information [Line Items] | |||||||||||
Revenue | $ 345,647 | $ 354,476 | $ 351,718 | $ 334,552 | $ 340,903 | $ 345,389 | $ 351,296 | $ 340,285 | $ 1,386,393 | $ 1,377,873 | $ 1,373,061 |
Gross Profit | 153,803 | 153,348 | 143,624 | 129,790 | 136,354 | 131,456 | 139,988 | 138,186 | 580,565 | 545,984 | 534,456 |
Income (loss) from operations | $ 23,118 | $ 8,869 | $ 5,591 | $ (5,695) | $ 656 | $ (18,840) | $ (9,093) | $ (11,911) | 31,883 | (39,188) | (127,601) |
Unallocated Amounts [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 17,208 | 13,160 | 21,146 | ||||||||
Gross Profit | (53,057) | (61,772) | (69,213) | ||||||||
Income (loss) from operations | (322,489) | (346,775) | (423,288) | ||||||||
Clinical and Financial Solutions [Member] | Operating Segments [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 1,072,605 | 1,079,330 | 1,094,177 | ||||||||
Gross Profit | 437,229 | 415,172 | 428,097 | ||||||||
Income (loss) from operations | 222,958 | 191,716 | 186,973 | ||||||||
Population Health [Member] | Operating Segments [Member] | |||||||||||
Segment Reporting Information [Line Items] | |||||||||||
Revenue | 296,580 | 285,383 | 257,738 | ||||||||
Gross Profit | 196,393 | 192,584 | 175,572 | ||||||||
Income (loss) from operations | $ 131,414 | $ 115,871 | $ 108,714 |
Supplemental Disclosures (Detai
Supplemental Disclosures (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Supplemental Cash Flow Elements [Abstract] | |||
Interest | $ 15,750 | $ 15,585 | $ 12,997 |
Income taxes paid, net of tax refunds | 5,037 | 7,104 | 7,944 |
Obligations incurred to purchase capitalized software or enter into capital leases | $ 393 | $ 4,800 | $ 0 |
Accrued Expenses (Detail)
Accrued Expenses (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Payables And Accruals [Abstract] | ||
Royalties, certain third party product costs and licenses | $ 16,456 | $ 23,946 |
Other | 45,565 | 55,021 |
Total accrued expenses | $ 62,021 | $ 78,967 |
Supplemental Disclosures - Addi
Supplemental Disclosures - Additional Information (Detail) | Dec. 31, 2015 |
Payables And Accruals [Abstract] | |
Maximum percentage accounted by individual expenses of total current liabilities | 5.00% |
Revenues by Geographic Area (De
Revenues by Geographic Area (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Schedule Of Revenues From External Customers [Line Items] | |||||||||||
Total revenue | $ 345,647 | $ 354,476 | $ 351,718 | $ 334,552 | $ 340,903 | $ 345,389 | $ 351,296 | $ 340,285 | $ 1,386,393 | $ 1,377,873 | $ 1,373,061 |
United States [Member] | |||||||||||
Schedule Of Revenues From External Customers [Line Items] | |||||||||||
Total revenue | 1,338,095 | 1,327,840 | 1,321,779 | ||||||||
Canada [Member] | |||||||||||
Schedule Of Revenues From External Customers [Line Items] | |||||||||||
Total revenue | 18,024 | 20,727 | 24,999 | ||||||||
Other International [Member] | |||||||||||
Schedule Of Revenues From External Customers [Line Items] | |||||||||||
Total revenue | $ 30,274 | $ 29,306 | $ 26,283 |
Long-Lived Assets by Geographic
Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands | Dec. 31, 2015 | Dec. 31, 2014 |
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | $ 125,617 | $ 145,830 |
United States [Member] | ||
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | 116,731 | 133,485 |
India [Member] | ||
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | 5,739 | 8,044 |
Israeli [Member] | ||
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | 1,786 | 2,142 |
Canada [Member] | ||
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | 545 | 935 |
Other International [Member] | ||
Long-Lived Assets by Geographical Areas [Line Items] | ||
Long lived assets | $ 816 | $ 1,224 |
Contingencies - Additional Info
Contingencies - Additional Information (Detail) - Pending Litigation [Member] - $ / Violation | 12 Months Ended | |
Dec. 31, 2015 | May. 01, 2012 | |
Pegasus Imaging Corporation [Member] | ||
Loss Contingencies [Line Items] | ||
Contingency allegations | The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. | |
Loss contingency action taken by defendant | Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. | |
Physicians Healthsource Inc [Member] | ||
Loss Contingencies [Line Items] | ||
Damages sought per alleged violation of the TCPA | 500 |
North American Site Consolid116
North American Site Consolidation Plan - Additional Information (Detail) $ in Thousands | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2015USD ($) | Sep. 30, 2015USD ($) | Jun. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Sep. 30, 2014USD ($) | Jun. 30, 2014USD ($) | Mar. 31, 2014USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Feb. 18, 2013OfficeWarehouse | |
Restructuring Cost And Reserve [Line Items] | ||||||||||||
Research and development | $ 45,995 | $ 47,702 | $ 44,367 | $ 46,727 | $ 41,538 | $ 45,962 | $ 53,016 | $ 52,305 | $ 184,791 | $ 192,821 | $ 199,751 | |
North American Site Consolidation Plan [Member] | ||||||||||||
Restructuring Cost And Reserve [Line Items] | ||||||||||||
Number of offices closed under the Site Consolidation Plan | Office | 12 | |||||||||||
Number of Warehouse closed under the Site Consolidation Plan | Warehouse | 1 | |||||||||||
Severance costs (benefits) | (2,200) | 20,100 | ||||||||||
Payments of severance costs | $ 2,000 | |||||||||||
Research and development | $ 3,900 |
Quarterly Financial Informat117
Quarterly Financial Information (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Quarterly Financial Information Disclosure [Abstract] | |||||||||||
Revenue | $ 345,647 | $ 354,476 | $ 351,718 | $ 334,552 | $ 340,903 | $ 345,389 | $ 351,296 | $ 340,285 | $ 1,386,393 | $ 1,377,873 | $ 1,373,061 |
Cost of revenue | 191,844 | 201,128 | 208,094 | 204,762 | 204,549 | 213,933 | 211,308 | 202,099 | 805,828 | 831,889 | 838,605 |
Gross profit | 153,803 | 153,348 | 143,624 | 129,790 | 136,354 | 131,456 | 139,988 | 138,186 | 580,565 | 545,984 | 534,456 |
Selling, general and administrative expenses | 79,354 | 91,043 | 86,749 | 82,029 | 85,038 | 97,034 | 86,663 | 89,946 | 339,175 | 358,681 | 419,599 |
Research and development | 45,995 | 47,702 | 44,367 | 46,727 | 41,538 | 45,962 | 53,016 | 52,305 | 184,791 | 192,821 | 199,751 |
Asset impairment charges | 1,203 | 22 | 293 | 26 | 256 | 188 | 1,751 | 195 | 1,544 | 2,390 | 11,454 |
Amortization of intangible and acquisition-related assets | 4,133 | 5,712 | 6,624 | 6,703 | 8,866 | 7,112 | 7,651 | 7,651 | 23,172 | 31,280 | 31,253 |
Income (loss) from operations | 23,118 | 8,869 | 5,591 | (5,695) | 656 | (18,840) | (9,093) | (11,911) | 31,883 | (39,188) | (127,601) |
Interest expense | (7,403) | (9,254) | (7,483) | (7,256) | (7,292) | (7,542) | (7,230) | (7,233) | (31,396) | (29,297) | (28,055) |
Other (expense) income, net | (98) | 423 | (28) | 1,886 | 397 | 171 | 230 | (32) | 2,183 | 766 | 7,310 |
Equity in net earnings of unconsolidated investments | (797) | (1,479) | 176 | 0 | (398) | 0 | 0 | 0 | (2,100) | (398) | 0 |
Income (loss) before income taxes | 14,820 | (1,441) | (1,744) | (11,065) | (6,637) | (26,211) | (16,093) | (19,176) | 570 | (68,117) | (148,346) |
Income tax (provision) benefit | 1,557 | (3,692) | (1,472) | 981 | 4,459 | 448 | (1,677) | (1,566) | (2,626) | 1,664 | 44,320 |
Net loss | 16,377 | (5,133) | (3,216) | (10,084) | (2,178) | (25,763) | (17,770) | (20,742) | (2,056) | (66,453) | (104,026) |
Less: Net income attributable to non-controlling interest | (50) | (111) | (9) | 0 | 0 | 0 | 0 | 0 | (170) | 0 | 0 |
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ 16,327 | $ (5,244) | $ (3,225) | $ (10,084) | $ (2,178) | $ (25,763) | $ (17,770) | $ (20,742) | $ (2,226) | $ (66,453) | $ (104,026) |
Loss per share - basic and diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders | $ 0.09 | $ (0.03) | $ (0.01) | $ (0.06) | $ (0.01) | $ (0.15) | $ (0.09) | $ (0.12) | $ (0.01) | $ (0.37) | $ (0.59) |
Quarterly Financial Informat118
Quarterly Financial Information (Unaudited) (Parenthetical) (Detail) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||||
Sep. 30, 2015 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Quarterly Financial Information Disclosure [Line Items] | |||||||
Deferred debt issuance cost written off with existing Credit Facility | $ 1,433 | $ 0 | $ 3,901 | ||||
Income Tax Benefit (Provision) [Member] | |||||||
Quarterly Financial Information Disclosure [Line Items] | |||||||
Tax Credit Carryforward, Valuation Allowance | $ 5,900 | $ 5,200 | $ 8,000 | $ 9,800 | |||
Interest Expense [Member] | |||||||
Quarterly Financial Information Disclosure [Line Items] | |||||||
Deferred debt issuance cost written off with existing Credit Facility | $ 1,400 |
Schedule II - Valuation And Qua
Schedule II - Valuation And Qualifying Accounts (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Valuation And Qualifying Accounts [Abstract] | |||
Beginning Balance | $ 36,047 | $ 54,252 | $ 45,320 |
Charged to Expenses/Against Revenue | 8,089 | 9,592 | 20,095 |
Deferred Revenue Reclassification | (363) | (5,340) | 1,116 |
Write-Offs, Net of Recoveries | (12,507) | (22,457) | (12,279) |
Ending Balance | $ 31,266 | $ 36,047 | $ 54,252 |